chr,position,beta,se,p,n,id,rsid,ea,nea,eaf,trait,gene
5,151194713,-0.426577,0.0115228,5.33335e-300,31568,eqtl-a-ENSG00000177556,rs4629586,A,C,0.417431,ENSG00000177556,ATOX1
5,151194713,-0.344677,0.0117153,2.94442e-190,5501,eqtl-a-ENSG00000213433,rs4629586,A,C,0.417431,ENSG00000213433,ATOX1
5,151194713,-0.23582,0.0119049,2.49977e-87,3831,eqtl-a-ENSG00000253921,rs4629586,A,C,0.417431,ENSG00000253921,ATOX1
5,151194713,0.124217,0.0120238,5.11329e-25,3831,eqtl-a-ENSG00000254226,rs4629586,A,C,0.417431,ENSG00000254226,ATOX1
5,151194713,-0.012251,0.0019,1.17001e-10,531774,ebi-a-GCST90002369,rs4629586,A,C,0.414705,Red cell distribution width,ATOX1
5,151194713,-0.0117279,0.00198263,2.80001e-09,514929,ebi-a-GCST90029001,rs4629586,A,C,0.415761,Red cell distribution width,ATOX1
5,151194713,-0.0123225,0.00215227,1e-08,408112,ebi-a-GCST90002404,rs4629586,A,C,0.415723,Red cell distribution width,ATOX1
5,151194713,-0.043819,0.0080455,5.17726e-08,,ubm-b-3916,rs4629586,A,C,0.41571,rfMRI connectivity ICA-features 3,ATOX1
5,151194713,-0.012405,0.00239296,2.1734e-07,350470,ukb-d-30110_irnt,rs4629586,A,C,0.416346,Platelet distribution width,ATOX1
5,151194713,-0.0113071,0.0021823,2.19999e-07,408112,ebi-a-GCST90002401,rs4629586,A,C,0.415401,Platelet distribution width,ATOX1
5,151194713,-0.040827,0.0079987,3.34041e-07,,ubm-b-1432,rs4629586,A,C,0.41571,wg_rh_intensity-contrast_supramarginal,ATOX1
5,151194713,-0.040642,0.0079988,3.77572e-07,,ubm-b-1409,rs4629586,A,C,0.41571,wg_rh_intensity-contrast_inferiorparietal,ATOX1
1,109817590,-0.158926,0.00249262,0,,ieu-b-108,rs12740374,T,G,0.221205,apolipoprotein B,CELSR2
1,109817590,-0.118727,0.00250345,0,,ieu-b-110,rs12740374,T,G,0.2212,LDL cholesterol,CELSR2
1,109817590,0.018837,0.002324,0,,ieu-b-4808,rs12740374,T,G,0.223883,25 hydroxyvitamin D level,CELSR2
1,109817590,-0.037823,0.00067684,0,342590,ukb-d-30640_raw,rs12740374,T,G,0.22176,Apoliprotein B,CELSR2
1,109817590,-0.1581,0.0028426,0,342590,ukb-d-30640_irnt,rs12740374,T,G,0.22176,Apoliprotein B,CELSR2
1,109817590,-0.1037,0.0024557,0,343621,ukb-d-30780_raw,rs12740374,T,G,0.22176,LDL direct,CELSR2
1,109817590,-0.1181,0.0028258,0,343621,ukb-d-30780_irnt,rs12740374,T,G,0.22176,LDL direct,CELSR2
1,109817590,-0.122687,0.00246436,0,437068,ebi-a-GCST90025954,rs12740374,T,G,0.221316,Direct low density lipoprotein cholesterol levels,CELSR2
1,109817590,-0.162473,0.00241851,0,435744,ebi-a-GCST90025952,rs12740374,T,G,0.221322,Apolipoprotein B levels,CELSR2
1,109817590,-0.162741,0.00227119,0,431167,ebi-a-GCST90002412,rs12740374,T,G,0.221249,Low density lipoprotein cholesterol levels,CELSR2
1,109817590,-0.102175,0.002459,0,437878,ebi-a-GCST90025953,rs12740374,T,G,0.221332,Total cholesterol levels,CELSR2
1,109817590,-0.1173,0.0027,0,343621,ebi-a-GCST90018961,rs12740374,T,G,0.195295,LDL cholesterol,CELSR2
1,109817590,0.695915,0.0133745,1.1289039792536e-308,31212,eqtl-a-ENSG00000134222,rs12740374,T,G,0.210449,ENSG00000134222,CELSR2
1,109817590,-0.0963675,0.00251806,1.6684019292536e-308,389864,ebi-a-GCST90014000,rs12740374,T,G,,Cholesterol levels (UKB data field 30690),CELSR2
1,109817590,-0.0934,0.0026,1.09901e-286,344278,ebi-a-GCST90018974,rs12740374,T,G,0.179291,Total cholesterol levels,CELSR2
1,109817590,-0.161,0.0044,2.40991e-272,94595,ebi-a-GCST002222,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.11157,0.0031799,3.21366e-269,344278,ukb-d-30690_raw,rs12740374,T,G,0.22177,Cholesterol,CELSR2
1,109817590,-0.096487,0.0027832,7.01455e-263,344278,ukb-d-30690_irnt,rs12740374,T,G,0.22177,Cholesterol,CELSR2
1,109817590,-0.126891,0.00373307,2.69774e-256,,ieu-b-5089,rs12740374,T,G,0.221626,LDL cholesterol,CELSR2
1,109817590,-0.827,0.0267,1.02329e-210,3301,prot-a-1277,rs12740374,T,G,0.22252,Granulins,CELSR2
1,109817590,-0.161,0.0044,1e-200,172820,ieu-a-300,rs12740374,T,G,0.2124,LDL cholesterol,CELSR2
1,109817590,-0.143663,0.00495486,6.69885e-191,,met-d-S_LDL_PL,rs12740374,T,G,0.221059,Phospholipids in small LDL,CELSR2
1,109817590,-0.1278,0.0043,7.65597e-187,94595,ebi-a-GCST002221,rs12740374,T,G,,"Cholesterol, total",CELSR2
1,109817590,-0.1278,0.0043,7.65597e-187,187071,ieu-a-301,rs12740374,T,G,0.2124,Total cholesterol,CELSR2
1,109817590,-0.143805,0.00495227,2.19786e-185,115082,ebi-a-GCST90092964,rs12740374,T,G,0.221064,Phospholipid levels in small LDL,CELSR2
1,109817590,-0.269572,0.00972019,6.60693e-175,349222,ebi-a-GCST90104006,rs12740374,T,G,0.221896,Familial combined hyperlipidemia defined by Consensus criteria,CELSR2
1,109817590,0.1723,0.0064,1.55955e-168,95454,ebi-a-GCST000759,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.1723,0.0064,1.55955e-168,95454,ebi-a-GCST000759,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.135366,0.00495913,1.90108e-168,,met-d-S_LDL_FC,rs12740374,T,G,0.221059,Free cholesterol in small LDL,CELSR2
1,109817590,-0.135763,0.00495705,3.80189e-165,115082,ebi-a-GCST90092960,rs12740374,T,G,0.221064,Free cholesterol levels in small LDL,CELSR2
1,109817590,-0.126726,0.00496656,9.7051e-147,,met-d-S_LDL_L,rs12740374,T,G,0.221059,Total lipids in small LDL,CELSR2
1,109817590,-0.1623,0.0063,1.93197e-145,290385,ebi-a-GCST90018989,rs12740374,T,G,0.163415,Medication use (HMG CoA reductase inhibitors),CELSR2
1,109817590,-0.125781,0.00495006,5.29663e-145,,met-d-L_LDL_P,rs12740374,T,G,0.221059,Concentration of large LDL particles,CELSR2
1,109817590,-0.126975,0.00496446,2.79898e-144,115082,ebi-a-GCST90092962,rs12740374,T,G,0.221064,Total lipid levels in small LDL,CELSR2
1,109817590,-0.125952,0.00494824,6.39735e-143,115082,ebi-a-GCST90092863,rs12740374,T,G,0.221064,Concentration of large LDL particles,CELSR2
1,109817590,-0.123434,0.00496198,8.09096e-139,,met-d-M_LDL_FC,rs12740374,T,G,0.221059,Free cholesterol in medium LDL,CELSR2
1,109817590,-0.123837,0.00496195,1.79887e-137,115082,ebi-a-GCST90092908,rs12740374,T,G,0.221064,Free cholesterol levels in medium LDL,CELSR2
1,109817590,-0.122226,0.00497291,6.09537e-136,,met-d-S_LDL_C,rs12740374,T,G,0.221059,Cholesterol in small LDL,CELSR2
1,109817590,-0.121446,0.00496391,2.30144e-134,,met-d-LDL_P,rs12740374,T,G,0.221059,Concentration of LDL particles,CELSR2
1,109817590,-0.122581,0.00497168,3.1989e-134,115082,ebi-a-GCST90092956,rs12740374,T,G,0.221064,Cholesterol levels in small LDL,CELSR2
1,109817590,-0.119841,0.00491446,1.09901e-133,,met-d-LDL_FC,rs12740374,T,G,0.221059,Free cholesterol in LDL,CELSR2
1,109817590,-0.121609,0.00496166,1.1995e-132,115082,ebi-a-GCST90092887,rs12740374,T,G,0.221064,Concentration of LDL particles,CELSR2
1,109817590,-0.120222,0.0049566,2.60016e-132,,met-d-LDL_PL,rs12740374,T,G,0.221059,Phospholipids in LDL,CELSR2
1,109817590,-0.1202,0.00491526,4.4978e-132,115082,ebi-a-GCST90092885,rs12740374,T,G,0.221064,Free cholesterol levels in LDL,CELSR2
1,109817590,-0.0187542,0.000776044,1.39959e-130,484598,ebi-a-GCST90038690,rs12740374,T,G,0.221701,High cholesterol,CELSR2
1,109817590,-0.120477,0.004956,1.59956e-130,115082,ebi-a-GCST90092888,rs12740374,T,G,0.221064,Phospholipid levels in LDL,CELSR2
1,109817590,0.116224,0.00478952,4.4978e-130,115082,ebi-a-GCST90092953,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in small HDL,CELSR2
1,109817590,0.1483,0.0062,2.06063e-129,100184,ebi-a-GCST000760,rs12740374,T,G,,"Cholesterol, total",CELSR2
1,109817590,0.114893,0.00480267,3.69828e-129,,met-d-S_HDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in small HDL,CELSR2
1,109817590,-0.118988,0.00497535,1.90108e-128,,met-d-M_LDL_PL,rs12740374,T,G,0.221059,Phospholipids in medium LDL,CELSR2
1,109817590,-0.110643,0.00471131,3.80189e-128,,met-d-S_HDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in small HDL,CELSR2
1,109817590,-0.119299,0.00497417,4.10204e-127,115082,ebi-a-GCST90092912,rs12740374,T,G,0.221064,Phospholipid levels in medium LDL,CELSR2
1,109817590,-0.117622,0.00495141,9.09913e-127,,met-d-LDL_L,rs12740374,T,G,0.221059,Total lipids in LDL,CELSR2
1,109817590,-0.115316,0.00489104,1.09901e-126,,met-d-ApoB_by_ApoA1,rs12740374,T,G,0.221059,Ratio of apolipoprotein B to apolipoprotein A1,CELSR2
1,109817590,-0.116925,0.00494653,1.39959e-125,,met-d-LDL_C,rs12740374,T,G,0.221059,LDL cholesterol,CELSR2
1,109817590,-0.116713,0.0049393,2.19786e-125,,met-d-Clinical_LDL_C,rs12740374,T,G,0.221059,Clinical LDL cholesterol,CELSR2
1,109817590,-0.117818,0.00495018,3.3037e-125,115082,ebi-a-GCST90092886,rs12740374,T,G,0.221064,Total lipid levels in LDL,CELSR2
1,109817590,-0.117191,0.00494617,4.19759e-124,115082,ebi-a-GCST90092883,rs12740374,T,G,0.221064,LDL cholesterol levels,CELSR2
1,109817590,-0.117024,0.00493966,4.4978e-124,115082,ebi-a-GCST90092814,rs12740374,T,G,0.221064,Clinical LDL cholesterol levels,CELSR2
1,109817590,-0.115691,0.00488654,6.5013e-124,115082,ebi-a-GCST90092810,rs12740374,T,G,0.221064,Ratio of apolipoprotein B to apolipoprotein A1 levels,CELSR2
1,109817590,-0.11517,0.00491176,1.30017e-123,,met-d-L_LDL_C,rs12740374,T,G,0.221059,Cholesterol in large LDL,CELSR2
1,109817590,-0.11507,0.00491936,5.39511e-123,,met-d-L_LDL_L,rs12740374,T,G,0.221059,Total lipids in large LDL,CELSR2
1,109817590,-0.113851,0.00487759,1.69824e-122,,met-d-L_LDL_FC,rs12740374,T,G,0.221059,Free cholesterol in large LDL,CELSR2
1,109817590,-0.115805,0.00496122,1.69824e-122,,met-d-ApoB,rs12740374,T,G,0.221059,Apolipoprotein B,CELSR2
1,109817590,-0.1154,0.00491196,4.69894e-122,115082,ebi-a-GCST90092856,rs12740374,T,G,0.221064,Cholesterol levels in large LDL,CELSR2
1,109817590,-0.018553,0.00079485,8.60994e-122,464736,ebi-a-GCST90029021,rs12740374,T,G,0.221282,High cholesterol,CELSR2
1,109817590,-0.114518,0.00492351,1.49968e-121,,met-d-L_LDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in large LDL,CELSR2
1,109817590,-0.115226,0.00491872,2.30144e-121,115082,ebi-a-GCST90092862,rs12740374,T,G,0.221064,Total lipid levels in large LDL,CELSR2
1,109817590,-0.110127,0.00470344,3.09742e-121,115082,ebi-a-GCST90092949,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in small HDL,CELSR2
1,109817590,-0.114164,0.00487891,4.29536e-121,115082,ebi-a-GCST90092860,rs12740374,T,G,0.221064,Free cholesterol levels in large LDL,CELSR2
1,109817590,-0.115903,0.0049586,7.7983e-121,115082,ebi-a-GCST90092809,rs12740374,T,G,0.221064,Apolipoprotein B levels,CELSR2
1,109817590,-0.114708,0.00492302,4.39542e-120,115082,ebi-a-GCST90092858,rs12740374,T,G,0.221064,Cholesteryl ester levels in large LDL,CELSR2
1,109817590,-0.114189,0.00495511,3.69828e-119,,met-d-LDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in LDL,CELSR2
1,109817590,-0.114407,0.00495394,5.29663e-118,115082,ebi-a-GCST90092884,rs12740374,T,G,0.221064,Cholesteryl ester levels in LDL,CELSR2
1,109817590,-0.113814,0.00497555,1.79887e-117,,met-d-M_LDL_L,rs12740374,T,G,0.221059,Total lipids in medium LDL,CELSR2
1,109817590,-0.112674,0.00492232,4.89779e-117,,met-d-M_VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in medium VLDL,CELSR2
1,109817590,-0.0187444,0.000815397,6.09537e-117,462933,ukb-b-10912,rs12740374,T,G,0.221164,"Non-cancer illness code, self-reported: high cholesterol",CELSR2
1,109817590,-0.114057,0.00497335,2.09894e-116,115082,ebi-a-GCST90092910,rs12740374,T,G,0.221064,Total lipid levels in medium LDL,CELSR2
1,109817590,-0.112868,0.00492175,2.19786e-116,115082,ebi-a-GCST90092918,rs12740374,T,G,0.221064,Cholesteryl ester levels in medium VLDL,CELSR2
1,109817590,-0.112839,0.00497269,6.29506e-116,,met-d-S_LDL_P,rs12740374,T,G,0.221059,Concentration of small LDL particles,CELSR2
1,109817590,-0.111935,0.00493079,1.30017e-115,,met-d-L_LDL_PL,rs12740374,T,G,0.221059,Phospholipids in large LDL,CELSR2
1,109817590,-0.112628,0.00497787,6.29506e-115,,met-d-M_LDL_C,rs12740374,T,G,0.221059,Cholesterol in medium LDL,CELSR2
1,109817590,-0.112303,0.00497078,9.2045e-115,,met-d-S_LDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in small LDL,CELSR2
1,109817590,-0.112167,0.00493109,1.49968e-114,115082,ebi-a-GCST90092864,rs12740374,T,G,0.221064,Phospholipid levels in large LDL,CELSR2
1,109817590,-0.112864,0.00496843,3.09742e-114,115082,ebi-a-GCST90092963,rs12740374,T,G,0.221064,Concentration of small LDL particles,CELSR2
1,109817590,-0.112923,0.00497627,5.29663e-114,115082,ebi-a-GCST90092904,rs12740374,T,G,0.221064,Cholesterol levels in medium LDL,CELSR2
1,109817590,-0.112602,0.0049693,1.09901e-113,115082,ebi-a-GCST90092958,rs12740374,T,G,0.221064,Cholesteryl ester levels in small LDL,CELSR2
1,109817590,-0.6382,0.0282,3.16228e-113,3301,prot-a-303,rs12740374,T,G,0.22252,Complement C1q tumor necrosis factor-related protein 1,CELSR2
1,109817590,0.0529442,0.00245205,2.30144e-111,398508,ebi-a-GCST90025955,rs12740374,T,G,0.221017,Apolipoprotein A1 levels,CELSR2
1,109817590,-0.145,0.0061,8.09096e-111,82932,ieu-a-781,rs12740374,T,G,0.2124,LDL cholesterol,CELSR2
1,109817590,-0.109788,0.00495414,3.49945e-110,,met-d-M_VLDL_C,rs12740374,T,G,0.221059,Cholesterol in medium VLDL,CELSR2
1,109817590,-0.10991,0.00495314,4.29536e-109,115082,ebi-a-GCST90092916,rs12740374,T,G,0.221064,Cholesterol levels in medium VLDL,CELSR2
1,109817590,-0.1311,0.0059,6.79204e-109,70814,ieu-b-4846,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.108623,0.00494118,1.59956e-108,,met-d-non_HDL_C,rs12740374,T,G,0.221059,Total cholesterol minus HDL-C,CELSR2
1,109817590,-0.186097,0.00842235,3.48337e-108,407746,ebi-a-GCST90013932,rs12740374,T,G,,High cholesterol (SPA correction),CELSR2
1,109817590,-0.189652,0.00870883,1.86638e-107,407746,ebi-a-GCST90013882,rs12740374,T,G,,High cholesterol (Firth correction),CELSR2
1,109817590,-0.108739,0.00494,2.19786e-107,115082,ebi-a-GCST90092930,rs12740374,T,G,0.221064,Total cholesterol minus HDL-C levels,CELSR2
1,109817590,-0.107267,0.00496874,8.20352e-105,,met-d-S_VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in small VLDL,CELSR2
1,109817590,-0.107157,0.00496338,2.19786e-103,115082,ebi-a-GCST90092972,rs12740374,T,G,0.221064,Free cholesterol levels in small VLDL,CELSR2
1,109817590,-0.105752,0.00497562,1.39959e-101,,met-d-M_LDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in medium LDL,CELSR2
1,109817590,-0.101489,0.0047929,1.59956e-101,,met-d-IDL_PL,rs12740374,T,G,0.221059,Phospholipids in IDL,CELSR2
1,109817590,-0.105986,0.00497291,8.70964e-101,115082,ebi-a-GCST90092906,rs12740374,T,G,0.221064,Cholesteryl ester levels in medium LDL,CELSR2
1,109817590,-0.104962,0.00498331,5.90065e-100,,met-d-M_LDL_P,rs12740374,T,G,0.221059,Concentration of medium LDL particles,CELSR2
1,109817590,-0.101234,0.00478991,3.80014e-99,115082,ebi-a-GCST90092839,rs12740374,T,G,0.221064,Phospholipid levels in IDL,CELSR2
1,109817590,-0.105127,0.00497979,6.4003e-99,115082,ebi-a-GCST90092911,rs12740374,T,G,0.221064,Concentration of medium LDL particles,CELSR2
1,109817590,-0.0999247,0.00480884,5.10035e-97,,met-d-IDL_FC,rs12740374,T,G,0.221059,Free cholesterol in IDL,CELSR2
1,109817590,-0.0998514,0.00480746,8.10028e-96,115082,ebi-a-GCST90092835,rs12740374,T,G,0.221064,Free cholesterol levels in IDL,CELSR2
1,109817590,-0.100509,0.00496711,3.90032e-93,,met-d-S_VLDL_C,rs12740374,T,G,0.221059,Cholesterol in small VLDL,CELSR2
1,109817590,-0.0968923,0.00480284,7.00003e-92,,met-d-IDL_L,rs12740374,T,G,0.221059,Total lipids in IDL,CELSR2
1,109817590,-0.100262,0.00495815,6.29941e-91,115082,ebi-a-GCST90092968,rs12740374,T,G,0.221064,Cholesterol levels in small VLDL,CELSR2
1,109817590,-0.0985005,0.00491626,2.60016e-90,,met-d-IDL_P,rs12740374,T,G,0.221059,Concentration of IDL particles,CELSR2
1,109817590,-0.0967477,0.00480191,2.80027e-90,115082,ebi-a-GCST90092837,rs12740374,T,G,0.221064,Total lipid levels in IDL,CELSR2
1,109817590,-0.0985665,0.00491609,1.99986e-89,115082,ebi-a-GCST90092838,rs12740374,T,G,0.221064,Concentration of IDL particles,CELSR2
1,109817590,-0.0988438,0.00496713,4.00037e-89,,met-d-M_VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in medium VLDL,CELSR2
1,109817590,-0.0962096,0.00485323,6.79986e-89,,met-d-Total_FC,rs12740374,T,G,0.221059,Total free cholesterol,CELSR2
1,109817590,-0.0987901,0.00496275,3.59998e-88,115082,ebi-a-GCST90092920,rs12740374,T,G,0.221064,Free cholesterol levels in medium VLDL,CELSR2
1,109817590,-0.0961379,0.00485135,2.09991e-87,115082,ebi-a-GCST90092988,rs12740374,T,G,0.221064,Total free cholesterol levels,CELSR2
1,109817590,-0.191891,0.00970023,4.24717e-87,407746,ebi-a-GCST90013969,rs12740374,T,G,,Cholesterol lowering medication use (UKB data field 6177_1) (SPA correction),CELSR2
1,109817590,-0.194331,0.00992165,9.56974e-87,407746,ebi-a-GCST90013919,rs12740374,T,G,,Cholesterol lowering medication use (UKB data field 6177_1) (Firth correction),CELSR2
1,109817590,-0.0939052,0.00479727,2.49977e-86,,met-d-IDL_C,rs12740374,T,G,0.221059,Cholesterol in IDL,CELSR2
1,109817590,-0.0961909,0.00493624,1.80011e-85,,met-d-Remnant_C,rs12740374,T,G,0.221059,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",CELSR2
1,109817590,-0.0938861,0.00479829,2.99985e-85,115082,ebi-a-GCST90092831,rs12740374,T,G,0.221064,Cholesterol levels in IDL,CELSR2
1,109817590,-0.0961513,0.00493378,1.39991e-84,115082,ebi-a-GCST90092943,rs12740374,T,G,0.221064,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",CELSR2
1,109817590,-0.0929409,0.00480921,1.69981e-84,,met-d-Total_C,rs12740374,T,G,0.221059,Total cholesterol,CELSR2
1,109817590,-0.0954689,0.00496117,1.80011e-84,,met-d-S_VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in small VLDL,CELSR2
1,109817590,-0.0954345,0.00495808,1.9002e-84,,met-d-S_VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in small VLDL,CELSR2
1,109817590,-0.0929169,0.00480882,3.50026e-83,115082,ebi-a-GCST90092985,rs12740374,T,G,0.221064,Total cholesterol levels,CELSR2
1,109817590,-0.0300486,0.00155942,9.79941e-83,209638,ukb-b-11740,rs12740374,T,G,0.221547,"Medication for cholesterol, blood pressure or diabetes: Cholesterol lowering medication",CELSR2
1,109817590,-0.0951286,0.00494692,2.09991e-82,115082,ebi-a-GCST90092976,rs12740374,T,G,0.221064,Phospholipid levels in small VLDL,CELSR2
1,109817590,-0.0951484,0.00495025,2.49977e-82,115082,ebi-a-GCST90092970,rs12740374,T,G,0.221064,Cholesteryl ester levels in small VLDL,CELSR2
1,109817590,-0.2104,0.011,2.99916e-82,,finn-b-RX_STATIN,rs12740374,T,G,0.2145,Statin medication,CELSR2
1,109817590,-0.0183231,0.000957477,1.37658e-81,337159,ukb-a-108,rs12740374,T,G,0.221518,Non-cancer illness code  self-reported: high cholesterol,CELSR2
1,109817590,-0.0908982,0.00479196,2.29985e-81,,met-d-Total_CE,rs12740374,T,G,0.221059,Total esterified cholesterol,CELSR2
1,109817590,-0.0910467,0.0047958,2.70023e-81,,met-d-IDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in IDL,CELSR2
1,109817590,-7.2666,0.381594,7.54571e-81,17373,ebi-a-GCST008037,rs12740374,T,G,0.206899,Low density lipoprotein cholesterol levels,CELSR2
1,109817590,-0.0910478,0.00479751,2.60016e-80,115082,ebi-a-GCST90092833,rs12740374,T,G,0.221064,Cholesteryl ester levels in IDL,CELSR2
1,109817590,-0.0909029,0.00479255,3.19963e-80,115082,ebi-a-GCST90092986,rs12740374,T,G,0.221064,Total esterified cholesterol levels,CELSR2
1,109817590,0.0442974,0.00235869,1.10002e-78,,ieu-b-107,rs12740374,T,G,0.220913,apolipoprotein A-I,CELSR2
1,109817590,-0.0914916,0.00496014,6.00067e-77,,met-d-M_VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in medium VLDL,CELSR2
1,109817590,0.0887005,0.00479191,1.69981e-76,115082,ebi-a-GCST90092853,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in large HDL,CELSR2
1,109817590,0.0451555,0.00244294,2.77524e-76,355859,ebi-a-GCST90013993,rs12740374,T,G,,Apolipoprotein A levels (UKB data field 30630),CELSR2
1,109817590,-0.0914653,0.00495519,4.49987e-76,115082,ebi-a-GCST90092924,rs12740374,T,G,0.221064,Phospholipid levels in medium VLDL,CELSR2
1,109817590,0.0878283,0.0048059,5.79963e-76,,met-d-L_HDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in large HDL,CELSR2
1,109817590,-0.089103,0.00495564,2.09991e-73,,met-d-M_VLDL_P,rs12740374,T,G,0.221059,Concentration of medium VLDL particles,CELSR2
1,109817590,-0.0819289,0.00461692,2.99985e-73,,met-d-L_HDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in large HDL,CELSR2
1,109817590,-0.0892367,0.00496939,5.79963e-73,,met-d-VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in VLDL,CELSR2
1,109817590,-0.0891177,0.00495031,1.9002e-72,115082,ebi-a-GCST90092923,rs12740374,T,G,0.221064,Concentration of medium VLDL particles,CELSR2
1,109817590,-0.250404,0.0141764,3.73594e-72,349222,ebi-a-GCST90104005,rs12740374,T,G,0.221896,Familial combined hyperlipidemia defined by Dutch criteria,CELSR2
1,109817590,-0.0891319,0.0049644,4.49987e-72,115082,ebi-a-GCST90092997,rs12740374,T,G,0.221064,Cholesteryl ester levels in VLDL,CELSR2
1,109817590,-0.0858537,0.00488167,6.90081e-71,,met-d-XS_VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in very small VLDL,CELSR2
1,109817590,-0.1064,0.0058,1.27292e-70,92475,ieu-a-782,rs12740374,T,G,0.2124,Total cholesterol,CELSR2
1,109817590,-0.0855402,0.0048176,1.59993e-70,115082,ebi-a-GCST90092969,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in small VLDL,CELSR2
1,109817590,0.0844752,0.00478729,1.10002e-69,115082,ebi-a-GCST90092979,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.081325,0.00461742,1.99986e-69,115082,ebi-a-GCST90092849,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in large HDL,CELSR2
1,109817590,-0.0845622,0.00483247,2.90001e-69,,met-d-S_VLDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0851144,0.00486034,1.20005e-68,115082,ebi-a-GCST90093032,rs12740374,T,G,0.221064,Free cholesterol levels in very small VLDL,CELSR2
1,109817590,0.0834599,0.0048057,2.09991e-68,,met-d-S_VLDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0861586,0.00493076,2.29985e-68,115082,ebi-a-GCST90093033,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.0843755,0.004902,2.70023e-68,,met-d-XS_VLDL_P,rs12740374,T,G,0.221059,Concentration of very small VLDL particles,CELSR2
1,109817590,-0.0855827,0.00493312,3.29989e-68,,met-d-XS_VLDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.0831842,0.00482191,1.50003e-67,,met-d-XS_VLDL_C,rs12740374,T,G,0.221059,Cholesterol in very small VLDL,CELSR2
1,109817590,-0.0826854,0.00481339,3.90032e-66,115082,ebi-a-GCST90093028,rs12740374,T,G,0.221064,Cholesterol levels in very small VLDL,CELSR2
1,109817590,-0.0840691,0.00489441,4.00037e-66,115082,ebi-a-GCST90092971,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0836641,0.00488115,7.39946e-66,115082,ebi-a-GCST90093035,rs12740374,T,G,0.221064,Concentration of very small VLDL particles,CELSR2
1,109817590,-7.29399,0.425997,1.01438e-65,17802,ebi-a-GCST008045,rs12740374,T,G,0.207594,Total cholesterol levels,CELSR2
1,109817590,-0.083292,0.0049008,3.59998e-65,,met-d-S_VLDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.080659,0.00479365,2.29985e-64,,met-d-XS_VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in very small VLDL,CELSR2
1,109817590,-0.080568,0.00476584,4.10015e-64,115082,ebi-a-GCST90092925,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0777907,0.00464452,9.09913e-64,,met-d-Sphingomyelins,rs12740374,T,G,0.221071,Sphingomyelins,CELSR2
1,109817590,-0.080171,0.00476654,2.29985e-63,,met-d-M_VLDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0802439,0.00478914,5.19996e-63,115082,ebi-a-GCST90093030,rs12740374,T,G,0.221064,Cholesteryl ester levels in very small VLDL,CELSR2
1,109817590,-0.0772128,0.00464049,3.59998e-62,115006,ebi-a-GCST90092982,rs12740374,T,G,0.221084,Sphingomyelin levels,CELSR2
1,109817590,0.046359,0.0027868,4.13523e-62,313387,ukb-d-30630_irnt,rs12740374,T,G,0.2215,Apoliprotein A,CELSR2
1,109817590,-0.0817061,0.00496101,1.10002e-61,,met-d-VLDL_C,rs12740374,T,G,0.221059,VLDL cholesterol,CELSR2
1,109817590,-0.0779713,0.00472697,4.00037e-61,115082,ebi-a-GCST90092977,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0815422,0.00495386,7.10068e-61,115082,ebi-a-GCST90092996,rs12740374,T,G,0.221064,VLDL cholesterol levels,CELSR2
1,109817590,-0.0769076,0.00475288,1.29987e-60,,met-d-S_VLDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0773372,0.00489855,5.19996e-58,,met-d-XS_VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in very small VLDL,CELSR2
1,109817590,-0.0768258,0.00488342,2.60016e-57,,met-d-XS_VLDL_L,rs12740374,T,G,0.221059,Total lipids in very small VLDL,CELSR2
1,109817590,-0.408779,0.0262508,2.69836e-57,349222,ebi-a-GCST90104007,rs12740374,T,G,0.221896,Familial combined hyperlipidemia defined by Mexico criteria,CELSR2
1,109817590,-0.0778089,0.00493394,2.99985e-57,,met-d-M_VLDL_L,rs12740374,T,G,0.221059,Total lipids in medium VLDL,CELSR2
1,109817590,-0.0750547,0.00471727,5.30029e-57,115082,ebi-a-GCST90092973,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0739725,0.00474328,2.80027e-56,,met-d-S_VLDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in small VLDL,CELSR2
1,109817590,-0.0287649,0.00182222,4.32514e-56,154702,ukb-a-488,rs12740374,T,G,0.221518,Medication for cholesterol  blood pressure or diabetes: Cholesterol lowering medication,CELSR2
1,109817590,-0.0777174,0.00492747,4.79954e-56,115082,ebi-a-GCST90092922,rs12740374,T,G,0.221064,Total lipid levels in medium VLDL,CELSR2
1,109817590,0.011924,0.00075586,4.81282e-56,313387,ukb-d-30630_raw,rs12740374,T,G,0.2215,Apoliprotein A,CELSR2
1,109817590,-0.0764455,0.00487081,1.59993e-55,115082,ebi-a-GCST90093036,rs12740374,T,G,0.221064,Phospholipid levels in very small VLDL,CELSR2
1,109817590,0.0355695,0.00236528,2.39994e-55,400754,ebi-a-GCST90025956,rs12740374,T,G,0.221111,HDL cholesterol levels,CELSR2
1,109817590,-0.076007,0.0048594,3.80014e-55,115082,ebi-a-GCST90093034,rs12740374,T,G,0.221064,Total lipid levels in very small VLDL,CELSR2
1,109817590,-0.0762694,0.00494077,5.10035e-55,,met-d-VLDL_P,rs12740374,T,G,0.221059,Concentration of VLDL particles,CELSR2
1,109817590,-0.1011,0.0065,5.66761e-55,296525,ebi-a-GCST005194,rs12740374,T,G,0.2214,Coronary artery disease,CELSR2
1,109817590,-0.0729239,0.00472338,8.99912e-54,115082,ebi-a-GCST90092921,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0758495,0.00492416,1.50003e-53,115082,ebi-a-GCST90093000,rs12740374,T,G,0.221064,Concentration of VLDL particles,CELSR2
1,109817590,-0.072627,0.00472353,1.9002e-53,,met-d-M_VLDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0118904,0.000787483,1.59993e-51,462933,ukb-b-11268,rs12740374,T,G,0.221164,Treatment/medication code: simvastatin,CELSR2
1,109817590,-0.0728653,0.00488041,2.09991e-50,115082,ebi-a-GCST90092945,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in small HDL,CELSR2
1,109817590,-0.072163,0.00491857,3.69999e-50,,met-d-S_VLDL_L,rs12740374,T,G,0.221059,Total lipids in small VLDL,CELSR2
1,109817590,-0.0716552,0.00490416,7.89951e-50,,met-d-S_VLDL_P,rs12740374,T,G,0.221059,Concentration of small VLDL particles,CELSR2
1,109817590,-0.0718855,0.00488801,2.70023e-49,,met-d-Total_L,rs12740374,T,G,0.221059,Total lipids in lipoprotein particles,CELSR2
1,109817590,-0.0710724,0.0048182,2.99985e-49,115082,ebi-a-GCST90092857,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in large LDL,CELSR2
1,109817590,-0.0715099,0.00491052,3.80014e-49,,met-d-S_HDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in small HDL,CELSR2
1,109817590,-0.0715984,0.00488053,1e-48,115082,ebi-a-GCST90092989,rs12740374,T,G,0.221064,Total lipid levels in lipoprotein particles,CELSR2
1,109817590,-0.071611,0.00489782,2.09991e-48,115082,ebi-a-GCST90092974,rs12740374,T,G,0.221064,Total lipid levels in small VLDL,CELSR2
1,109817590,-0.0711145,0.00488192,4.60045e-48,115082,ebi-a-GCST90092975,rs12740374,T,G,0.221064,Concentration of small VLDL particles,CELSR2
1,109817590,0.0680218,0.0046825,8.19974e-48,115082,ebi-a-GCST90092927,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.4269,0.0294,9.54993e-48,3301,prot-a-2284,rs12740374,T,G,0.22252,Group XIIB secretory phospholipase A2-like protein,CELSR2
1,109817590,-0.0698808,0.00484061,1.39991e-47,,met-d-L_LDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in large LDL,CELSR2
1,109817590,0.0674388,0.0046915,5.00035e-47,,met-d-M_VLDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0692155,0.00493111,9.09913e-46,,met-d-VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in VLDL,CELSR2
1,109817590,-0.20416,0.0144995,4.99804e-45,30463,eqtl-a-ENSG00000116299,rs12740374,T,G,0.210449,ENSG00000116299,CELSR2
1,109817590,-0.0669292,0.00492323,5.40008e-45,,met-d-L_LDL_TG,rs12740374,T,G,0.221059,Triglycerides in large LDL,CELSR2
1,109817590,-0.0689646,0.00492077,1.29987e-44,115082,ebi-a-GCST90092998,rs12740374,T,G,0.221064,Free cholesterol levels in VLDL,CELSR2
1,109817590,-0.0156573,0.00113025,1.20005e-43,249710,ukb-b-17805,rs12740374,T,G,0.220882,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Cholesterol lowering medication",CELSR2
1,109817590,-0.127,0.0092,2.33722e-43,29212,ieu-b-4845,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.00739058,0.000537723,5.50047e-43,463010,ukb-b-12651,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: E78.0 Pure hypercholesterolaemia,CELSR2
1,109817590,-0.063415,0.0046654,4.40048e-42,115082,ebi-a-GCST90092917,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.00576576,0.000425545,8.00018e-42,462933,ukb-b-10008,rs12740374,T,G,0.221164,Treatment/medication code: atorvastatin,CELSR2
1,109817590,-0.0655764,0.00486355,1.99986e-41,115082,ebi-a-GCST90092866,rs12740374,T,G,0.221064,Triglyceride levels in large LDL,CELSR2
1,109817590,-0.0627688,0.00467586,2.19989e-41,,met-d-M_VLDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in medium VLDL,CELSR2
1,109817590,0.0312804,0.00235129,3.19963e-40,435516,ebi-a-GCST90025989,rs12740374,T,G,0.221398,Insulin-like growth factor 1 levels,CELSR2
1,109817590,-0.0640555,0.00489002,3.40017e-40,,met-d-XL_VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in very large VLDL,CELSR2
1,109817590,-0.0640288,0.00490859,8.4004e-40,,met-d-L_VLDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in large VLDL,CELSR2
1,109817590,-0.0624855,0.00491362,1.29987e-39,,met-d-LDL_TG,rs12740374,T,G,0.221059,Triglycerides in LDL,CELSR2
1,109817590,0.138022,0.0140707,1.45881e-39,24515,ebi-a-GCST90101745,rs12740374,T,G,,Low density lipoprotein cholesterol levels,CELSR2
1,109817590,-0.0620425,0.00489524,2.29985e-39,,met-d-M_LDL_TG,rs12740374,T,G,0.221059,Triglycerides in medium LDL,CELSR2
1,109817590,-0.0640137,0.00488505,3.10027e-39,115082,ebi-a-GCST90093018,rs12740374,T,G,0.221064,Cholesteryl ester levels in very large VLDL,CELSR2
1,109817590,-0.0638698,0.00489945,7.59976e-39,115082,ebi-a-GCST90092870,rs12740374,T,G,0.221064,Cholesteryl ester levels in large VLDL,CELSR2
1,109817590,-0.384929,0.030245,8.63575e-39,349222,ebi-a-GCST90104003,rs12740374,T,G,0.221896,Familial combined hyperlipidemia defined by Brunzell criteria,CELSR2
1,109817590,0.0590296,0.00464553,1.99986e-38,,met-d-M_HDL_PL,rs12740374,T,G,0.221059,Phospholipids in medium HDL,CELSR2
1,109817590,0.0598285,0.0046357,4.19952e-38,115082,ebi-a-GCST90092900,rs12740374,T,G,0.221064,Phospholipid levels in medium HDL,CELSR2
1,109817590,-0.0596786,0.004647,9.49948e-38,115082,ebi-a-GCST90092919,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in medium VLDL,CELSR2
1,109817590,-0.0632955,0.0049443,1.59993e-37,115056,ebi-a-GCST90093007,rs12740374,T,G,0.221058,Cholesteryl esters to total lipids ratio in very large HDL,CELSR2
1,109817590,-0.0589475,0.00466359,5.50047e-37,,met-d-M_VLDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in medium VLDL,CELSR2
1,109817590,0.20468,0.01612,1.1272e-36,11103,ebi-a-GCST008593,rs12740374,T,G,,Low density lipoprotein cholesterol levels,CELSR2
1,109817590,0.0288629,0.00229106,2.19989e-36,,ieu-b-109,rs12740374,T,G,0.221008,HDL cholesterol,CELSR2
1,109817590,-0.0612143,0.00485897,2.19989e-36,115082,ebi-a-GCST90092890,rs12740374,T,G,0.221064,Triglyceride levels in LDL,CELSR2
1,109817590,-0.0116587,0.000926596,2.69215e-36,337159,ukb-a-121,rs12740374,T,G,0.221518,Treatment/medication code: simvastatin,CELSR2
1,109817590,-0.0619416,0.00496758,3.29989e-36,,met-d-XL_HDL_CE_pct,rs12740374,T,G,0.22105,Cholesteryl esters to total lipids ratio in very large HDL,CELSR2
1,109817590,-0.0608652,0.00484602,3.50026e-36,115082,ebi-a-GCST90092914,rs12740374,T,G,0.221064,Triglyceride levels in medium LDL,CELSR2
1,109817590,-0.0575533,0.00462788,5.60015e-36,,met-d-XL_HDL_FC,rs12740374,T,G,0.221059,Free cholesterol in very large HDL,CELSR2
1,109817590,-0.103964,0.00832224,8.19974e-36,547261,ebi-a-GCST005195,rs12740374,T,G,,Coronary artery disease,CELSR2
1,109817590,-0.0600107,0.00490743,2.29985e-35,,met-d-VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in VLDL,CELSR2
1,109817590,-0.0572091,0.00462896,4.40048e-35,115082,ebi-a-GCST90093008,rs12740374,T,G,0.221064,Free cholesterol levels in very large HDL,CELSR2
1,109817590,-0.0589449,0.00484565,3.29989e-34,,met-d-PUFA,rs12740374,T,G,0.221071,Polyunsaturated fatty acids,CELSR2
1,109817590,-0.0596906,0.00489545,3.40017e-34,115082,ebi-a-GCST90093001,rs12740374,T,G,0.221064,Phospholipid levels in VLDL,CELSR2
1,109817590,0.0583109,0.00480963,7.89951e-34,114160,ebi-a-GCST90093027,rs12740374,T,G,0.220936,Triglycerides to total lipids ratio in very large VLDL,CELSR2
1,109817590,0.0285275,0.00235541,9.18121e-34,357810,ebi-a-GCST90014007,rs12740374,T,G,,High density lipoprotein cholesterol levels (UKB data field 30760),CELSR2
1,109817590,-0.0582124,0.00482137,1.50003e-33,115006,ebi-a-GCST90092939,rs12740374,T,G,0.221084,Polyunsaturated fatty acid levels,CELSR2
1,109817590,0.0297407,0.00246724,1.84247e-33,387834,ebi-a-GCST90014008,rs12740374,T,G,,IGF 1 (UKB data field 30770),CELSR2
1,109817590,0.0574953,0.00481734,1e-32,,met-d-XL_VLDL_TG_pct,rs12740374,T,G,0.220936,Triglycerides to total lipids ratio in very large VLDL,CELSR2
1,109817590,0.0569046,0.00477919,1.10002e-32,115082,ebi-a-GCST90092967,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in small LDL,CELSR2
1,109817590,-0.0572469,0.00485222,1.50003e-32,,met-d-Omega_6,rs12740374,T,G,0.221071,Omega-6 fatty acids,CELSR2
1,109817590,-0.00335496,0.000282999,2.02722e-32,1159871,ebi-a-GCST90026654,rs12740374,T,G,0.2146,Estimated glomerular filtration rate (creatinine),CELSR2
1,109817590,0.0280957,0.00238103,2.19989e-32,437660,ebi-a-GCST90025946,rs12740374,T,G,0.221363,Creatinine levels,CELSR2
1,109817590,0.0556758,0.00481421,5.79963e-32,,met-d-S_LDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in small LDL,CELSR2
1,109817590,-0.0570049,0.00484875,6.4998e-32,115006,ebi-a-GCST90092933,rs12740374,T,G,0.221084,Omega-6 fatty acid levels,CELSR2
1,109817590,0.0309,0.0026,7.12689e-32,315133,ebi-a-GCST90018956,rs12740374,T,G,0.192392,HDL cholesterol,CELSR2
1,109817590,-0.105831,0.009013,8.39073e-32,58825,ebi-a-GCST011365,rs12740374,T,G,0.211569,Myocardial infarction,CELSR2
1,109817590,-0.0155709,0.00133217,1.49968e-31,180203,ukb-a-448,rs12740374,T,G,0.221518,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: Cholesterol lowering medication,CELSR2
1,109817590,-0.0564521,0.0048555,2.99985e-31,115071,ebi-a-GCST90092869,rs12740374,T,G,0.221055,Cholesterol to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.0542092,0.00466485,3.19963e-31,115082,ebi-a-GCST90092845,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in large HDL,CELSR2
1,109817590,-0.108166,0.00932469,4.10015e-31,72866,ebi-a-GCST90018741,rs12740374,T,G,0.070493,LDL cholesterol,CELSR2
1,109817590,0.0571301,0.00494708,5.19996e-31,,met-d-L_VLDL_TG_pct,rs12740374,T,G,0.221049,Triglycerides to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.0564513,0.00485427,6.70039e-31,,met-d-L_VLDL_C_pct,rs12740374,T,G,0.221049,Cholesterol to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.0535507,0.00468244,6.70039e-31,,met-d-L_HDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in large HDL,CELSR2
1,109817590,-0.0578161,0.0050079,7.8001e-31,111638,ebi-a-GCST90093043,rs12740374,T,G,0.221399,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,-0.0578175,0.00500837,8.30042e-31,,met-d-XXL_VLDL_CE_pct,rs12740374,T,G,0.221399,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,0.0566371,0.0049455,2.29985e-30,115071,ebi-a-GCST90092879,rs12740374,T,G,0.221055,Triglycerides to total lipids ratio in large VLDL,CELSR2
1,109817590,0.0198848,0.00174031,3.10027e-30,209638,ukb-b-12014,rs12740374,T,G,0.221547,"Medication for cholesterol, blood pressure or diabetes: None of the above",CELSR2
1,109817590,0.0244,0.0021,5.70033e-30,344104,ebi-a-GCST90018979,rs12740374,T,G,0.176224,Serum creatinine levels,CELSR2
1,109817590,0.031133,0.0027407,6.72357e-30,315133,ukb-d-30760_irnt,rs12740374,T,G,0.2216,HDL cholesterol,CELSR2
1,109817590,-0.0538133,0.00475072,9.60064e-30,114160,ebi-a-GCST90093019,rs12740374,T,G,0.220936,Cholesteryl esters to total lipids ratio in very large VLDL,CELSR2
1,109817590,0.170368,0.0150267,1.25228e-29,11103,ebi-a-GCST008594,rs12740374,T,G,,Total cholesterol levels,CELSR2
1,109817590,-0.056008,0.00497929,2.39994e-29,115082,ebi-a-GCST90092859,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in large LDL,CELSR2
1,109817590,0.0507105,0.00461229,3.50026e-29,,met-d-M_HDL_L,rs12740374,T,G,0.221059,Total lipids in medium HDL,CELSR2
1,109817590,-0.202908,0.0181007,3.64334e-29,178726,ebi-a-GCST90018769,rs12740374,T,G,0.0718384,Medication use (HMG CoA reductase inhibitors),CELSR2
1,109817590,-0.0555479,0.0049834,4.70002e-29,,met-d-L_LDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in large LDL,CELSR2
1,109817590,0.011775,0.0010547,6.13056e-29,315133,ukb-d-30760_raw,rs12740374,T,G,0.2216,HDL cholesterol,CELSR2
1,109817590,0.0514076,0.00460519,6.20012e-29,115082,ebi-a-GCST90092898,rs12740374,T,G,0.221064,Total lipid levels in medium HDL,CELSR2
1,109817590,-0.00556256,0.000500477,1.07845e-28,337159,ukb-a-176,rs12740374,T,G,0.221518,Treatment/medication code: atorvastatin,CELSR2
1,109817590,-0.0182852,0.00255288,1.10002e-28,348806,ebi-a-GCST90025993,rs12740374,T,G,0.220798,Lipoprotein (a) levels,CELSR2
1,109817590,0.025875,0.0023314,1.28914e-28,344104,ukb-d-30700_irnt,rs12740374,T,G,0.22181,Creatinine,CELSR2
1,109817590,-0.0533242,0.00485933,1.29987e-28,,met-d-L_VLDL_C,rs12740374,T,G,0.221059,Cholesterol in large VLDL,CELSR2
1,109817590,-0.0529547,0.00476703,1.39991e-28,,met-d-XL_VLDL_CE_pct,rs12740374,T,G,0.220936,Cholesteryl esters to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.112,0.01013,2.12178e-28,,bbj-a-31,rs12740374,T,G,0.0719,Low-density-lipoprotein cholesterol,CELSR2
1,109817590,0.0229829,0.00208094,2.33077e-28,389678,ebi-a-GCST90014001,rs12740374,T,G,,Creatinine levels (UKB data field 30700),CELSR2
1,109817590,-0.0481065,0.00447027,3.10027e-28,,met-d-XL_HDL_P,rs12740374,T,G,0.221059,Concentration of very large HDL particles,CELSR2
1,109817590,-0.0532475,0.00484518,4.30031e-28,115082,ebi-a-GCST90092889,rs12740374,T,G,0.221064,Average diameter for LDL particles,CELSR2
1,109817590,-0.0531556,0.00484978,5.90065e-28,115082,ebi-a-GCST90092868,rs12740374,T,G,0.221064,Cholesterol levels in large VLDL,CELSR2
1,109817590,-0.0520074,0.0047509,6.90081e-28,114160,ebi-a-GCST90093017,rs12740374,T,G,0.220936,Cholesterol to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.1161,0.0106,7.0648e-28,470931,ebi-a-GCST90018793,rs12740374,T,G,0.183218,Angina pectoris,CELSR2
1,109817590,-0.051526,0.00472546,1.10002e-27,115056,ebi-a-GCST90093005,rs12740374,T,G,0.221058,Cholesterol to total lipids ratio in very large HDL,CELSR2
1,109817590,0.0528179,0.00486262,1.69981e-27,115082,ebi-a-GCST90092915,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in medium LDL,CELSR2
1,109817590,-0.0480365,0.00447924,1.80011e-27,,met-d-XL_HDL_C,rs12740374,T,G,0.221059,Cholesterol in very large HDL,CELSR2
1,109817590,-0.0522463,0.00487333,2.90001e-27,,met-d-LA,rs12740374,T,G,0.221071,Linoleic acid,CELSR2
1,109817590,-0.0742586,0.00688368,3.90032e-27,135808,ebi-a-GCST90018754,rs12740374,T,G,0.071605,Total cholesterol levels,CELSR2
1,109817590,-0.0534822,0.00492421,4.40048e-27,,met-d-L_VLDL_FC_pct,rs12740374,T,G,0.221049,Free cholesterol to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.0530297,0.00492024,4.40048e-27,115071,ebi-a-GCST90092873,rs12740374,T,G,0.221055,Free cholesterol to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.0524547,0.00487511,5.30029e-27,115006,ebi-a-GCST90092880,rs12740374,T,G,0.221084,Linoleic acid levels,CELSR2
1,109817590,-0.08065,0.007513,6.90876e-27,,bbj-a-54,rs12740374,T,G,0.0719,Total cholesterol,CELSR2
1,109817590,-0.0526531,0.00485894,7.50067e-27,,met-d-LDL_size,rs12740374,T,G,0.221059,Average diameter for LDL particles,CELSR2
1,109817590,-0.0511615,0.00476473,7.89951e-27,,met-d-XL_VLDL_C_pct,rs12740374,T,G,0.220936,Cholesterol to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.0477359,0.00446991,1.29987e-26,115082,ebi-a-GCST90093011,rs12740374,T,G,0.221064,Concentration of very large HDL particles,CELSR2
1,109817590,-0.134548,0.012418,1.66994e-26,19270,met-c-881,rs12740374,T,G,0.216125,Cholesterol esters in large VLDL,CELSR2
1,109817590,-0.0477394,0.00448045,1.69981e-26,115082,ebi-a-GCST90093004,rs12740374,T,G,0.221064,Cholesterol levels in very large HDL,CELSR2
1,109817590,-0.128763,0.011921,1.93999e-26,21552,met-c-882,rs12740374,T,G,0.218925,Free cholesterol in large LDL,CELSR2
1,109817590,-0.0501105,0.00474648,2.99985e-26,,met-d-XL_HDL_C_pct,rs12740374,T,G,0.22105,Cholesterol to total lipids ratio in very large HDL,CELSR2
1,109817590,-0.0502054,0.00475479,4.60045e-26,115071,ebi-a-GCST90092871,rs12740374,T,G,0.221055,Cholesteryl esters to total lipids ratio in large VLDL,CELSR2
1,109817590,-0.133287,0.01242,4.97966e-26,19270,met-c-905,rs12740374,T,G,0.216125,Cholesterol esters in medium LDL,CELSR2
1,109817590,-0.127518,0.011917,5.72005e-26,21549,met-c-880,rs12740374,T,G,0.218922,Total cholesterol in large LDL,CELSR2
1,109817590,-0.0518567,0.00493216,7.39946e-26,115082,ebi-a-GCST90092836,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in IDL,CELSR2
1,109817590,0.0512693,0.00490583,9.20026e-26,,met-d-M_LDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in medium LDL,CELSR2
1,109817590,-0.126845,0.011904,1.05003e-25,21556,met-c-895,rs12740374,T,G,0.21893,Total cholesterol in LDL,CELSR2
1,109817590,-0.0513233,0.00493163,1.20005e-25,,met-d-IDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in IDL,CELSR2
1,109817590,0.0491432,0.00469336,1.20005e-25,115082,ebi-a-GCST90093039,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.132191,0.012425,1.27997e-25,19270,met-c-883,rs12740374,T,G,0.216125,Total lipids in large LDL,CELSR2
1,109817590,0.029168,0.0027941,1.65463e-25,342439,ukb-d-30770_irnt,rs12740374,T,G,0.22182,IGF-1,CELSR2
1,109817590,-0.113277,0.0108889,2.40215e-25,352063,ebi-a-GCST90013868,rs12740374,T,G,,Coronary artery disease (SPA correction),CELSR2
1,109817590,-0.125906,0.01191,2.49e-25,21556,met-c-904,rs12740374,T,G,0.21893,Total cholesterol in medium LDL,CELSR2
1,109817590,-0.0500212,0.00475437,2.49977e-25,,met-d-L_VLDL_CE_pct,rs12740374,T,G,0.221049,Cholesteryl esters to total lipids ratio in large VLDL,CELSR2
1,109817590,0.107826,0.0142008,2.95053e-25,24612,ebi-a-GCST90101747,rs12740374,T,G,,Total cholesterol levels,CELSR2
1,109817590,-0.114668,0.011129,3.11458e-25,352063,ebi-a-GCST90013864,rs12740374,T,G,,Coronary artery disease (Firth correction),CELSR2
1,109817590,-0.0482776,0.00491034,8.49963e-25,,met-d-IDL_TG,rs12740374,T,G,0.221059,Triglycerides in IDL,CELSR2
1,109817590,0.16293,0.015847,8.59211e-25,342439,ukb-d-30770_raw,rs12740374,T,G,0.22182,IGF-1,CELSR2
1,109817590,0.0481177,0.00471844,1.20005e-24,,met-d-XS_VLDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.129437,0.012427,1.22011e-24,19270,met-c-884,rs12740374,T,G,0.216125,Concentration of large LDL particles,CELSR2
1,109817590,-0.1781,0.01741,1.46487e-24,,ukb-e-30640_CSA,rs12740374,T,G,0.7381,Apolipoprotein B,CELSR2
1,109817590,-0.0476466,0.00473123,1.69981e-24,,met-d-Total_PL,rs12740374,T,G,0.221059,Total phospholipids in lipoprotein particles,CELSR2
1,109817590,-0.0110815,0.00109551,1.99986e-24,477807,ebi-a-GCST90029019,rs12740374,T,G,0.221282,Cardiovascular disease,CELSR2
1,109817590,-0.0446006,0.0044486,2.60016e-24,,met-d-XL_HDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in very large HDL,CELSR2
1,109817590,-0.0108442,0.00107875,2.70023e-24,484598,ebi-a-GCST90038595,rs12740374,T,G,0.221701,Cardiovascular disease,CELSR2
1,109817590,-0.0486099,0.00485257,2.80027e-24,,met-d-XL_VLDL_C,rs12740374,T,G,0.221059,Cholesterol in very large VLDL,CELSR2
1,109817590,-0.122541,0.011909,3.25987e-24,21553,met-c-924,rs12740374,T,G,0.218926,Total cholesterol in small LDL,CELSR2
1,109817590,-0.128162,0.012419,3.51965e-24,19270,met-c-906,rs12740374,T,G,0.216125,Total lipids in medium LDL,CELSR2
1,109817590,0.0493122,0.00497175,3.90032e-24,,met-d-L_LDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in large LDL,CELSR2
1,109817590,-0.0033,3e-04,4.05789e-24,165726,ebi-a-GCST90103633,rs12740374,T,G,0.2157,Estimated glomerular filtration rate (creatinine),CELSR2
1,109817590,-0.0033,3e-04,5.27351e-24,1004040,ebi-a-GCST90103634,rs12740374,T,G,0.2207,Estimated glomerular filtration rate (creatinine),CELSR2
1,109817590,-0.1837,0.0182,6.06038e-24,,ukb-e-LDLC_CSA,rs12740374,T,G,0.7373,"LDL direct, adjusted by medication",CELSR2
1,109817590,0.048419,0.00482302,1e-23,115082,ebi-a-GCST90092867,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in large LDL,CELSR2
1,109817590,-0.126591,0.012433,1.10002e-23,19270,met-c-867,rs12740374,T,G,0.216125,Total cholesterol in IDL,CELSR2
1,109817590,-0.0484733,0.00484576,1.50003e-23,115082,ebi-a-GCST90093016,rs12740374,T,G,0.221064,Cholesterol levels in very large VLDL,CELSR2
1,109817590,-0.0477834,0.00478403,1.69981e-23,115082,ebi-a-GCST90092961,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in small LDL,CELSR2
1,109817590,-0.00645425,0.000646441,1.79846e-23,361194,ukb-d-I9_IHD,rs12740374,T,G,0.221809,"Ischaemic heart disease, wide definition",CELSR2
1,109817590,-0.047115,0.00472222,1.9002e-23,115082,ebi-a-GCST90092991,rs12740374,T,G,0.221064,Total phospholipid levels in lipoprotein particles,CELSR2
1,109817590,0.145115,0.0145498,1.98884e-23,25923,eqtl-a-ENSG00000168765,rs12740374,T,G,0.210449,ENSG00000168765,CELSR2
1,109817590,-0.2979,0.0299,2.0893e-23,3301,prot-a-326,rs12740374,T,G,0.22252,Carbonic anhydrase-related protein 10,CELSR2
1,109817590,-0.0442997,0.00444984,2.39994e-23,115082,ebi-a-GCST90093006,rs12740374,T,G,0.221064,Cholesteryl ester levels in very large HDL,CELSR2
1,109817590,-0.1203,0.0121,2.88403e-23,461823,ebi-a-GCST90018877,rs12740374,T,G,0.182548,Myocardial infarction,CELSR2
1,109817590,-0.125431,0.01242,3.10027e-23,19270,met-c-907,rs12740374,T,G,0.216125,Concentration of medium LDL particles,CELSR2
1,109817590,-0.512236,0.048708,3.48337e-23,1323,ebi-a-GCST90010219,rs12740374,T,G,0.201,Granulins levels,CELSR2
1,109817590,-0.119845,0.011931,4.00959e-23,21547,met-c-885,rs12740374,T,G,0.21892,Phospholipids in large LDL,CELSR2
1,109817590,-0.113549,0.011482,4.6302e-23,42457,ebi-a-GCST003116,rs12740374,T,G,0.213262,Coronary artery disease,CELSR2
1,109817590,-0.113549,0.011482,4.6302e-23,184305,ieu-a-7,rs12740374,T,G,0.213262,Coronary heart disease,CELSR2
1,109817590,-0.117437,0.011941,7.97076e-23,397554,ebi-a-GCST90013936,rs12740374,T,G,,Angina (SPA correction),CELSR2
1,109817590,0.0487532,0.0049593,8.30042e-23,115082,ebi-a-GCST90092865,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in large LDL,CELSR2
1,109817590,-0.0491304,0.00497968,8.49963e-23,,met-d-XL_VLDL_PL_pct,rs12740374,T,G,0.220936,Phospholipids to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.0488215,0.00497584,1e-22,114160,ebi-a-GCST90093025,rs12740374,T,G,0.220936,Phospholipids to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.11909,0.0122448,1.05657e-22,397554,ebi-a-GCST90013886,rs12740374,T,G,,Angina (Firth correction),CELSR2
1,109817590,0.044031,0.00457707,1.10002e-22,,met-d-M_HDL_P,rs12740374,T,G,0.221059,Concentration of medium HDL particles,CELSR2
1,109817590,0.34102,0.0348026,1.14051e-22,400,ebi-a-GCST90085768,rs12740374,T,G,,Progranulin plasma levels,CELSR2
1,109817590,-0.0466685,0.00481514,1.20005e-22,,met-d-S_LDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in small LDL,CELSR2
1,109817590,-0.00530767,0.000542537,1.33999e-22,361194,ukb-d-I9_CORATHER,rs12740374,T,G,0.221809,Coronary atherosclerosis,CELSR2
1,109817590,-0.1164,0.0119,1.4481e-22,343026,ebi-a-GCST90018915,rs12740374,T,G,0.173605,Stable angina pectoris,CELSR2
1,109817590,0.0446624,0.00457104,1.50003e-22,115082,ebi-a-GCST90092899,rs12740374,T,G,0.221064,Concentration of medium HDL particles,CELSR2
1,109817590,-0.118024,0.011939,1.71989e-22,21556,met-c-868,rs12740374,T,G,0.21893,Free cholesterol in IDL,CELSR2
1,109817590,0.141483,0.0145523,2.42493e-22,31212,eqtl-a-ENSG00000134202,rs12740374,T,G,0.210449,ENSG00000134202,CELSR2
1,109817590,-0.0459034,0.00472387,2.49977e-22,115082,ebi-a-GCST90092847,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in large HDL,CELSR2
1,109817590,-0.0468124,0.00484767,4.60045e-22,115082,ebi-a-GCST90092841,rs12740374,T,G,0.221064,Triglyceride levels in IDL,CELSR2
1,109817590,-0.069,0.0072,5.78762e-22,153639,ebi-a-GCST90018982,rs12740374,T,G,0.140867,Medication use (antithrombotic agents),CELSR2
1,109817590,-0.0461589,0.00487133,7.10068e-22,,met-d-VLDL_L,rs12740374,T,G,0.221059,Total lipids in VLDL,CELSR2
1,109817590,0.0468583,0.00487144,8.10028e-22,,met-d-L_LDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in large LDL,CELSR2
1,109817590,-0.0449349,0.00475349,1.59993e-21,,met-d-L_HDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in large HDL,CELSR2
1,109817590,-0.120212,0.012442,1.77011e-21,19270,met-c-869,rs12740374,T,G,0.216125,Total lipids in IDL,CELSR2
1,109817590,-0.0458193,0.00485902,4.10015e-21,115082,ebi-a-GCST90092999,rs12740374,T,G,0.221064,Total lipid levels in VLDL,CELSR2
1,109817590,-0.04565,0.00485437,5.30029e-21,115082,ebi-a-GCST90092947,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in small HDL,CELSR2
1,109817590,0.0189527,0.00203842,1.45278e-20,154702,ukb-a-489,rs12740374,T,G,0.221518,Medication for cholesterol  blood pressure or diabetes: None of the above,CELSR2
1,109817590,-0.112502,0.011921,1.65997e-20,21555,met-c-908,rs12740374,T,G,0.218929,Phospholipids in medium LDL,CELSR2
1,109817590,-0.111948,0.011945,2.22024e-20,21556,met-c-871,rs12740374,T,G,0.21893,Phospholipids in IDL,CELSR2
1,109817590,-0.0231675,0.00257124,4.10015e-20,400938,ebi-a-GCST90025992,rs12740374,T,G,0.221096,Serum albumin levels,CELSR2
1,109817590,-0.115891,0.012444,4.6505e-20,19270,met-c-870,rs12740374,T,G,0.216125,Concentration of IDL particles,CELSR2
1,109817590,0.0435856,0.00476177,5.50047e-20,115082,ebi-a-GCST90092842,rs12740374,T,G,0.221064,Triglycerides to total lipids ratio in IDL,CELSR2
1,109817590,-0.115575,0.012419,5.53988e-20,19270,met-c-925,rs12740374,T,G,0.216125,Total lipids in small LDL,CELSR2
1,109817590,-0.0440007,0.0048994,7.19946e-20,,met-d-S_HDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in small HDL,CELSR2
1,109817590,0.0411524,0.00458907,8.80035e-20,,met-d-M_HDL_CE,rs12740374,T,G,0.221059,Cholesteryl esters in medium HDL,CELSR2
1,109817590,0.0415388,0.00458726,1.39991e-19,115082,ebi-a-GCST90092894,rs12740374,T,G,0.221064,Cholesteryl ester levels in medium HDL,CELSR2
1,109817590,-0.0436516,0.00480342,1.69981e-19,,met-d-DHA,rs12740374,T,G,0.221071,Docosahexaenoic acid,CELSR2
1,109817590,-0.1474,0.0163,1.85695e-19,,finn-b-E4_LIPOPROT,rs12740374,T,G,0.2143,Disorders of lipoprotein metabolism and other lipidaemias,CELSR2
1,109817590,-0.0422566,0.00471867,3.40017e-19,115006,ebi-a-GCST90092816,rs12740374,T,G,0.221084,Docosahexaenoic acid levels,CELSR2
1,109817590,-0.0422842,0.0048058,3.80014e-19,,met-d-L_VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in large VLDL,CELSR2
1,109817590,0.0422392,0.00479923,8.10028e-19,,met-d-IDL_TG_pct,rs12740374,T,G,0.221059,Triglycerides to total lipids ratio in IDL,CELSR2
1,109817590,-0.0414643,0.00468435,8.60003e-19,115082,ebi-a-GCST90093029,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in very small VLDL,CELSR2
1,109817590,0.0215461,0.0024352,8.931e-19,496946,ebi-a-GCST90000618,rs12740374,T,G,0.223491,Serum 25-Hydroxyvitamin D levels,CELSR2
1,109817590,-0.111387,0.012426,1.16011e-18,19270,met-c-926,rs12740374,T,G,0.216125,Concentration of small LDL particles,CELSR2
1,109817590,-0.00350008,0.000397815,1.39991e-18,463010,ukb-b-1668,rs12740374,T,G,0.221167,Diagnoses - main ICD10: I25.1 Atherosclerotic heart disease,CELSR2
1,109817590,-0.2635,0.03,1.51356e-18,3301,prot-a-1112,rs12740374,T,G,0.22252,Four-jointed box protein 1,CELSR2
1,109817590,-0.0420874,0.0047961,1.69981e-18,115082,ebi-a-GCST90092872,rs12740374,T,G,0.221064,Free cholesterol levels in large VLDL,CELSR2
1,109817590,-0.0404501,0.00470698,4.60045e-18,,met-d-XS_VLDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in very small VLDL,CELSR2
1,109817590,0.0401553,0.00471317,5.40008e-18,,met-d-M_HDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in medium HDL,CELSR2
1,109817590,0.0388552,0.0045721,5.60015e-18,,met-d-M_HDL_C,rs12740374,T,G,0.221059,Cholesterol in medium HDL,CELSR2
1,109817590,-0.11127,0.0128803,5.70033e-18,17505,ebi-a-GCST011364,rs12740374,T,G,0.222239,Myocardial infarction,CELSR2
1,109817590,0.0406165,0.00471167,6.70039e-18,115082,ebi-a-GCST90092901,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in medium HDL,CELSR2
1,109817590,0.0393094,0.00456955,7.8001e-18,115082,ebi-a-GCST90092892,rs12740374,T,G,0.221064,Cholesterol levels in medium HDL,CELSR2
1,109817590,0.0384566,0.0044818,9.3994e-18,115082,ebi-a-GCST90092827,rs12740374,T,G,0.221064,Phospholipid levels in HDL,CELSR2
1,109817590,-0.0707,0.0082,9.78814e-18,112010,ebi-a-GCST90018995,rs12740374,T,G,0.128745,Medication use (salicylic acid and derivatives),CELSR2
1,109817590,0.037569,0.00449147,1.20005e-17,,met-d-HDL_PL,rs12740374,T,G,0.221059,Phospholipids in HDL,CELSR2
1,109817590,-0.0411674,0.00481298,1.20005e-17,114160,ebi-a-GCST90093021,rs12740374,T,G,0.220936,Free cholesterol to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.00360371,0.00042519,2.09991e-17,484598,ebi-a-GCST90038609,rs12740374,T,G,0.221701,Angina,CELSR2
1,109817590,0.0198925,0.00235246,2.76567e-17,417580,ebi-a-GCST90000615,rs12740374,T,G,0.223623,Serum 25-Hydroxyvitamin D levels,CELSR2
1,109817590,-0.00515987,0.000610514,2.90001e-17,445693,ukb-b-20300,rs12740374,T,G,0.221189,Treatment speciality of consultant (recoded): Cardiology,CELSR2
1,109817590,0.0207723,0.0025314,3.59998e-17,418691,ebi-a-GCST90025967,rs12740374,T,G,0.223334,Vitamin D levels,CELSR2
1,109817590,0.01982,0.0023529,3.64922e-17,417580,ebi-a-GCST90000616,rs12740374,T,G,0.223598,Serum 25-Hydroxyvitamin D levels,CELSR2
1,109817590,-0.00520624,0.000618769,3.69999e-17,484598,ebi-a-GCST90038605,rs12740374,T,G,0.221701,Cardiac problem,CELSR2
1,109817590,-0.0403818,0.00481878,4.70002e-17,,met-d-XL_VLDL_FC_pct,rs12740374,T,G,0.220936,Free cholesterol to total lipids ratio in very large VLDL,CELSR2
1,109817590,-0.1793,0.02141,5.50174e-17,,ukb-e-30640_AFR,rs12740374,T,G,0.744,Apolipoprotein B,CELSR2
1,109817590,-0.101083,0.011951,5.64937e-17,21488,met-c-933,rs12740374,T,G,0.218855,Serum total cholesterol,CELSR2
1,109817590,-0.0408591,0.0049289,5.79963e-17,,met-d-Total_FA,rs12740374,T,G,0.221071,Total fatty acids,CELSR2
1,109817590,-0.0392685,0.00482706,6.20012e-17,,met-d-M_VLDL_TG,rs12740374,T,G,0.221059,Triglycerides in medium VLDL,CELSR2
1,109817590,0.0196043,0.0023575,9.12011e-17,417580,ebi-a-GCST90000617,rs12740374,T,G,0.223623,Serum 25-Hydroxyvitamin D levels,CELSR2
1,109817590,-0.0203014,0.00253015,1.59993e-16,400482,ebi-a-GCST90025995,rs12740374,T,G,0.221124,Serum total protein level,CELSR2
1,109817590,0.0186,0.0023,1.71317e-16,450243,ebi-a-GCST90000025,rs12740374,T,G,0.2214,Appendicular lean mass,CELSR2
1,109817590,-0.00178029,0.000216555,1.99986e-16,462933,ukb-b-12465,rs12740374,T,G,0.221164,Operation code: coronary artery bypass grafts (cabg),CELSR2
1,109817590,0.0195356,0.00238927,2.92483e-16,417580,ebi-a-GCST90000614,rs12740374,T,G,0.223598,Serum 25-Hydroxyvitamin D levels,CELSR2
1,109817590,-0.00357792,0.000438293,3.29989e-16,462933,ukb-b-8650,rs12740374,T,G,0.221164,"Non-cancer illness code, self-reported: angina",CELSR2
1,109817590,-0.0399806,0.00490075,3.40017e-16,115006,ebi-a-GCST90092987,rs12740374,T,G,0.221084,Total fatty acid levels,CELSR2
1,109817590,-0.102778,0.012456,4.08037e-16,19270,met-c-955,rs12740374,T,G,0.216125,Phospholipids in very small VLDL,CELSR2
1,109817590,0.018837,0.002324,5.25654e-16,,ieu-b-4812,rs12740374,T,G,0.223883,25 hydroxyvitamin D level,CELSR2
1,109817590,-0.35832,0.0452381,5.50935e-16,349222,ebi-a-GCST90104004,rs12740374,T,G,0.221896,Familial combined hyperlipidemia defined by Goldstein criteria,CELSR2
1,109817590,-0.0389796,0.00481513,5.70033e-16,115082,ebi-a-GCST90092926,rs12740374,T,G,0.221064,Triglyceride levels in medium VLDL,CELSR2
1,109817590,-0.039932,0.00498128,8.30042e-16,,met-d-XXL_VLDL_C_pct,rs12740374,T,G,0.221399,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,-0.0376996,0.00484683,8.9002e-16,,met-d-S_LDL_TG,rs12740374,T,G,0.221059,Triglycerides in small LDL,CELSR2
1,109817590,-0.00290254,0.000361606,1.10002e-15,484598,ebi-a-GCST90038610,rs12740374,T,G,0.221701,Myocardial infarction,CELSR2
1,109817590,-0.14,0.02,1.1471e-15,9961,ebi-a-GCST005068,rs12740374,T,G,,LDL cholesterol,CELSR2
1,109817590,-0.0398967,0.00498135,1.20005e-15,111638,ebi-a-GCST90093041,rs12740374,T,G,0.221399,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,-0.133876,0.0258155,1.32465e-15,10389,ebi-a-GCST90101741,rs12740374,T,G,0.270982,Low density lipoprotein cholesterol levels,CELSR2
1,109817590,-0.100613,0.0126156,1.5202e-15,171875,ieu-a-798,rs12740374,T,G,0.200899,Myocardial infarction,CELSR2
1,109817590,0.0343,0.0041,1.68694e-15,94595,ebi-a-GCST002223,rs12740374,T,G,,HDL cholesterol,CELSR2
1,109817590,0.0343,0.0041,1.68694e-15,186888,ieu-a-299,rs12740374,T,G,0.2124,HDL cholesterol,CELSR2
1,109817590,0.0386652,0.00487105,2.09991e-15,115082,ebi-a-GCST90092902,rs12740374,T,G,0.221064,Triglyceride levels in medium HDL,CELSR2
1,109817590,-0.0212923,0.00270043,3.15065e-15,357968,ebi-a-GCST90013990,rs12740374,T,G,,Albumin levels (UKB data field 30600),CELSR2
1,109817590,-0.00364959,0.000463613,3.49865e-15,337199,ukb-a-534,rs12740374,T,G,0.221518,Diagnoses - main ICD10: I25 Chronic ischaemic heart disease,CELSR2
1,109817590,-0.0346382,0.00446424,4.30031e-15,,met-d-XL_HDL_L,rs12740374,T,G,0.221059,Total lipids in very large HDL,CELSR2
1,109817590,-0.00149391,0.000190634,4.60045e-15,462933,ukb-b-6474,rs12740374,T,G,0.221164,Treatment/medication code: ezetimibe,CELSR2
1,109817590,-0.118061,0.014949,5.03037e-15,13495,met-c-853,rs12740374,T,G,0.213254,Free cholesterol to esterified cholesterol ratio,CELSR2
1,109817590,-0.00342564,0.000440074,7.00003e-15,461880,ukb-b-8468,rs12740374,T,G,0.221186,Vascular/heart problems diagnosed by doctor: Angina,CELSR2
1,109817590,0.0375952,0.00490721,1e-14,,met-d-M_HDL_TG,rs12740374,T,G,0.221059,Triglycerides in medium HDL,CELSR2
1,109817590,0.2326,0.0301,1.02329e-14,3301,prot-a-2033,rs12740374,T,G,0.22252,Neogenin,CELSR2
1,109817590,0.0190608,0.00246967,1.20005e-14,408112,ebi-a-GCST90002397,rs12740374,T,G,0.221719,Mean spheric corpuscular volume,CELSR2
1,109817590,-0.2313,0.0301,1.41254e-14,3301,prot-a-1332,rs12740374,T,G,0.22252,Hemojuvelin,CELSR2
1,109817590,-0.0359255,0.00479732,1.80011e-14,,met-d-L_VLDL_P,rs12740374,T,G,0.221059,Concentration of large VLDL particles,CELSR2
1,109817590,-0.0380018,0.00489096,1.99986e-14,,met-d-Omega_3,rs12740374,T,G,0.221071,Omega-3 fatty acids,CELSR2
1,109817590,-0.0357986,0.00480148,2.19989e-14,,met-d-L_VLDL_L,rs12740374,T,G,0.221059,Total lipids in large VLDL,CELSR2
1,109817590,-0.00644191,0.000843336,2.19989e-14,462933,ukb-b-8755,rs12740374,T,G,0.221164,Treatment/medication code: aspirin,CELSR2
1,109817590,-0.0341041,0.00446359,2.19989e-14,115082,ebi-a-GCST90093010,rs12740374,T,G,0.221064,Total lipid levels in very large HDL,CELSR2
1,109817590,-0.0367741,0.00481433,2.19989e-14,115082,ebi-a-GCST90092966,rs12740374,T,G,0.221064,Triglyceride levels in small LDL,CELSR2
1,109817590,0.34322,0.04511,2.78035e-14,344104,ukb-d-30700_raw,rs12740374,T,G,0.22181,Creatinine,CELSR2
1,109817590,-0.00160933,0.000211877,3.10027e-14,463010,ukb-b-11064,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: Z95.1 Presence of aortocoronary bypass graft,CELSR2
1,109817590,-0.0361124,0.00476106,3.29989e-14,115006,ebi-a-GCST90092931,rs12740374,T,G,0.221084,Omega-3 fatty acid levels,CELSR2
1,109817590,0.0174772,0.00233778,3.69999e-14,436939,ebi-a-GCST90025959,rs12740374,T,G,0.221322,C-reactive protein levels,CELSR2
1,109817590,-0.00281257,0.000372443,4.30031e-14,462933,ukb-b-15829,rs12740374,T,G,0.221164,"Non-cancer illness code, self-reported: heart attack/myocardial infarction",CELSR2
1,109817590,-0.00653194,0.000868337,5.40008e-14,457547,ukb-b-7137,rs12740374,T,G,0.221124,"Medication for pain relief, constipation, heartburn: Aspirin",CELSR2
1,109817590,-0.034995,0.00479374,7.89951e-14,,met-d-L_VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in large VLDL,CELSR2
1,109817590,-0.00279703,0.000374557,8.19974e-14,461880,ukb-b-11590,rs12740374,T,G,0.221186,Vascular/heart problems diagnosed by doctor: Heart attack,CELSR2
1,109817590,-0.0356991,0.00478657,8.80035e-14,115082,ebi-a-GCST90092875,rs12740374,T,G,0.221064,Concentration of large VLDL particles,CELSR2
1,109817590,-0.035619,0.00479273,1.10002e-13,115082,ebi-a-GCST90092874,rs12740374,T,G,0.221064,Total lipid levels in large VLDL,CELSR2
1,109817590,0.0141991,0.00185161,1.39991e-13,673878,ebi-a-GCST90029008,rs12740374,T,G,0.2213,Height,CELSR2
1,109817590,-0.1467,0.02,2.05589e-13,,finn-b-E4_HYPERCHOL,rs12740374,T,G,0.2149,Pure hypercholesterolaemia,CELSR2
1,109817590,-0.0317114,0.0044051,2.09991e-13,,met-d-M_HDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in medium HDL,CELSR2
1,109817590,0.0140228,0.0018514,2.39994e-13,458235,ebi-a-GCST90025949,rs12740374,T,G,0.221298,Height,CELSR2
1,109817590,-0.0344208,0.0047113,2.80027e-13,115082,ebi-a-GCST90092861,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in large LDL,CELSR2
1,109817590,-0.00406951,0.000560099,3.69999e-13,461416,ukb-b-16376,rs12740374,T,G,0.22115,Main speciality of consultant (recoded): Cardiology,CELSR2
1,109817590,-0.0347656,0.00478506,3.69999e-13,115082,ebi-a-GCST90092876,rs12740374,T,G,0.221064,Phospholipid levels in large VLDL,CELSR2
1,109817590,0.0174386,0.0025137,4.60045e-13,372420,ebi-a-GCST90025983,rs12740374,T,G,0.222209,Direct bilirubin levels,CELSR2
1,109817590,-0.0336636,0.00465349,4.70002e-13,115082,ebi-a-GCST90093031,rs12740374,T,G,0.221064,Cholesteryl esters to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.089496,0.012195,5.00035e-13,20686,met-c-843,rs12740374,T,G,0.218729,Apolipoprotein B,CELSR2
1,109817590,-0.00368259,0.000510252,5.31863e-13,337159,ukb-a-62,rs12740374,T,G,0.221518,Non-cancer illness code  self-reported: angina,CELSR2
1,109817590,-0.0170824,0.00234479,5.79963e-13,437651,ebi-a-GCST90025966,rs12740374,T,G,0.221332,Gamma glutamyl transferase levels,CELSR2
1,109817590,0.0326718,0.00455899,7.70016e-13,115056,ebi-a-GCST90093013,rs12740374,T,G,0.221058,Phospholipids to total lipids ratio in very large HDL,CELSR2
1,109817590,-0.00891767,0.00124901,9.30037e-13,407557,ukb-b-18408,rs12740374,T,G,0.221087,Illnesses of father: Heart disease,CELSR2
1,109817590,-0.0333107,0.00473502,1e-12,,met-d-L_LDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in large LDL,CELSR2
1,109817590,0.0317065,0.00456336,1e-12,,met-d-XL_HDL_PL_pct,rs12740374,T,G,0.22105,Phospholipids to total lipids ratio in very large HDL,CELSR2
1,109817590,-0.00329358,0.000463362,1.17951e-12,361194,ukb-d-I9_CHD_NOREV,rs12740374,T,G,0.221809,Major coronary heart disease event excluding revascularizations,CELSR2
1,109817590,-0.00329358,0.000463362,1.17951e-12,361194,ukb-d-I9_CHD,rs12740374,T,G,0.221809,Major coronary heart disease event,CELSR2
1,109817590,0.0191632,0.00269676,1.19454e-12,373045,ebi-a-GCST90014016,rs12740374,T,G,,Vitamin D levels (UKB data field 30890),CELSR2
1,109817590,-0.020958,0.0029634,1.52581e-12,315268,ukb-d-30600_irnt,rs12740374,T,G,0.22158,Albumin,CELSR2
1,109817590,-0.1232,0.01745,1.67919e-12,,ukb-e-30780_CSA,rs12740374,T,G,0.7374,LDL direct,CELSR2
1,109817590,-0.054646,0.0077426,1.69434e-12,315268,ukb-d-30600_raw,rs12740374,T,G,0.22158,Albumin,CELSR2
1,109817590,-0.0310165,0.00440068,1.80011e-12,115082,ebi-a-GCST90092897,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in medium HDL,CELSR2
1,109817590,-0.00158352,0.000225003,1.95704e-12,337159,ukb-a-191,rs12740374,T,G,0.221518,Treatment/medication code: ezetimibe,CELSR2
1,109817590,-0.102391,0.0145755,2.14092e-12,23156,eqtl-a-ENSG00000134184,rs12740374,T,G,0.210449,ENSG00000134184,CELSR2
1,109817590,-0.00255932,0.000364396,2.19989e-12,463010,ukb-b-15686,rs12740374,T,G,0.221167,"Diagnoses - secondary ICD10: I20.9 Angina pectoris, unspecified",CELSR2
1,109817590,-0.0139846,0.00199246,2.19989e-12,462933,ukb-b-3656,rs12740374,T,G,0.221164,Number of treatments/medications taken,CELSR2
1,109817590,-0.00177863,0.000253823,2.39994e-12,462933,ukb-b-7869,rs12740374,T,G,0.221164,Operation code: coronary angioplasty (ptca) +/- stent,CELSR2
1,109817590,-0.0326649,0.00468256,2.49977e-12,,met-d-XS_VLDL_CE_pct,rs12740374,T,G,0.221059,Cholesteryl esters to total lipids ratio in very small VLDL,CELSR2
1,109817590,-0.0167277,0.00257399,3.19963e-12,400792,ebi-a-GCST90025990,rs12740374,T,G,0.221135,Calcium levels,CELSR2
1,109817590,-0.00353779,0.000511118,4.47095e-12,336683,ukb-a-436,rs12740374,T,G,0.221518,Vascular/heart problems diagnosed by doctor: Angina,CELSR2
1,109817590,0.0107378,0.00156107,6.00067e-12,461950,ukb-b-10787,rs12740374,T,G,0.221181,Standing height,CELSR2
1,109817590,-0.076,0.0112,1.06807e-11,21758,ebi-a-GCST90012000,rs12740374,T,G,0.223,E-selectin levels,CELSR2
1,109817590,-0.1031,0.0152,1.13894e-11,,finn-b-I9_CORATHER_EXNONE,rs12740374,T,G,0.2145,Coronary atherosclerosis (no controls excluded),CELSR2
1,109817590,-0.1042,0.0154,1.17896e-11,,finn-b-I9_CORATHER,rs12740374,T,G,0.2146,Coronary atherosclerosis,CELSR2
1,109817590,-0.10125,0.014924,1.69005e-11,13495,met-c-858,rs12740374,T,G,0.213254,Free cholesterol,CELSR2
1,109817590,-0.00939275,0.00139803,1.84035e-11,190094,ukb-d-2654_2,rs12740374,T,G,0.219857,Non-butter spread type details: Flora Pro-Active or Benecol,CELSR2
1,109817590,-0.0314186,0.00481258,2.19989e-11,,met-d-XL_VLDL_FC,rs12740374,T,G,0.221059,Free cholesterol in very large VLDL,CELSR2
1,109817590,-0.110233,0.0300241,2.21055e-11,10486,ebi-a-GCST90101743,rs12740374,T,G,0.271287,Total cholesterol levels,CELSR2
1,109817590,-0.0322478,0.00482351,2.29985e-11,115082,ebi-a-GCST90092832,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in IDL,CELSR2
1,109817590,-0.0314884,0.00473215,2.80027e-11,115082,ebi-a-GCST90092909,rs12740374,T,G,0.221064,Free cholesterol to total lipids ratio in medium LDL,CELSR2
1,109817590,-0.0596,0.009,3.49784e-11,224024,ebi-a-GCST90018986,rs12740374,T,G,0.154134,Medication use (beta blocking agents),CELSR2
1,109817590,0.0963618,0.0145784,3.84858e-11,30998,eqtl-a-ENSG00000031698,rs12740374,T,G,0.210449,ENSG00000031698,CELSR2
1,109817590,-0.0320708,0.00492429,4.10015e-11,,met-d-SFA,rs12740374,T,G,0.221071,Saturated fatty acids,CELSR2
1,109817590,-0.0328087,0.0049746,4.19952e-11,115082,ebi-a-GCST90092905,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in medium LDL,CELSR2
1,109817590,0.40669,0.061651,4.21211e-11,329247,ukb-d-30890_raw,rs12740374,T,G,0.22378,Vitamin D,CELSR2
1,109817590,-0.0181,0.0027,4.23156e-11,315268,ebi-a-GCST90018945,rs12740374,T,G,0.180278,Serum albumin levels,CELSR2
1,109817590,-0.0303175,0.0046727,4.30031e-11,,met-d-Cholines,rs12740374,T,G,0.221071,Total cholines,CELSR2
1,109817590,-0.080427,0.0122,4.3401e-11,314921,ukb-d-30860_raw,rs12740374,T,G,0.22162,Total protein,CELSR2
1,109817590,-0.019923,0.0030246,4.49469e-11,314921,ukb-d-30860_irnt,rs12740374,T,G,0.22162,Total protein,CELSR2
1,109817590,-0.0306795,0.00489224,5.10035e-11,,met-d-XS_VLDL_TG,rs12740374,T,G,0.221059,Triglycerides in very small VLDL,CELSR2
1,109817590,0.019272,0.0029381,5.42126e-11,329247,ukb-d-30890_irnt,rs12740374,T,G,0.22378,Vitamin D,CELSR2
1,109817590,-0.00128416,0.000196453,6.29941e-11,462933,ukb-b-13664,rs12740374,T,G,0.221164,Treatment/medication code: rosuvastatin,CELSR2
1,109817590,0.0294848,0.00451484,6.4998e-11,115082,ebi-a-GCST90092896,rs12740374,T,G,0.221064,Free cholesterol levels in medium HDL,CELSR2
1,109817590,-0.00949534,0.0014587,7.5544e-11,292053,ukb-a-201,rs12740374,T,G,0.221518,Illnesses of father: Heart disease,CELSR2
1,109817590,-0.0312383,0.00480258,7.8001e-11,115082,ebi-a-GCST90093020,rs12740374,T,G,0.221064,Free cholesterol levels in very large VLDL,CELSR2
1,109817590,-0.0181,0.0028,8.51138e-11,314921,ebi-a-GCST90018976,rs12740374,T,G,0.17711,Serum total protein level,CELSR2
1,109817590,0.00955988,0.00147791,9.8992e-11,454463,ukb-b-9685,rs12740374,T,G,0.22129,Trunk predicted mass,CELSR2
1,109817590,-0.1314,0.0204,1.11301e-10,,finn-b-I9_REVASC,rs12740374,T,G,0.215,Coronary revascularization (ANGIO or CABG),CELSR2
1,109817590,0.0287611,0.00452193,1.2e-10,,met-d-M_HDL_FC,rs12740374,T,G,0.221059,Free cholesterol in medium HDL,CELSR2
1,109817590,0.00955295,0.00148265,1.2e-10,454508,ukb-b-17409,rs12740374,T,G,0.221286,Trunk fat-free mass,CELSR2
1,109817590,-0.03102,0.00485108,1.29999e-10,,met-d-IDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in IDL,CELSR2
1,109817590,-0.0305333,0.00475978,1.29999e-10,,met-d-M_LDL_FC_pct,rs12740374,T,G,0.221059,Free cholesterol to total lipids ratio in medium LDL,CELSR2
1,109817590,0.0316468,0.00491966,1.29999e-10,115082,ebi-a-GCST90092952,rs12740374,T,G,0.221064,Phospholipid levels in small HDL,CELSR2
1,109817590,-0.1109,0.0174,1.67799e-10,456468,ebi-a-GCST90018932,rs12740374,T,G,0.184131,Unstable angina pectoris,CELSR2
1,109817590,-0.0302647,0.00472796,1.7e-10,,met-d-Unsaturation,rs12740374,T,G,0.221071,Degree of unsaturation,CELSR2
1,109817590,0.0156,0.0024,1.72302e-10,575531,ebi-a-GCST90029070,rs12740374,T,G,,C-reactive protein levels,CELSR2
1,109817590,-0.0296544,0.00466366,2e-10,115006,ebi-a-GCST90092812,rs12740374,T,G,0.221084,Total cholines levels,CELSR2
1,109817590,-0.131,0.02059,2.00498e-10,,ukb-e-30780_AFR,rs12740374,T,G,0.7442,LDL direct,CELSR2
1,109817590,-0.0311228,0.00489592,2.1e-10,115006,ebi-a-GCST90092980,rs12740374,T,G,0.221084,Saturated fatty acid levels,CELSR2
1,109817590,-0.0149617,0.00235617,2.15293e-10,389672,ebi-a-GCST90014004,rs12740374,T,G,,Gamma glutamyltransferase levels (UKB data field 30730),CELSR2
1,109817590,-0.0834,0.0131,2.23398e-10,,finn-b-E4_METABOLIA,rs12740374,T,G,0.2145,Metabolic disorders,CELSR2
1,109817590,-0.126903,0.019998,2.27997e-10,98109,ieu-a-9,rs12740374,T,G,0.219548,Coronary heart disease,CELSR2
1,109817590,0.0312068,0.0049254,2.39999e-10,,met-d-S_HDL_PL,rs12740374,T,G,0.221059,Phospholipids in small HDL,CELSR2
1,109817590,0.0163582,0.00258602,2.52209e-10,389057,ebi-a-GCST90014002,rs12740374,T,G,,C reactive protein levels (UKB data field 30710),CELSR2
1,109817590,-0.03194,0.00497573,3.09999e-10,,met-d-M_LDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in medium LDL,CELSR2
1,109817590,-0.00622151,0.000989098,3.17695e-10,337159,ukb-a-132,rs12740374,T,G,0.221518,Treatment/medication code: aspirin,CELSR2
1,109817590,0.00985447,0.00157302,3.69999e-10,249710,ukb-b-20379,rs12740374,T,G,0.220882,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: None of the above",CELSR2
1,109817590,0.00931472,0.00148816,3.89996e-10,454850,ukb-b-13354,rs12740374,T,G,0.221296,Whole body fat-free mass,CELSR2
1,109817590,-0.0294446,0.00471188,4.09996e-10,115006,ebi-a-GCST90092994,rs12740374,T,G,0.221084,Degree of unsaturation,CELSR2
1,109817590,-0.041,0.0066,4.54402e-10,237530,ebi-a-GCST90018988,rs12740374,T,G,0.158064,Medication use (agents acting on the renin-angiotensin system),CELSR2
1,109817590,0.0155596,0.00249768,4.67617e-10,332739,ebi-a-GCST90013997,rs12740374,T,G,,Direct bilirubin levels (UKB data field 30660),CELSR2
1,109817590,0.0141008,0.00226583,4.86911e-10,389834,ebi-a-GCST90014003,rs12740374,T,G,,Cystatin C levels (UKB data field 30720),CELSR2
1,109817590,-0.11,0.02,5.27509e-10,9817,ebi-a-GCST005065,rs12740374,T,G,,"Cholesterol, total",CELSR2
1,109817590,-0.0141565,0.00236601,5.30005e-10,437532,ebi-a-GCST90025957,rs12740374,T,G,0.221356,Triglyceride levels,CELSR2
1,109817590,-0.00131604,0.000212108,5.49997e-10,462933,ukb-b-18062,rs12740374,T,G,0.221164,Treatment/medication code: lipitor 10mg tablet,CELSR2
1,109817590,0.0280083,0.00454123,6.90001e-10,115082,ebi-a-GCST90092808,rs12740374,T,G,0.221064,Apolipoprotein A1 levels,CELSR2
1,109817590,-0.077854,0.012456,7.37004e-10,19270,met-c-872,rs12740374,T,G,0.216125,Triglycerides in IDL,CELSR2
1,109817590,0.00915855,0.00149063,8e-10,454888,ukb-b-14540,rs12740374,T,G,0.221299,Whole body water mass,CELSR2
1,109817590,-0.0306354,0.00498552,8e-10,115082,ebi-a-GCST90092957,rs12740374,T,G,0.221064,Cholesterol to total lipids ratio in small LDL,CELSR2
1,109817590,-0.0826,0.0135,8.56091e-10,,finn-b-I9_IHD,rs12740374,T,G,0.2145,"Ischaemic heart disease, wide definition",CELSR2
1,109817590,0.017632,0.002875,8.65207e-10,343524,ukb-d-30710_irnt,rs12740374,T,G,0.22177,C-reactive protein,CELSR2
1,109817590,-0.077459,0.012465,9.1601e-10,19270,met-c-953,rs12740374,T,G,0.216125,Total lipids in very small VLDL,CELSR2
1,109817590,0.0142466,0.00231036,9.29994e-10,437846,ebi-a-GCST90025945,rs12740374,T,G,0.221343,Cystatin C levels,CELSR2
1,109817590,-0.00621654,0.00101623,9.53125e-10,333581,ukb-a-452,rs12740374,T,G,0.221518,Medication for pain relief  constipation  heartburn: Aspirin,CELSR2
1,109817590,-0.1672,0.0273,9.78498e-10,,finn-b-I9_CABG,rs12740374,T,G,0.2154,Coronary artery bypass grafting,CELSR2
1,109817590,0.0273893,0.00454706,9.90011e-10,,met-d-ApoA1,rs12740374,T,G,0.221059,Apolipoprotein A1,CELSR2
1,109817590,-0.0822,0.0135,1.19201e-09,,finn-b-I9_ISCHHEART,rs12740374,T,G,0.2145,Ischemic heart diseases,CELSR2
1,109817590,0.0286479,0.00471866,1.29999e-09,115082,ebi-a-GCST90092854,rs12740374,T,G,0.221064,Triglyceride levels in large HDL,CELSR2
1,109817590,0.0141936,0.00232411,1.40001e-09,535537,ebi-a-GCST90028997,rs12740374,T,G,0.221211,Mean sphered cell volume,CELSR2
1,109817590,-0.0292795,0.00483394,1.40001e-09,115082,ebi-a-GCST90093038,rs12740374,T,G,0.221064,Triglyceride levels in very small VLDL,CELSR2
1,109817590,0.00889679,0.0014519,1.5e-09,534045,ebi-a-GCST90029025,rs12740374,T,G,0.221417,Basal metabolic rate,CELSR2
1,109817590,-0.0156693,0.00261358,1.6e-09,415311,ebi-a-GCST006701,rs12740374,T,G,0.221783,Parental longevity (father's attained age),CELSR2
1,109817590,-0.1186,0.0197,1.60602e-09,,finn-b-I9_REVACS_EXNONE,rs12740374,T,G,0.2145,Emergency coronary revascularization (for ACS) (no controls excluded),CELSR2
1,109817590,-0.1186,0.0197,1.60602e-09,,finn-b-I9_REVASC_EXNONE,rs12740374,T,G,0.2145,Coronary revascularization (ANGIO or CABG) (no controls excluded),CELSR2
1,109817590,-0.103341,0.0171373,1.63999e-09,86995,ebi-a-GCST000998,rs12740374,T,G,0.21146,Coronary heart disease,CELSR2
1,109817590,-0.103341,0.0171373,1.63999e-09,81176,ieu-a-8,rs12740374,T,G,0.21146,Coronary heart disease,CELSR2
1,109817590,0.0133548,0.00223896,1.7e-09,437736,ebi-a-GCST90025976,rs12740374,T,G,0.221213,Mean sphered cell volume,CELSR2
1,109817590,0.0877895,0.0145822,1.74201e-09,31212,eqtl-a-ENSG00000181754,rs12740374,T,G,0.210449,ENSG00000181754,CELSR2
1,109817590,0.0266849,0.00445541,2.1e-09,115082,ebi-a-GCST90092825,rs12740374,T,G,0.221064,Total lipid levels in HDL,CELSR2
1,109817590,-0.00133559,0.000223164,2.19999e-09,463010,ukb-b-15748,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: Z95.5 Presence of coronary angioplasty implant and graft,CELSR2
1,109817590,-0.1604,0.0269,2.48702e-09,,finn-b-E4_HYPERLIPNAS,rs12740374,T,G,0.2153,"Hyperlipidaemia, other/unspecified",CELSR2
1,109817590,-0.0140787,0.00246436,2.59998e-09,437724,ebi-a-GCST90025979,rs12740374,T,G,0.221325,Alanine aminotransferase levels,CELSR2
1,109817590,-0.0574,0.0097,2.97303e-09,977323,ebi-a-GCST009541,rs12740374,T,G,,Heart failure,CELSR2
1,109817590,-0.0144405,0.00240166,3.2e-09,397043,ebi-a-GCST90025958,rs12740374,T,G,0.221106,Sex hormone-binding globulin levels,CELSR2
1,109817590,0.00876812,0.0014816,3.29997e-09,454753,ukb-b-19520,rs12740374,T,G,0.221296,Arm fat-free mass (right),CELSR2
1,109817590,0.0272289,0.00477103,3.59998e-09,,met-d-L_HDL_TG,rs12740374,T,G,0.221059,Triglycerides in large HDL,CELSR2
1,109817590,0.0259461,0.00446167,4.30002e-09,,met-d-HDL_L,rs12740374,T,G,0.221059,Total lipids in HDL,CELSR2
1,109817590,-0.00204528,0.000348322,4.31459e-09,337199,ukb-a-532,rs12740374,T,G,0.221518,Diagnoses - main ICD10: I20 Angina pectoris,CELSR2
1,109817590,-0.074327,0.012464,4.31996e-09,19270,met-c-954,rs12740374,T,G,0.216125,Concentration of very small VLDL particles,CELSR2
1,109817590,-0.00124084,0.000211497,4.39997e-09,463010,ukb-b-16662,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: I25.2 Old myocardial infarction,CELSR2
1,109817590,-0.087897,0.014933,4.58997e-09,13474,met-c-935,rs12740374,T,G,0.213401,Sphingomyelins,CELSR2
1,109817590,0.0168713,0.00287987,4.67875e-09,344729,ukb-d-30270_irnt,rs12740374,T,G,0.221741,Mean sphered cell volume,CELSR2
1,109817590,-0.00606295,0.00103692,5.00795e-09,361194,ukb-d-IX_CIRCULATORY,rs12740374,T,G,0.221809,Diseases of the circulatory system,CELSR2
1,109817590,0.0288882,0.00501354,5.39995e-09,,met-d-XXL_VLDL_TG_pct,rs12740374,T,G,0.221399,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,-0.00162958,0.000279384,5.49997e-09,463010,ukb-b-8184,rs12740374,T,G,0.221167,"Diagnoses - secondary ICD10: I25.9 Chronic ischaemic heart disease, unspecified",CELSR2
1,109817590,-0.00226118,0.000387831,5.5372e-09,361194,ukb-d-I9_MI_STRICT,rs12740374,T,G,0.221809,"Myocardial infarction, strict",CELSR2
1,109817590,-0.00226118,0.000387831,5.5372e-09,361194,ukb-d-I9_MI,rs12740374,T,G,0.221809,Myocardial infarction,CELSR2
1,109817590,-0.1172,0.02018,6.28999e-09,,ukb-e-30690_AFR,rs12740374,T,G,0.744,Cholesterol,CELSR2
1,109817590,-0.00251853,0.000436542,7.96856e-09,337159,ukb-a-63,rs12740374,T,G,0.221518,Non-cancer illness code  self-reported: heart attack/myocardial infarction,CELSR2
1,109817590,-0.00581546,0.00100056,8e-09,368929,ebi-a-GCST90012110,rs12740374,T,G,0.221727,Sex hormone-binding globulin levels adjusted for BMI,CELSR2
1,109817590,-0.069774,0.011953,8.00995e-09,21554,met-c-927,rs12740374,T,G,0.218928,Total cholesterol in small VLDL,CELSR2
1,109817590,0.0102,0.0018,8.15098e-09,360388,ebi-a-GCST90018959,rs12740374,T,G,0.174675,Height,CELSR2
1,109817590,-0.0271477,0.00491807,8.30004e-09,,met-d-MUFA,rs12740374,T,G,0.221071,Monounsaturated fatty acids,CELSR2
1,109817590,-0.0267508,0.00479487,8.50002e-09,,met-d-XL_VLDL_PL,rs12740374,T,G,0.221059,Phospholipids in very large VLDL,CELSR2
1,109817590,-0.00252512,0.000438611,8.56604e-09,336683,ukb-a-434,rs12740374,T,G,0.221518,Vascular/heart problems diagnosed by doctor: Heart attack,CELSR2
1,109817590,-0.0295783,0.00499186,8.9e-09,,met-d-S_LDL_C_pct,rs12740374,T,G,0.221059,Cholesterol to total lipids ratio in small LDL,CELSR2
1,109817590,0.0361,0.0058,9.7699e-09,92577,ieu-a-780,rs12740374,T,G,0.2124,HDL cholesterol,CELSR2
1,109817590,-0.026076,0.0047808,1.09999e-08,,met-d-L_VLDL_TG,rs12740374,T,G,0.221059,Triglycerides in large VLDL,CELSR2
1,109817590,0.0130721,0.00220134,1.09999e-08,426824,ebi-a-GCST006979,rs12740374,T,G,0.22183,Heel bone mineral density,CELSR2
1,109817590,0.014951,0.0026195,1.14609e-08,344264,ukb-d-30720_irnt,rs12740374,T,G,0.22179,Cystatin C,CELSR2
1,109817590,-0.0268788,0.00488139,1.2e-08,,met-d-XL_HDL_TG,rs12740374,T,G,0.221059,Triglycerides in very large HDL,CELSR2
1,109817590,-0.149,0.0262,1.276e-08,,finn-b-I9_CABG_EXNONE,rs12740374,T,G,0.2145,Coronary artery bypass grafting (no controls excluded),CELSR2
1,109817590,0.00839294,0.00147669,1.29999e-08,454746,ukb-b-16698,rs12740374,T,G,0.221292,Arm predicted mass (right),CELSR2
1,109817590,-0.00157118,0.000277017,1.40001e-08,463010,ukb-b-7436,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: I25.1 Atherosclerotic heart disease,CELSR2
1,109817590,0.0284407,0.00501116,1.40001e-08,111638,ebi-a-GCST90093051,rs12740374,T,G,0.221399,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,CELSR2
1,109817590,-0.00485928,0.000861872,1.7e-08,363542,ukb-b-14371,rs12740374,T,G,0.220962,Illnesses of siblings: Heart disease,CELSR2
1,109817590,0.0154,0.0028,2.14699e-08,353466,ebi-a-GCST90018950,rs12740374,T,G,0.193363,C-reactive protein,CELSR2
1,109817590,0.00871853,0.00156011,2.30001e-08,454835,ukb-b-12828,rs12740374,T,G,0.221296,Leg fat-free mass (right),CELSR2
1,109817590,0.0173226,0.00303339,2.30001e-08,244730,ebi-a-GCST90000027,rs12740374,T,G,0.221072,Appendicular lean mass,CELSR2
1,109817590,0.00873667,0.00156538,2.39999e-08,454874,ukb-b-16446,rs12740374,T,G,0.221299,Basal metabolic rate,CELSR2
1,109817590,0.0200929,0.00336423,2.39999e-08,205513,ebi-a-GCST90000026,rs12740374,T,G,0.221743,Appendicular lean mass,CELSR2
1,109817590,-0.0151183,0.00272744,2.97269e-08,357831,ebi-a-GCST90013999,rs12740374,T,G,,Calcium levels (UKB data field 30680),CELSR2
1,109817590,-0.0265135,0.00478552,2.99999e-08,115082,ebi-a-GCST90093024,rs12740374,T,G,0.221064,Phospholipid levels in very large VLDL,CELSR2
1,109817590,-0.0926,0.0168,3.62402e-08,,finn-b-I9_ANGINA,rs12740374,T,G,0.215,Angina pectoris,CELSR2
1,109817590,-0.0871,0.0158,3.64099e-08,,finn-b-I9_CHD,rs12740374,T,G,0.2145,Major coronary heart disease event,CELSR2
1,109817590,0.00826694,0.00150463,3.89996e-08,454655,ukb-b-9093,rs12740374,T,G,0.221299,Arm predicted mass (left),CELSR2
1,109817590,0.00848754,0.00155005,4.39997e-08,454834,ukb-b-14310,rs12740374,T,G,0.221296,Leg predicted mass (right),CELSR2
1,109817590,-0.09473,0.0174,5.23299e-08,,ukb-e-30690_CSA,rs12740374,T,G,0.7374,Cholesterol,CELSR2
1,109817590,-0.0259549,0.00477387,5.39995e-08,115082,ebi-a-GCST90092878,rs12740374,T,G,0.221064,Triglyceride levels in large VLDL,CELSR2
1,109817590,0.019,0.0036,5.60003e-08,252881,ieu-a-89,rs12740374,T,G,0.302,Height,CELSR2
1,109817590,-0.0329,0.006,6.20297e-08,99900,ebi-a-GCST000755,rs12740374,T,G,,HDL cholesterol,CELSR2
1,109817590,-0.0262822,0.00489333,7.79992e-08,115006,ebi-a-GCST90092928,rs12740374,T,G,0.221084,Monounsaturated fatty acid levels,CELSR2
1,109817590,0.0133011,0.0024808,8.24803e-08,365403,ebi-a-GCST90014022,rs12740374,T,G,,Bone mineral density,CELSR2
1,109817590,0.00804522,0.00151066,1e-07,454672,ukb-b-19925,rs12740374,T,G,0.221296,Arm fat-free mass (left),CELSR2
1,109817590,-0.0257491,0.00483971,1e-07,115082,ebi-a-GCST90093014,rs12740374,T,G,0.221064,Triglyceride levels in very large HDL,CELSR2
1,109817590,-0.0143145,0.00269005,1e-07,389166,ebi-a-GCST006697,rs12740374,T,G,0.221677,"Parental longevity (combined parental attained age, Martingale residuals)",CELSR2
1,109817590,-0.024464,0.00477552,1.09999e-07,,met-d-XL_VLDL_P,rs12740374,T,G,0.221059,Concentration of very large VLDL particles,CELSR2
1,109817590,-0.000944527,0.000178226,1.2e-07,463010,ukb-b-15491,rs12740374,T,G,0.221167,Operative procedures - main OPCS: K45.3 Anastomosis of mammary artery to left anterior descending coronary artery,CELSR2
1,109817590,-0.0092,0.0017,1.24601e-07,7365,met-a-307,rs12740374,T,G,0.2147,Cholesterol,CELSR2
1,109817590,-0.0131,0.0025,1.28e-07,344104,ebi-a-GCST90018954,rs12740374,T,G,0.179894,Gamma glutamyl transpeptidase,CELSR2
1,109817590,-0.0856,0.0162,1.299e-07,,finn-b-I9_ANGINA_EXNONE,rs12740374,T,G,0.2145,Angina pectoris (no controls excluded),CELSR2
1,109817590,-0.1588,0.0302,1.44544e-07,3301,prot-a-2760,rs12740374,T,G,0.22252,Sodium-coupled monocarboxylate transporter 1,CELSR2
1,109817590,-0.078929,0.014983,1.49001e-07,13504,met-c-856,rs12740374,T,G,0.213446,Omega-6 fatty acids,CELSR2
1,109817590,-0.0016442,0.000312899,1.5e-07,463010,ukb-b-9592,rs12740374,T,G,0.221167,Operative procedures - main OPCS: K63.3 Angiocardiography of left side of heart NEC,CELSR2
1,109817590,-0.00134628,0.000256387,1.5e-07,463010,ukb-b-15797,rs12740374,T,G,0.221167,Operative procedures - main OPCS: K63.4 Coronary arteriography using two catheters,CELSR2
1,109817590,-0.00184244,0.00035141,1.6e-07,463010,ukb-b-2205,rs12740374,T,G,0.221167,Diagnoses - secondary ICD10: Z82.4 Family history of ischaemic heart disease and other diseases of the circulatory system,CELSR2
1,109817590,-0.07,0.0134,1.61102e-07,,finn-b-I9_CVD_HARD,rs12740374,T,G,0.2145,Hard cardiovascular diseases,CELSR2
1,109817590,0.0096063,0.00183496,1.64945e-07,330995,ukb-a-293,rs12740374,T,G,0.221518,Trunk predicted mass,CELSR2
1,109817590,0.00963763,0.00184095,1.64953e-07,331030,ukb-a-292,rs12740374,T,G,0.221518,Trunk fat-free mass,CELSR2
1,109817590,-0.071526,0.013753,2.03002e-07,15726,met-c-851,rs12740374,T,G,0.21719,Average number of double bonds in a fatty acid chain,CELSR2
1,109817590,-0.0129,0.0025,2.15998e-07,344136,ebi-a-GCST90018943,rs12740374,T,G,0.176084,Alanine aminotransferase levels,CELSR2
1,109817590,0.0080335,0.00155079,2.19999e-07,454799,ukb-b-17271,rs12740374,T,G,0.221295,Leg predicted mass (left),CELSR2
1,109817590,-0.0942404,0.0182627,2.46587e-07,212453,bbj-a-159,rs12740374,T,G,0.0715713,Coronary artery disease,CELSR2
1,109817590,-0.0130497,0.00254982,2.5e-07,446811,ebi-a-GCST90029026,rs12740374,T,G,0.221029,Lung function (FEV1/FVC),CELSR2
1,109817590,-0.0842,0.0163,2.625e-07,242659,ebi-a-GCST90018983,rs12740374,T,G,0.15717,Medication use (vasodilators used in cardiac diseases),CELSR2
1,109817590,-0.0126473,0.00246394,2.852e-07,389733,ebi-a-GCST90013992,rs12740374,T,G,,Alanine aminotransferase levels (UKB data field 30620),CELSR2
1,109817590,-0.0120148,0.00234401,2.96545e-07,337159,ukb-a-24,rs12740374,T,G,0.221518,Number of treatments/medications taken,CELSR2
1,109817590,0.0094904,0.00185838,3.27967e-07,180203,ukb-a-449,rs12740374,T,G,0.221518,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: None of the above,CELSR2
1,109817590,-0.0128132,0.00254371,3.40001e-07,371898,ebi-a-GCST90025978,rs12740374,T,G,0.221026,Lung function (FEV1/FVC),CELSR2
1,109817590,-0.0015302,0.000300317,3.50002e-07,462933,ukb-b-17378,rs12740374,T,G,0.221164,Treatment/medication code: bisoprolol,CELSR2
1,109817590,-0.0245706,0.00487889,3.59998e-07,,met-d-S_HDL_FC,rs12740374,T,G,0.221059,Free cholesterol in small HDL,CELSR2
1,109817590,0.00794349,0.00156103,3.59998e-07,454805,ukb-b-16099,rs12740374,T,G,0.221293,Leg fat-free mass (left),CELSR2
1,109817590,0.0152,0.003,3.67799e-07,350741,ebi-a-GCST90095038,rs12740374,T,G,0.2784,Height,CELSR2
1,109817590,-0.076545,0.014954,3.73001e-07,13525,met-c-893,rs12740374,T,G,0.21352,"18:2, linoleic acid (LA)",CELSR2
1,109817590,-0.0241796,0.00476475,3.89996e-07,115082,ebi-a-GCST90093023,rs12740374,T,G,0.221064,Concentration of very large VLDL particles,CELSR2
1,109817590,-0.00158575,0.000313664,4.29309e-07,337199,ukb-a-533,rs12740374,T,G,0.221518,Diagnoses - main ICD10: I21 Acute myocardial infarction,CELSR2
1,109817590,-0.4254,0.0842,4.35702e-07,76511,ieu-b-4832,rs12740374,T,G,,Estimated glomerular filtration rate,CELSR2
1,109817590,-0.0251954,0.0049595,4.90004e-07,,met-d-S_LDL_PL_pct,rs12740374,T,G,0.221059,Phospholipids to total lipids ratio in small LDL,CELSR2
1,109817590,-0.02497,0.00496297,4.90004e-07,115082,ebi-a-GCST90092965,rs12740374,T,G,0.221064,Phospholipids to total lipids ratio in small LDL,CELSR2
1,109817590,0.0136,0.0027,4.90501e-07,349856,ebi-a-GCST90018962,rs12740374,T,G,0.189788,Lymphocyte count,CELSR2
1,109817590,-0.00229583,0.000466561,5e-07,437267,ebi-a-GCST90013405,rs12740374,T,G,0.221304,Liver enzyme levels (alanine transaminase),CELSR2
1,109817590,0.0122674,0.00235843,5.1e-07,509277,ebi-a-GCST90028994,rs12740374,T,G,0.221254,White blood cell count (lymphocyte),CELSR2
1,109817590,0.010341,0.00207691,6.39411e-07,336474,ukb-a-389,rs12740374,T,G,0.221518,Standing height,CELSR2
1,109817590,0.011468,0.002304,6.58006e-07,486823,ebi-a-GCST90002322,rs12740374,T,G,0.221645,Mean corpuscular hemoglobin,CELSR2
1,109817590,-0.00586073,0.00111619,6.69993e-07,370125,ebi-a-GCST90012111,rs12740374,T,G,0.221712,Sex hormone-binding globulin levels,CELSR2
1,109817590,0.0131,0.0026,7.10395e-07,350473,ebi-a-GCST90018966,rs12740374,T,G,0.181226,Mean corpuscular volume,CELSR2
1,109817590,-0.0122115,0.00246881,7.56397e-07,389562,ebi-a-GCST90014014,rs12740374,T,G,,Triglyceride levels (UKB data field 30870),CELSR2
1,109817590,-0.0240698,0.00486683,7.59994e-07,115082,ebi-a-GCST90092948,rs12740374,T,G,0.221064,Free cholesterol levels in small HDL,CELSR2
1,109817590,-0.00118044,0.000238789,7.69999e-07,463010,ukb-b-14206,rs12740374,T,G,0.221167,"Diagnoses - main ICD10: I20.9 Angina pectoris, unspecified",CELSR2
1,109817590,0.0126329,0.00255837,7.89878e-07,395949,ebi-a-GCST90013982,rs12740374,T,G,,Lymphocyte count (UKB data field 30120),CELSR2
1,109817590,-0.127541,0.0258623,8.15849e-07,161206,ebi-a-GCST90018657,rs12740374,T,G,0.0721943,Myocardial infarction,CELSR2
1,109817590,0.00931389,0.00189094,8.41298e-07,810865,ebi-a-GCST90000059,rs12740374,T,G,0.2221,Diastolic blood pressure,CELSR2
1,109817590,-0.0101041,0.00205388,8.70001e-07,462933,ukb-b-4063,rs12740374,T,G,0.221164,Number of self-reported non-cancer illnesses,CELSR2
1,109817590,0.010729,0.002181,8.85992e-07,544127,ebi-a-GCST90002334,rs12740374,T,G,0.22107,Mean corpuscular volume,CELSR2
1,109817590,0.0109876,0.002222,9.09997e-07,445855,ebi-a-GCST90025982,rs12740374,T,G,0.221368,Heel bone mineral density T score,CELSR2
1,109817590,-0.1482,0.0302,9.33254e-07,3301,prot-a-1779,rs12740374,T,G,0.22252,Low-density lipoprotein receptor-related protein 1B,CELSR2
1,109817590,0.073457,0.014923,9.43996e-07,13530,met-c-847,rs12740374,T,G,0.213444,Average number of methylene groups per double bond,CELSR2
2,187532373,0.293047,0.0199929,1.20809e-48,31568,eqtl-a-ENSG00000138448,rs2595391,G,T,0.0966293,ENSG00000138448,ITGAV
2,187532373,-0.1126,0.0205,3.71903e-08,59957,ebi-a-GCST004131,rs2595391,G,T,,Inflammatory bowel disease,ITGAV
2,187532373,0.0183273,0.00358963,8.40001e-08,371898,ebi-a-GCST90025978,rs2595391,G,T,0.099978,Lung function (FEV1/FVC),ITGAV
2,187532373,0.0181079,0.00363279,2.1e-07,400159,ebi-a-GCST90025948,rs2595391,G,T,0.0999927,Serum phosphate levels,ITGAV
2,187532373,0.0185196,0.00357125,2.15144e-07,357302,ebi-a-GCST90014010,rs2595391,G,T,,Phosphate levels (UKB data field 30810),ITGAV
2,187532373,0.0166368,0.00339937,2.80001e-07,446811,ebi-a-GCST90029026,rs2595391,G,T,0.1093,Lung function (FEV1/FVC),ITGAV
2,187532373,-0.0139911,0.00316802,5.89997e-07,513859,ebi-a-GCST90028992,rs2595391,G,T,0.109442,White blood cell count (eosinophil),ITGAV
2,187532373,-0.062755,0.012766,8.89201e-07,,ubm-b-1695,rs2595391,G,T,0.10809,IDP_dMRI_TBSS_L1_Uncinate_fasciculus_L,ITGAV
1,55505647,-0.348456,0.00793088,0,,ieu-b-110,rs11591147,T,G,0.017468,LDL cholesterol,PCSK9
1,55505647,-0.345954,0.00790085,0,,ieu-b-108,rs11591147,T,G,0.017452,apolipoprotein B,PCSK9
1,55505647,0.046744,0.007316,0,,ieu-b-4808,rs11591147,T,G,0.01799,25 hydroxyvitamin D level,PCSK9
1,55505647,-0.34847,0.0088975,0,343621,ukb-d-30780_irnt,rs11591147,T,G,0.017695,LDL direct,PCSK9
1,55505647,-0.30026,0.007733,0,343621,ukb-d-30780_raw,rs11591147,T,G,0.017695,LDL direct,PCSK9
1,55505647,-0.32722,0.00790383,0,437878,ebi-a-GCST90025953,rs11591147,T,G,0.0176564,Total cholesterol levels,PCSK9
1,55505647,-0.359718,0.00792081,0,437068,ebi-a-GCST90025954,rs11591147,T,G,0.0176575,Direct low density lipoprotein cholesterol levels,PCSK9
1,55505647,-0.3485,0.0089,0,343621,ebi-a-GCST90018961,rs11591147,T,G,0.017695,LDL cholesterol,PCSK9
1,55505647,-0.457849,0.0071963,0,431167,ebi-a-GCST90002412,rs11591147,T,G,0.017455,Low density lipoprotein cholesterol levels,PCSK9
1,55505647,-0.353467,0.0077769,0,435744,ebi-a-GCST90025952,rs11591147,T,G,0.0176423,Apolipoprotein B levels,PCSK9
1,55505647,-0.34563,0.0089759,1.1125369292536e-308,342590,ukb-d-30640_irnt,rs11591147,T,G,0.01767,Apoliprotein B,PCSK9
1,55505647,-0.080862,0.0021375,1.1126154472536e-308,342590,ukb-d-30640_raw,rs11591147,T,G,0.01767,Apoliprotein B,PCSK9
1,55505647,-0.3124,0.0088,1.87932e-278,344278,ebi-a-GCST90018974,rs11591147,T,G,0.017689,Total cholesterol levels,PCSK9
1,55505647,-0.3124,0.0087614,6.06736e-278,344278,ukb-d-30690_irnt,rs11591147,T,G,0.017689,Cholesterol,PCSK9
1,55505647,-0.35498,0.010011,6.3387e-275,344278,ukb-d-30690_raw,rs11591147,T,G,0.017689,Cholesterol,PCSK9
1,55505647,-0.343211,0.0118485,1e-187,,ieu-b-5089,rs11591147,T,G,0.017409,LDL cholesterol,PCSK9
1,55505647,-0.497,0.018,8.57038e-143,94595,ebi-a-GCST002222,rs11591147,T,G,,LDL cholesterol,PCSK9
1,55505647,-0.497,0.018,8.57038e-143,77417,ieu-a-300,rs11591147,T,G,0.01715,LDL cholesterol,PCSK9
1,55505647,-0.497,0.018,1.57036e-142,77417,ieu-a-781,rs11591147,T,G,0.01715,LDL cholesterol,PCSK9
1,55505647,-0.6142,0.0245,6.62217e-139,,finn-b-RX_STATIN,rs11591147,T,G,0.03609,Statin medication,PCSK9
1,55505647,-0.345814,0.0155699,2.19786e-113,,met-d-IDL_P,rs11591147,T,G,0.017458,Concentration of IDL particles,PCSK9
1,55505647,-0.344374,0.0155892,1.09901e-110,,met-d-M_VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in medium VLDL,PCSK9
1,55505647,-0.346654,0.0155694,7.99834e-110,115082,ebi-a-GCST90092838,rs11591147,T,G,0.017457,Concentration of IDL particles,PCSK9
1,55505647,-0.344073,0.0155873,5.59758e-108,115082,ebi-a-GCST90092918,rs11591147,T,G,0.017457,Cholesteryl ester levels in medium VLDL,PCSK9
1,55505647,-0.327845,0.0151793,2.50035e-107,,met-d-IDL_PL,rs11591147,T,G,0.017458,Phospholipids in IDL,PCSK9
1,55505647,-0.325843,0.0152298,7.99834e-106,,met-d-IDL_FC,rs11591147,T,G,0.017458,Free cholesterol in IDL,PCSK9
1,55505647,-0.333805,0.0156922,1.30017e-105,,met-d-S_LDL_PL,rs11591147,T,G,0.017458,Phospholipids in small LDL,PCSK9
1,55505647,-0.327491,0.0151697,2.30144e-103,115082,ebi-a-GCST90092839,rs11591147,T,G,0.017457,Phospholipid levels in IDL,PCSK9
1,55505647,-0.331001,0.0157057,2.69774e-103,,met-d-S_LDL_FC,rs11591147,T,G,0.017458,Free cholesterol in small LDL,PCSK9
1,55505647,-0.332079,0.015677,5.99791e-103,,met-d-L_LDL_P,rs11591147,T,G,0.017458,Concentration of large LDL particles,PCSK9
1,55505647,-0.319346,0.0152108,5.49541e-102,,met-d-IDL_L,rs11591147,T,G,0.017458,Total lipids in IDL,PCSK9
1,55505647,-0.316586,0.0150958,6.19441e-102,,met-d-M_VLDL_PL_pct,rs11591147,T,G,0.017458,Phospholipids to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.32431,0.0154475,7.39605e-102,,met-d-L_LDL_FC,rs11591147,T,G,0.017458,Free cholesterol in large LDL,PCSK9
1,55505647,-0.326041,0.0152253,9.7949e-102,115082,ebi-a-GCST90092835,rs11591147,T,G,0.017457,Free cholesterol levels in IDL,PCSK9
1,55505647,-0.325042,0.0155643,5.99791e-101,,met-d-LDL_FC,rs11591147,T,G,0.017458,Free cholesterol in LDL,PCSK9
1,55505647,-0.317008,0.0151931,6.99842e-101,,met-d-IDL_C,rs11591147,T,G,0.017458,Cholesterol in IDL,PCSK9
1,55505647,-0.332415,0.0156839,1.10002e-99,115082,ebi-a-GCST90092964,rs11591147,T,G,0.017457,Phospholipid levels in small LDL,PCSK9
1,55505647,-0.316218,0.0151816,1.9002e-99,,met-d-XS_VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in very small VLDL,PCSK9
1,55505647,-0.327361,0.0156899,2.09991e-99,,met-d-M_VLDL_C,rs11591147,T,G,0.017458,Cholesterol in medium VLDL,PCSK9
1,55505647,-0.324712,0.0156429,2.70023e-99,,met-d-Clinical_LDL_C,rs11591147,T,G,0.017458,Clinical LDL cholesterol,PCSK9
1,55505647,-0.330722,0.0156712,7.29962e-99,115082,ebi-a-GCST90092863,rs11591147,T,G,0.017457,Concentration of large LDL particles,PCSK9
1,55505647,-0.324428,0.0157124,3.59998e-98,,met-d-ApoB,rs11591147,T,G,0.017458,Apolipoprotein B,PCSK9
1,55505647,-0.319329,0.0152077,6.90081e-98,115082,ebi-a-GCST90092837,rs11591147,T,G,0.017457,Total lipid levels in IDL,PCSK9
1,55505647,-0.329559,0.0156991,7.70016e-98,115082,ebi-a-GCST90092960,rs11591147,T,G,0.017457,Free cholesterol levels in small LDL,PCSK9
1,55505647,-0.311618,0.0151884,1.29987e-97,,met-d-IDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in IDL,PCSK9
1,55505647,-0.316447,0.0150935,1.29987e-97,115082,ebi-a-GCST90092925,rs11591147,T,G,0.017457,Phospholipids to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.323486,0.0154516,2.49977e-97,115082,ebi-a-GCST90092860,rs11591147,T,G,0.017457,Free cholesterol levels in large LDL,PCSK9
1,55505647,-0.316902,0.0151673,6.09958e-97,115082,ebi-a-GCST90093030,rs11591147,T,G,0.017457,Cholesteryl ester levels in very small VLDL,PCSK9
1,55505647,-0.313688,0.0152712,8.49963e-97,,met-d-XS_VLDL_C,rs11591147,T,G,0.017458,Cholesterol in very small VLDL,PCSK9
1,55505647,-0.321517,0.0157209,8.80035e-97,,met-d-LDL_P,rs11591147,T,G,0.017458,Concentration of LDL particles,PCSK9
1,55505647,-0.317132,0.0151963,1e-96,115082,ebi-a-GCST90092831,rs11591147,T,G,0.017457,Cholesterol levels in IDL,PCSK9
1,55505647,-0.32703,0.0156867,1.59993e-96,115082,ebi-a-GCST90092916,rs11591147,T,G,0.017457,Cholesterol levels in medium VLDL,PCSK9
1,55505647,-0.324014,0.0155667,3.19963e-96,115082,ebi-a-GCST90092885,rs11591147,T,G,0.017457,Free cholesterol levels in LDL,PCSK9
1,55505647,-0.311225,0.0153046,3.40017e-95,,met-d-S_VLDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.323797,0.015644,3.59998e-95,115082,ebi-a-GCST90092814,rs11591147,T,G,0.017457,Clinical LDL cholesterol levels,PCSK9
1,55505647,-0.323815,0.015704,1.80011e-94,115082,ebi-a-GCST90092809,rs11591147,T,G,0.017457,Apolipoprotein B levels,PCSK9
1,55505647,-0.314264,0.0152441,1.99986e-94,115082,ebi-a-GCST90093028,rs11591147,T,G,0.017457,Cholesterol levels in very small VLDL,PCSK9
1,55505647,-0.31541,0.015616,3.50026e-94,,met-d-L_LDL_PL,rs11591147,T,G,0.017458,Phospholipids in large LDL,PCSK9
1,55505647,-0.315588,0.0156977,1.50003e-93,,met-d-LDL_PL,rs11591147,T,G,0.017458,Phospholipids in LDL,PCSK9
1,55505647,-0.31172,0.0151938,1.50003e-93,115082,ebi-a-GCST90092833,rs11591147,T,G,0.017457,Cholesteryl ester levels in IDL,PCSK9
1,55505647,-0.32044,0.0157137,1.99986e-92,115082,ebi-a-GCST90092887,rs11591147,T,G,0.017457,Concentration of LDL particles,PCSK9
1,55505647,-0.310713,0.0152574,3.40017e-92,115082,ebi-a-GCST90092969,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in small VLDL,PCSK9
1,55505647,0.304621,0.0152198,4.20049e-92,,met-d-S_VLDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.305311,0.0154901,1.69981e-91,,met-d-ApoB_by_ApoA1,rs11591147,T,G,0.017458,Ratio of apolipoprotein B to apolipoprotein A1,PCSK9
1,55505647,-0.31186,0.0156489,2.29985e-91,,met-d-non_HDL_C,rs11591147,T,G,0.017458,Total cholesterol minus HDL-C,PCSK9
1,55505647,-0.308049,0.015521,9.60064e-91,,met-d-S_VLDL_CE_pct,rs11591147,T,G,0.017458,Cholesteryl esters to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.310958,0.0157147,9.70063e-91,,met-d-M_LDL_FC,rs11591147,T,G,0.017458,Free cholesterol in medium LDL,PCSK9
1,55505647,-0.3341,0.0174,2.74979e-90,85729,ieu-a-782,rs11591147,T,G,0.01715,Total cholesterol,PCSK9
1,55505647,-0.307951,0.0155557,2.80027e-90,,met-d-L_LDL_C,rs11591147,T,G,0.017458,Cholesterol in large LDL,PCSK9
1,55505647,-0.314459,0.0156168,3.59998e-90,115082,ebi-a-GCST90092864,rs11591147,T,G,0.017457,Phospholipid levels in large LDL,PCSK9
1,55505647,-0.308137,0.0155798,3.80014e-90,,met-d-L_LDL_L,rs11591147,T,G,0.017458,Total lipids in large LDL,PCSK9
1,55505647,-0.308812,0.0156332,7.29962e-90,,met-d-Remnant_C,rs11591147,T,G,0.017458,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",PCSK9
1,55505647,-0.306972,0.0157293,1.69981e-89,,met-d-S_LDL_L,rs11591147,T,G,0.017458,Total lipids in small LDL,PCSK9
1,55505647,0.303948,0.0151614,2.09991e-89,115082,ebi-a-GCST90092979,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.3144,0.0156957,2.99985e-89,115082,ebi-a-GCST90092888,rs11591147,T,G,0.017457,Phospholipid levels in LDL,PCSK9
1,55505647,-0.311201,0.0156451,4.79954e-88,115082,ebi-a-GCST90092930,rs11591147,T,G,0.017457,Total cholesterol minus HDL-C levels,PCSK9
1,55505647,-0.308006,0.0155007,7.29962e-88,115082,ebi-a-GCST90092971,rs11591147,T,G,0.017457,Cholesteryl esters to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.305375,0.0157494,1.10002e-87,,met-d-S_LDL_C,rs11591147,T,G,0.017458,Cholesterol in small LDL,PCSK9
1,55505647,-0.304518,0.0156658,1.9002e-87,,met-d-LDL_C,rs11591147,T,G,0.017458,LDL cholesterol,PCSK9
1,55505647,-0.303807,0.0156813,5.50047e-87,,met-d-LDL_L,rs11591147,T,G,0.017458,Total lipids in LDL,PCSK9
1,55505647,-0.308882,0.0156254,5.60015e-87,115082,ebi-a-GCST90092943,rs11591147,T,G,0.017457,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",PCSK9
1,55505647,-0.305326,0.0154758,1.20005e-86,115082,ebi-a-GCST90092810,rs11591147,T,G,0.017457,Ratio of apolipoprotein B to apolipoprotein A1 levels,PCSK9
1,55505647,-0.306667,0.0155563,1.69981e-86,115082,ebi-a-GCST90092856,rs11591147,T,G,0.017457,Cholesterol levels in large LDL,PCSK9
1,55505647,-0.309686,0.0157146,1.9002e-86,115082,ebi-a-GCST90092908,rs11591147,T,G,0.017457,Free cholesterol levels in medium LDL,PCSK9
1,55505647,-0.306902,0.0155777,2.09991e-86,115082,ebi-a-GCST90092862,rs11591147,T,G,0.017457,Total lipid levels in large LDL,PCSK9
1,55505647,-0.289047,0.0149596,2.90001e-86,,met-d-M_VLDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.3341,0.0173,8.82673e-86,94595,ebi-a-GCST002221,rs11591147,T,G,,"Cholesterol, total",PCSK9
1,55505647,-0.3341,0.0173,8.82673e-86,85729,ieu-a-301,rs11591147,T,G,0.01715,Total cholesterol,PCSK9
1,55505647,-0.301058,0.0157487,2.19989e-85,,met-d-S_LDL_P,rs11591147,T,G,0.017458,Concentration of small LDL particles,PCSK9
1,55505647,-0.298785,0.0155929,8.9002e-85,,met-d-L_LDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in large LDL,PCSK9
1,55505647,-0.294484,0.0154604,2.49977e-84,,met-d-XS_VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in very small VLDL,PCSK9
1,55505647,-0.305666,0.0157226,3.50026e-84,115082,ebi-a-GCST90092962,rs11591147,T,G,0.017457,Total lipid levels in small LDL,PCSK9
1,55505647,-0.303215,0.0156646,1.80011e-83,115082,ebi-a-GCST90092883,rs11591147,T,G,0.017457,LDL cholesterol levels,PCSK9
1,55505647,-0.289129,0.014959,3.10027e-83,115082,ebi-a-GCST90092921,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.304099,0.0157454,4.10015e-83,115082,ebi-a-GCST90092956,rs11591147,T,G,0.017457,Cholesterol levels in small LDL,PCSK9
1,55505647,-0.302525,0.0156773,5.70033e-83,115082,ebi-a-GCST90092886,rs11591147,T,G,0.017457,Total lipid levels in LDL,PCSK9
1,55505647,-0.294853,0.0153928,8.80035e-82,115082,ebi-a-GCST90093032,rs11591147,T,G,0.017457,Free cholesterol levels in very small VLDL,PCSK9
1,55505647,-0.295031,0.0157362,1.69981e-81,,met-d-S_VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in small VLDL,PCSK9
1,55505647,-0.300449,0.0157351,2.80027e-81,115082,ebi-a-GCST90092963,rs11591147,T,G,0.017457,Concentration of small LDL particles,PCSK9
1,55505647,-0.297334,0.0155913,4.40048e-81,115082,ebi-a-GCST90092858,rs11591147,T,G,0.017457,Cholesteryl ester levels in large LDL,PCSK9
1,55505647,-0.0475535,0.00251519,5.10035e-81,484598,ebi-a-GCST90038690,rs11591147,T,G,0.016707,High cholesterol,PCSK9
1,55505647,-0.292396,0.015693,6.29941e-81,,met-d-LDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in LDL,PCSK9
1,55505647,-0.0475441,0.00251913,8.60003e-81,464736,ebi-a-GCST90029021,rs11591147,T,G,0.017467,High cholesterol,PCSK9
1,55505647,-0.505435,0.0266022,1.71317e-80,407746,ebi-a-GCST90013932,rs11591147,T,G,,High cholesterol (SPA correction),PCSK9
1,55505647,-0.572069,0.0322675,2.03704e-80,407746,ebi-a-GCST90013882,rs11591147,T,G,,High cholesterol (Firth correction),PCSK9
1,55505647,-0.285377,0.0153703,7.00003e-80,,met-d-Total_FC,rs11591147,T,G,0.017458,Total free cholesterol,PCSK9
1,55505647,-0.284725,0.0155248,5.90065e-79,,met-d-XS_VLDL_P,rs11591147,T,G,0.017458,Concentration of very small VLDL particles,PCSK9
1,55505647,-0.288209,0.0157571,1.29987e-78,,met-d-M_LDL_PL,rs11591147,T,G,0.017458,Phospholipids in medium LDL,PCSK9
1,55505647,-0.294517,0.0157191,2.49977e-78,115082,ebi-a-GCST90092972,rs11591147,T,G,0.017457,Free cholesterol levels in small VLDL,PCSK9
1,55505647,0.271331,0.0148581,4.79954e-77,,met-d-M_VLDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.29102,0.0156892,8.30042e-77,115082,ebi-a-GCST90092884,rs11591147,T,G,0.017457,Cholesteryl ester levels in LDL,PCSK9
1,55505647,-0.284735,0.0153643,1.10002e-76,115082,ebi-a-GCST90092988,rs11591147,T,G,0.017457,Total free cholesterol levels,PCSK9
1,55505647,-0.273314,0.0150525,1.29987e-76,,met-d-S_VLDL_PL_pct,rs11591147,T,G,0.017458,Phospholipids to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.283365,0.0157426,1.99986e-76,,met-d-S_LDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in small LDL,PCSK9
1,55505647,-0.272525,0.0150221,1.99986e-76,,met-d-S_VLDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.285235,0.0154587,5.10035e-76,115082,ebi-a-GCST90093035,rs11591147,T,G,0.017457,Concentration of very small VLDL particles,PCSK9
1,55505647,-0.623922,0.0368034,9.2406e-76,349222,ebi-a-GCST90104006,rs11591147,T,G,0.017589,Familial combined hyperlipidemia defined by Consensus criteria,PCSK9
1,55505647,-0.282081,0.0157311,4.20049e-75,,met-d-M_VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in medium VLDL,PCSK9
1,55505647,-0.273043,0.0152309,1.39991e-74,,met-d-Total_C,rs11591147,T,G,0.017458,Total cholesterol,PCSK9
1,55505647,0.270634,0.0148296,2.09991e-74,115082,ebi-a-GCST90092927,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.286793,0.0157533,4.70002e-74,115082,ebi-a-GCST90092912,rs11591147,T,G,0.017457,Phospholipid levels in medium LDL,PCSK9
1,55505647,-0.0470181,0.0025856,6.79986e-74,462933,ukb-b-10912,rs11591147,T,G,0.017452,"Non-cancer illness code, self-reported: high cholesterol",PCSK9
1,55505647,-0.272239,0.0149704,6.79986e-74,115082,ebi-a-GCST90092977,rs11591147,T,G,0.017457,Phospholipids to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.271361,0.0149397,1e-73,115082,ebi-a-GCST90092973,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in small VLDL,PCSK9
1,55505647,-0.278645,0.0157382,1.59993e-73,,met-d-VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in VLDL,PCSK9
1,55505647,-0.27823,0.0157651,4.00037e-73,,met-d-M_LDL_C,rs11591147,T,G,0.017458,Cholesterol in medium LDL,PCSK9
1,55505647,-0.278609,0.0157823,9.60064e-73,,met-d-M_LDL_P,rs11591147,T,G,0.017458,Concentration of medium LDL particles,PCSK9
1,55505647,-0.276574,0.0157577,1.20005e-72,,met-d-M_LDL_L,rs11591147,T,G,0.017458,Total lipids in medium LDL,PCSK9
1,55505647,-0.2753,0.015731,4.00037e-72,,met-d-S_VLDL_C,rs11591147,T,G,0.017458,Cholesterol in small VLDL,PCSK9
1,55505647,-0.282243,0.0157379,6.4003e-72,115082,ebi-a-GCST90092958,rs11591147,T,G,0.017457,Cholesteryl ester levels in small LDL,PCSK9
1,55505647,-0.281851,0.0157171,6.4998e-72,115082,ebi-a-GCST90092920,rs11591147,T,G,0.017457,Free cholesterol levels in medium VLDL,PCSK9
1,55505647,-0.26614,0.0151763,1.20005e-71,,met-d-Total_CE,rs11591147,T,G,0.017458,Total esterified cholesterol,PCSK9
1,55505647,-0.2722,0.0152296,1.9002e-71,115082,ebi-a-GCST90092985,rs11591147,T,G,0.017457,Total cholesterol levels,PCSK9
1,55505647,-0.278681,0.0157224,2.70023e-70,115082,ebi-a-GCST90092997,rs11591147,T,G,0.017457,Cholesteryl ester levels in VLDL,PCSK9
1,55505647,-0.266589,0.015466,4.79954e-70,,met-d-XS_VLDL_L,rs11591147,T,G,0.017458,Total lipids in very small VLDL,PCSK9
1,55505647,-0.272622,0.0156233,1.39991e-69,,met-d-XS_VLDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.27799,0.0157711,1.50003e-69,115082,ebi-a-GCST90092911,rs11591147,T,G,0.017457,Concentration of medium LDL particles,PCSK9
1,55505647,-0.27701,0.0157599,3.69999e-69,115082,ebi-a-GCST90092904,rs11591147,T,G,0.017457,Cholesterol levels in medium LDL,PCSK9
1,55505647,-0.275018,0.0157026,1.10002e-68,115082,ebi-a-GCST90092968,rs11591147,T,G,0.017457,Cholesterol levels in small VLDL,PCSK9
1,55505647,-0.273288,0.0156158,1.39991e-68,115082,ebi-a-GCST90093033,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.275282,0.0157507,2.09991e-68,115082,ebi-a-GCST90092910,rs11591147,T,G,0.017457,Total lipid levels in medium LDL,PCSK9
1,55505647,-0.265257,0.0151781,2.19989e-68,115082,ebi-a-GCST90092986,rs11591147,T,G,0.017457,Total esterified cholesterol levels,PCSK9
1,55505647,-0.254368,0.0148086,2.80027e-68,,met-d-M_VLDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.266913,0.0153898,2.19989e-67,115082,ebi-a-GCST90093034,rs11591147,T,G,0.017457,Total lipid levels in very small VLDL,PCSK9
1,55505647,-0.26118,0.0155139,3.29989e-67,,met-d-XS_VLDL_PL,rs11591147,T,G,0.017458,Phospholipids in very small VLDL,PCSK9
1,55505647,0.254171,0.0149434,1e-66,,met-d-XS_VLDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.253651,0.0147754,4.70002e-66,115082,ebi-a-GCST90092917,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in medium VLDL,PCSK9
1,55505647,0.254105,0.014864,1.59993e-65,115082,ebi-a-GCST90093039,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.260113,0.0157122,7.29962e-65,,met-d-S_VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in small VLDL,PCSK9
1,55505647,-0.261364,0.015426,2.19989e-64,115082,ebi-a-GCST90093036,rs11591147,T,G,0.017457,Phospholipid levels in very small VLDL,PCSK9
1,55505647,-0.259031,0.015758,4.60045e-64,,met-d-M_LDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in medium LDL,PCSK9
1,55505647,-0.3623,0.0215,9.42758e-64,290385,ebi-a-GCST90018989,rs11591147,T,G,0.017203,Medication use (HMG CoA reductase inhibitors),PCSK9
1,55505647,-0.253538,0.0157089,2.39994e-62,,met-d-M_VLDL_PL,rs11591147,T,G,0.017458,Phospholipids in medium VLDL,PCSK9
1,55505647,-0.3619,0.0217,3.08035e-62,64115,ieu-b-4846,rs11591147,T,G,,LDL cholesterol,PCSK9
1,55505647,-0.239095,0.0149209,7.00003e-62,,met-d-S_HDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in small HDL,PCSK9
1,55505647,-0.259988,0.0156775,9.20026e-62,115082,ebi-a-GCST90092970,rs11591147,T,G,0.017457,Cholesteryl ester levels in small VLDL,PCSK9
1,55505647,-0.239063,0.0147697,8.10028e-61,,met-d-M_VLDL_CE_pct,rs11591147,T,G,0.017458,Cholesteryl esters to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.257865,0.0157493,2.99985e-60,115082,ebi-a-GCST90092906,rs11591147,T,G,0.017457,Cholesteryl ester levels in medium LDL,PCSK9
1,55505647,0.248023,0.0152796,3.90032e-60,,met-d-XL_VLDL_TG_pct,rs11591147,T,G,0.017402,Triglycerides to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.24792,0.0157024,1.39991e-59,,met-d-S_VLDL_PL,rs11591147,T,G,0.017458,Phospholipids in small VLDL,PCSK9
1,55505647,-0.238043,0.0147171,7.59976e-59,115082,ebi-a-GCST90092919,rs11591147,T,G,0.017457,Cholesteryl esters to total lipids ratio in medium VLDL,PCSK9
1,55505647,-0.246169,0.0157117,8.10028e-59,,met-d-VLDL_C,rs11591147,T,G,0.017458,VLDL cholesterol,PCSK9
1,55505647,0.246654,0.0152551,8.4004e-59,114160,ebi-a-GCST90093027,rs11591147,T,G,0.017401,Triglycerides to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.253243,0.0156932,1.39991e-58,115082,ebi-a-GCST90092924,rs11591147,T,G,0.017457,Phospholipid levels in medium VLDL,PCSK9
1,55505647,-0.244027,0.0153741,2.90001e-58,,met-d-L_VLDL_C_pct,rs11591147,T,G,0.017455,Cholesterol to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.238926,0.0148959,6.70039e-58,115082,ebi-a-GCST90092949,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in small HDL,PCSK9
1,55505647,-0.244262,0.015378,8.19974e-57,115071,ebi-a-GCST90092869,rs11591147,T,G,0.017454,Cholesterol to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.228354,0.014707,1.29987e-56,,met-d-Sphingomyelins,rs11591147,T,G,0.017465,Sphingomyelins,PCSK9
1,55505647,-0.236525,0.0150577,1.39991e-56,,met-d-L_VLDL_CE_pct,rs11591147,T,G,0.017455,Cholesteryl esters to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.240222,0.0156947,1.50003e-56,,met-d-M_VLDL_P,rs11591147,T,G,0.017458,Concentration of medium VLDL particles,PCSK9
1,55505647,-0.247599,0.015667,2.90001e-56,115082,ebi-a-GCST90092976,rs11591147,T,G,0.017457,Phospholipid levels in small VLDL,PCSK9
1,55505647,-0.23145,0.0149072,5.40008e-56,,met-d-XS_VLDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.483319,0.0306848,6.7515e-56,407746,ebi-a-GCST90013969,rs11591147,T,G,,Cholesterol lowering medication use (UKB data field 6177_1) (SPA correction),PCSK9
1,55505647,-0.520457,0.034515,7.48342e-56,407746,ebi-a-GCST90013919,rs11591147,T,G,,Cholesterol lowering medication use (UKB data field 6177_1) (Firth correction),PCSK9
1,55505647,-0.236934,0.015059,8.9002e-56,115071,ebi-a-GCST90092871,rs11591147,T,G,0.017454,Cholesteryl esters to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.246233,0.015689,1.59993e-55,115082,ebi-a-GCST90092996,rs11591147,T,G,0.017457,VLDL cholesterol levels,PCSK9
1,55505647,-0.0476105,0.00303454,1.86552e-55,337159,ukb-a-108,rs11591147,T,G,0.0174556,Non-cancer illness code  self-reported: high cholesterol,PCSK9
1,55505647,-0.243038,0.0157945,4.49987e-55,,met-d-XL_VLDL_PL_pct,rs11591147,T,G,0.017402,Phospholipids to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.231585,0.0148354,6.20012e-55,115082,ebi-a-GCST90093029,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.244698,0.0157823,3.19963e-54,114160,ebi-a-GCST90093025,rs11591147,T,G,0.017401,Phospholipids to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.227522,0.0146943,4.49987e-54,115006,ebi-a-GCST90092982,rs11591147,T,G,0.017464,Sphingomyelin levels,PCSK9
1,55505647,-0.240097,0.0156777,6.09958e-53,115082,ebi-a-GCST90092923,rs11591147,T,G,0.017457,Concentration of medium VLDL particles,PCSK9
1,55505647,-0.214168,0.0146219,2.90001e-52,,met-d-L_HDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in large HDL,PCSK9
1,55505647,0.232522,0.0156681,1.10002e-50,,met-d-L_VLDL_TG_pct,rs11591147,T,G,0.017455,Triglycerides to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.526401,0.034732,2.02023e-50,15985,met-c-882,rs11591147,T,G,0.030715,Free cholesterol in large LDL,PCSK9
1,55505647,-0.523828,0.034717,5.68984e-50,15985,met-c-880,rs11591147,T,G,0.030715,Total cholesterol in large LDL,PCSK9
1,55505647,0.232351,0.015663,8.80035e-50,115071,ebi-a-GCST90092879,rs11591147,T,G,0.017454,Triglycerides to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.21604,0.0148298,1.69981e-49,,met-d-XS_VLDL_CE_pct,rs11591147,T,G,0.017458,Cholesteryl esters to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.072924,0.00496521,7.8001e-49,209638,ukb-b-11740,rs11591147,T,G,0.017316,"Medication for cholesterol, blood pressure or diabetes: Cholesterol lowering medication",PCSK9
1,55505647,-0.51831,0.034723,8.60003e-49,15985,met-c-881,rs11591147,T,G,0.030715,Cholesterol esters in large VLDL,PCSK9
1,55505647,-0.214652,0.0146235,8.80035e-49,115082,ebi-a-GCST90092849,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in large HDL,PCSK9
1,55505647,-0.215908,0.0147377,1.29987e-48,115082,ebi-a-GCST90093031,rs11591147,T,G,0.017457,Cholesteryl esters to total lipids ratio in very small VLDL,PCSK9
1,55505647,-0.516356,0.034738,2.07014e-48,15985,met-c-883,rs11591147,T,G,0.030715,Total lipids in large LDL,PCSK9
1,55505647,-0.515236,0.03472,2.84971e-48,15985,met-c-895,rs11591147,T,G,0.030715,Total cholesterol in LDL,PCSK9
1,55505647,-0.509737,0.034729,2.83009e-47,15985,met-c-904,rs11591147,T,G,0.030715,Total cholesterol in medium LDL,PCSK9
1,55505647,-0.508809,0.034744,4.45964e-47,15985,met-c-884,rs11591147,T,G,0.030715,Concentration of large LDL particles,PCSK9
1,55505647,-0.505043,0.034776,1.27997e-46,15985,met-c-868,rs11591147,T,G,0.030715,Free cholesterol in IDL,PCSK9
1,55505647,-0.506389,0.034749,1.38995e-46,15985,met-c-905,rs11591147,T,G,0.030715,Cholesterol esters in medium LDL,PCSK9
1,55505647,-0.505262,0.034777,1.46994e-46,15985,met-c-885,rs11591147,T,G,0.030715,Phospholipids in large LDL,PCSK9
1,55505647,0.213926,0.0152204,3.19963e-46,,met-d-L_HDL_PL_pct,rs11591147,T,G,0.017458,Phospholipids to total lipids ratio in large HDL,PCSK9
1,55505647,-0.216625,0.0152842,3.29989e-46,,met-d-XL_VLDL_FC_pct,rs11591147,T,G,0.017402,Free cholesterol to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.500952,0.034735,1.23994e-45,15985,met-c-906,rs11591147,T,G,0.030715,Total lipids in medium LDL,PCSK9
1,55505647,-0.216328,0.0152657,1.39991e-45,114160,ebi-a-GCST90093021,rs11591147,T,G,0.017401,Free cholesterol to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.499655,0.034767,1.54989e-45,15985,met-c-867,rs11591147,T,G,0.030715,Total cholesterol in IDL,PCSK9
1,55505647,0.213601,0.0151761,5.40008e-45,115082,ebi-a-GCST90092853,rs11591147,T,G,0.017457,Phospholipids to total lipids ratio in large HDL,PCSK9
1,55505647,-0.494053,0.034737,1.90985e-44,15985,met-c-907,rs11591147,T,G,0.030715,Concentration of medium LDL particles,PCSK9
1,55505647,-0.210743,0.0156476,2.70023e-44,,met-d-VLDL_P,rs11591147,T,G,0.017458,Concentration of VLDL particles,PCSK9
1,55505647,-0.210941,0.0151127,4.10015e-44,,met-d-XL_VLDL_C_pct,rs11591147,T,G,0.017402,Cholesterol to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.209061,0.0150689,9.09913e-44,114160,ebi-a-GCST90093017,rs11591147,T,G,0.017401,Cholesterol to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.487758,0.034812,1.59001e-43,15985,met-c-871,rs11591147,T,G,0.030715,Phospholipids in IDL,PCSK9
1,55505647,-0.207062,0.0154805,2.99985e-43,,met-d-Total_L,rs11591147,T,G,0.017458,Total lipids in lipoprotein particles,PCSK9
1,55505647,-0.483451,0.034733,6.4003e-43,15985,met-c-924,rs11591147,T,G,0.030715,Total cholesterol in small LDL,PCSK9
1,55505647,-0.480746,0.034793,3.32966e-42,15985,met-c-869,rs11591147,T,G,0.030715,Total lipids in IDL,PCSK9
1,55505647,0.202951,0.0151993,6.4998e-42,,met-d-IDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in IDL,PCSK9
1,55505647,-0.210914,0.0155949,1.10002e-41,115082,ebi-a-GCST90093000,rs11591147,T,G,0.017457,Concentration of VLDL particles,PCSK9
1,55505647,0.199836,0.0152102,3.19963e-41,,met-d-S_HDL_PL_pct,rs11591147,T,G,0.017458,Phospholipids to total lipids ratio in small HDL,PCSK9
1,55505647,0.20278,0.0150806,3.19963e-41,115082,ebi-a-GCST90092842,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in IDL,PCSK9
1,55505647,0.204804,0.0155369,3.29989e-41,,met-d-M_LDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.475228,0.03479,3.63999e-41,15985,met-c-908,rs11591147,T,G,0.030715,Phospholipids in medium LDL,PCSK9
1,55505647,-0.203142,0.01512,4.30031e-41,,met-d-XL_VLDL_CE_pct,rs11591147,T,G,0.017402,Cholesteryl esters to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.206283,0.0154567,1.29987e-40,115082,ebi-a-GCST90092989,rs11591147,T,G,0.017457,Total lipid levels in lipoprotein particles,PCSK9
1,55505647,-0.200937,0.0150683,1.39991e-40,114160,ebi-a-GCST90093019,rs11591147,T,G,0.017401,Cholesteryl esters to total lipids ratio in very large VLDL,PCSK9
1,55505647,-0.0771513,0.00578468,1.48149e-40,154702,ukb-a-488,rs11591147,T,G,0.0174556,Medication for cholesterol  blood pressure or diabetes: Cholesterol lowering medication,PCSK9
1,55505647,0.204022,0.0154,4.60045e-40,115082,ebi-a-GCST90092915,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.197424,0.0156259,7.59976e-40,,met-d-M_VLDL_L,rs11591147,T,G,0.017458,Total lipids in medium VLDL,PCSK9
1,55505647,-0.464499,0.034806,1.82012e-39,15985,met-c-870,rs11591147,T,G,0.030715,Concentration of IDL particles,PCSK9
1,55505647,0.199045,0.0151685,2.49977e-39,115082,ebi-a-GCST90092953,rs11591147,T,G,0.017457,Phospholipids to total lipids ratio in small HDL,PCSK9
1,55505647,-0.460207,0.034861,4.91021e-39,15985,met-c-933,rs11591147,T,G,0.030715,Serum total cholesterol,PCSK9
1,55505647,-0.195553,0.015617,5.30029e-39,,met-d-VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in VLDL,PCSK9
1,55505647,-0.461159,0.034751,6.07016e-39,15985,met-c-925,rs11591147,T,G,0.030715,Total lipids in small LDL,PCSK9
1,55505647,-0.197244,0.0156054,1.29987e-36,115082,ebi-a-GCST90092922,rs11591147,T,G,0.017457,Total lipid levels in medium VLDL,PCSK9
1,55505647,0.189415,0.0152468,2.80027e-36,,met-d-S_LDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in small LDL,PCSK9
1,55505647,-0.444171,0.034787,3.36977e-36,15985,met-c-926,rs11591147,T,G,0.030715,Concentration of small LDL particles,PCSK9
1,55505647,-0.195725,0.0155842,3.50026e-36,115082,ebi-a-GCST90092998,rs11591147,T,G,0.017457,Free cholesterol levels in VLDL,PCSK9
1,55505647,0.189082,0.015428,1.20005e-35,,met-d-L_LDL_TG_pct,rs11591147,T,G,0.017458,Triglycerides to total lipids ratio in large LDL,PCSK9
1,55505647,-0.177244,0.0146566,1.80011e-35,,met-d-XL_HDL_FC,rs11591147,T,G,0.017458,Free cholesterol in very large HDL,PCSK9
1,55505647,0.187938,0.0151358,2.09991e-35,115082,ebi-a-GCST90092967,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in small LDL,PCSK9
1,55505647,-0.495239,0.0397,3.44985e-35,13492,met-c-858,rs11591147,T,G,0.028751,Free cholesterol,PCSK9
1,55505647,0.188325,0.0152746,6.29941e-35,115082,ebi-a-GCST90092867,rs11591147,T,G,0.017457,Triglycerides to total lipids ratio in large LDL,PCSK9
1,55505647,-0.182593,0.0149208,1.99986e-34,115082,ebi-a-GCST90092861,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in large LDL,PCSK9
1,55505647,-0.182051,0.014996,2.49977e-34,,met-d-L_LDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in large LDL,PCSK9
1,55505647,-0.437941,0.035298,2.49977e-34,15270,met-c-843,rs11591147,T,G,0.031101,Apolipoprotein B,PCSK9
1,55505647,-0.183353,0.0153304,5.00035e-34,,met-d-L_LDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in large LDL,PCSK9
1,55505647,-0.178287,0.01466,5.00035e-34,115082,ebi-a-GCST90093008,rs11591147,T,G,0.017457,Free cholesterol levels in very large HDL,PCSK9
1,55505647,-0.0297996,0.00249708,7.89951e-33,462933,ukb-b-11268,rs11591147,T,G,0.017452,Treatment/medication code: simvastatin,PCSK9
1,55505647,-0.181934,0.0152593,8.99912e-33,115082,ebi-a-GCST90092857,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in large LDL,PCSK9
1,55505647,-0.421474,0.034866,9.18967e-33,15985,met-c-955,rs11591147,T,G,0.030715,Phospholipids in very small VLDL,PCSK9
1,55505647,-0.184283,0.015583,2.90001e-32,115071,ebi-a-GCST90092873,rs11591147,T,G,0.017454,Free cholesterol to total lipids ratio in large VLDL,PCSK9
1,55505647,-21.5141,1.82341,3.95913e-32,17373,ebi-a-GCST008037,rs11591147,T,G,0.00678129,Low density lipoprotein cholesterol levels,PCSK9
1,55505647,-0.183899,0.0155956,5.60015e-32,,met-d-L_VLDL_FC_pct,rs11591147,T,G,0.017455,Free cholesterol to total lipids ratio in large VLDL,PCSK9
1,55505647,-0.173356,0.0155457,2.70023e-31,,met-d-L_VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in large VLDL,PCSK9
1,55505647,-0.461292,0.039818,1.63005e-30,13492,met-c-853,rs11591147,T,G,0.028751,Free cholesterol to esterified cholesterol ratio,PCSK9
1,55505647,-0.171934,0.0153635,5.10035e-30,,met-d-IDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in IDL,PCSK9
1,55505647,-0.167983,0.0154869,7.39946e-30,,met-d-XL_VLDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in very large VLDL,PCSK9
1,55505647,-0.169602,0.0155773,8.10028e-30,,met-d-S_VLDL_L,rs11591147,T,G,0.017458,Total lipids in small VLDL,PCSK9
1,55505647,-0.167029,0.0153439,8.99912e-30,,met-d-PUFA,rs11591147,T,G,0.017465,Polyunsaturated fatty acids,PCSK9
1,55505647,-0.172523,0.0152762,1.39991e-29,115082,ebi-a-GCST90092832,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in IDL,PCSK9
1,55505647,-0.166015,0.0153646,3.19963e-29,,met-d-Omega_6,rs11591147,T,G,0.017465,Omega-6 fatty acids,PCSK9
1,55505647,-0.17375,0.0155166,4.19952e-29,115082,ebi-a-GCST90092870,rs11591147,T,G,0.017457,Cholesteryl ester levels in large VLDL,PCSK9
1,55505647,-0.163618,0.015542,2.60016e-28,,met-d-VLDL_PL,rs11591147,T,G,0.017458,Phospholipids in VLDL,PCSK9
1,55505647,-0.158048,0.0149839,6.00067e-28,,met-d-Total_PL,rs11591147,T,G,0.017458,Total phospholipids in lipoprotein particles,PCSK9
1,55505647,-0.163175,0.0155316,6.00067e-28,,met-d-S_VLDL_P,rs11591147,T,G,0.017458,Concentration of small VLDL particles,PCSK9
1,55505647,-0.167284,0.0152671,6.09958e-28,115006,ebi-a-GCST90092939,rs11591147,T,G,0.017464,Polyunsaturated fatty acid levels,PCSK9
1,55505647,-0.169587,0.0155115,8.00018e-28,115082,ebi-a-GCST90092974,rs11591147,T,G,0.017457,Total lipid levels in small VLDL,PCSK9
1,55505647,-0.4097,0.0377,1.58891e-27,,finn-b-E4_LIPOPROT,rs11591147,T,G,0.03607,Disorders of lipoprotein metabolism and other lipidaemias,PCSK9
1,55505647,-0.167989,0.015471,1.80011e-27,115082,ebi-a-GCST90093018,rs11591147,T,G,0.017457,Cholesteryl ester levels in very large VLDL,PCSK9
1,55505647,-0.165697,0.0153538,3.80014e-27,115006,ebi-a-GCST90092933,rs11591147,T,G,0.017464,Omega-6 fatty acid levels,PCSK9
1,55505647,-0.156709,0.0154315,4.40048e-26,,met-d-LA,rs11591147,T,G,0.017465,Linoleic acid,PCSK9
1,55505647,-0.163783,0.015504,4.40048e-26,115082,ebi-a-GCST90093001,rs11591147,T,G,0.017457,Phospholipid levels in VLDL,PCSK9
1,55505647,-0.163232,0.0154611,4.70002e-26,115082,ebi-a-GCST90092975,rs11591147,T,G,0.017457,Concentration of small VLDL particles,PCSK9
1,55505647,-0.0309811,0.00293635,5.07925e-26,337159,ukb-a-121,rs11591147,T,G,0.0174556,Treatment/medication code: simvastatin,PCSK9
1,55505647,-0.157164,0.0149554,7.89951e-26,115082,ebi-a-GCST90092991,rs11591147,T,G,0.017457,Total phospholipid levels in lipoprotein particles,PCSK9
1,55505647,-0.161458,0.0158094,2.29985e-25,,met-d-S_LDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in small LDL,PCSK9
1,55505647,-0.3691,0.0356,3.04369e-25,26680,ieu-b-4845,rs11591147,T,G,,LDL cholesterol,PCSK9
1,55505647,-21.1719,2.06018,8.97016e-25,17802,ebi-a-GCST008045,rs11591147,T,G,0.00675004,Total cholesterol levels,PCSK9
1,55505647,-0.160412,0.0157892,2.99985e-24,115082,ebi-a-GCST90092957,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in small LDL,PCSK9
1,55505647,-0.155986,0.0154372,5.30029e-24,115006,ebi-a-GCST90092880,rs11591147,T,G,0.017464,Linoleic acid levels,PCSK9
1,55505647,-0.134484,0.0141575,3.19963e-23,,met-d-XL_HDL_P,rs11591147,T,G,0.017458,Concentration of very large HDL particles,PCSK9
1,55505647,-0.133135,0.0141859,9.20026e-23,,met-d-XL_HDL_C,rs11591147,T,G,0.017458,Cholesterol in very large HDL,PCSK9
1,55505647,-0.2406,0.0247,1.85481e-22,296525,ebi-a-GCST005194,rs11591147,T,G,0.0164,Coronary artery disease,PCSK9
1,55505647,-0.148066,0.0157583,4.40048e-22,,met-d-M_LDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.33771,0.034863,1.03992e-21,15985,met-c-927,rs11591147,T,G,0.030715,Total cholesterol in small VLDL,PCSK9
1,55505647,-0.149405,0.0156202,1.10002e-21,115082,ebi-a-GCST90092836,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in IDL,PCSK9
1,55505647,-0.134641,0.0141563,1.9002e-21,115082,ebi-a-GCST90093011,rs11591147,T,G,0.017457,Concentration of very large HDL particles,PCSK9
1,55505647,-0.14791,0.0156186,2.90001e-21,,met-d-IDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in IDL,PCSK9
1,55505647,-0.14823,0.0157547,5.00035e-21,115082,ebi-a-GCST90092905,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.133317,0.0141897,5.70033e-21,115082,ebi-a-GCST90093004,rs11591147,T,G,0.017457,Cholesterol levels in very large HDL,PCSK9
1,55505647,-0.332251,0.034884,6.21012e-21,15985,met-c-953,rs11591147,T,G,0.030715,Total lipids in very small VLDL,PCSK9
1,55505647,-0.450003,0.051396,8.51726e-21,349222,ebi-a-GCST90104005,rs11591147,T,G,0.017589,Familial combined hyperlipidemia defined by Dutch criteria,PCSK9
1,55505647,-0.326381,0.034883,3.01023e-20,15985,met-c-872,rs11591147,T,G,0.030715,Triglycerides in IDL,PCSK9
1,55505647,-0.368426,0.039901,3.74024e-20,13473,met-c-935,rs11591147,T,G,0.028653,Sphingomyelins,PCSK9
1,55505647,-0.0325758,0.00357901,8.9002e-20,249710,ukb-b-17805,rs11591147,T,G,0.017507,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Cholesterol lowering medication",PCSK9
1,55505647,-0.322207,0.034887,9.53016e-20,15985,met-c-954,rs11591147,T,G,0.030715,Concentration of very small VLDL particles,PCSK9
1,55505647,-0.4152,0.0459,1.45613e-19,,finn-b-E4_HYPERCHOL,rs11591147,T,G,0.03638,Pure hypercholesterolaemia,PCSK9
1,55505647,-0.130509,0.0153896,4.19952e-19,,met-d-L_VLDL_C,rs11591147,T,G,0.017458,Cholesterol in large VLDL,PCSK9
1,55505647,-0.118896,0.0140889,8.69961e-19,,met-d-XL_HDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in very large HDL,PCSK9
1,55505647,-0.236991,0.0269669,1.50003e-18,547261,ebi-a-GCST005195,rs11591147,T,G,,Coronary artery disease,PCSK9
1,55505647,-0.2602,0.0297,1.83021e-18,,finn-b-E4_METABOLIA,rs11591147,T,G,0.03609,Metabolic disorders,PCSK9
1,55505647,-0.131401,0.0154444,3.19963e-18,,met-d-IDL_CE_pct,rs11591147,T,G,0.017458,Cholesteryl esters to total lipids ratio in IDL,PCSK9
1,55505647,-0.13349,0.0155518,4.49987e-18,,met-d-S_HDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in small HDL,PCSK9
1,55505647,-0.134034,0.0153884,5.40008e-18,,met-d-LDL_size,rs11591147,T,G,0.017458,Average diameter for LDL particles,PCSK9
1,55505647,-0.130216,0.0152497,6.79986e-18,,met-d-S_LDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in small LDL,PCSK9
1,55505647,-0.1319,0.0153128,7.10068e-18,115082,ebi-a-GCST90092834,rs11591147,T,G,0.017457,Cholesteryl esters to total lipids ratio in IDL,PCSK9
1,55505647,-0.131785,0.0153448,8.80035e-18,115082,ebi-a-GCST90092889,rs11591147,T,G,0.017457,Average diameter for LDL particles,PCSK9
1,55505647,0.0613934,0.00788205,1e-17,398508,ebi-a-GCST90025955,rs11591147,T,G,0.0176185,Apolipoprotein A1 levels,PCSK9
1,55505647,-0.124616,0.0153683,1.29987e-17,,met-d-XL_VLDL_C,rs11591147,T,G,0.017458,Cholesterol in very large VLDL,PCSK9
1,55505647,-0.132121,0.0154563,1.29987e-17,115082,ebi-a-GCST90092945,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in small HDL,PCSK9
1,55505647,-0.130846,0.0153594,1.59993e-17,115082,ebi-a-GCST90092868,rs11591147,T,G,0.017457,Cholesterol levels in large VLDL,PCSK9
1,55505647,-0.128726,0.0151511,1.99986e-17,115082,ebi-a-GCST90092961,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in small LDL,PCSK9
1,55505647,-0.122724,0.0148294,2.09991e-17,,met-d-L_HDL_C_pct,rs11591147,T,G,0.017458,Cholesterol to total lipids ratio in large HDL,PCSK9
1,55505647,-0.11885,0.0140927,3.40017e-17,115082,ebi-a-GCST90093006,rs11591147,T,G,0.017457,Cholesteryl ester levels in very large HDL,PCSK9
1,55505647,-0.13284,0.015896,4.60045e-17,,met-d-XXL_VLDL_CE_pct,rs11591147,T,G,0.017428,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,PCSK9
1,55505647,-0.3174,0.0379,5.84655e-17,461823,ebi-a-GCST90018877,rs11591147,T,G,0.0229433,Myocardial infarction,PCSK9
1,55505647,-0.125544,0.015592,8.69961e-17,,met-d-L_LDL_TG,rs11591147,T,G,0.017458,Triglycerides in large LDL,PCSK9
1,55505647,-0.121975,0.0147737,1.50003e-16,115082,ebi-a-GCST90092845,rs11591147,T,G,0.017457,Cholesterol to total lipids ratio in large HDL,PCSK9
1,55505647,-0.131079,0.0158946,1.59993e-16,111638,ebi-a-GCST90093043,rs11591147,T,G,0.017427,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,PCSK9
1,55505647,-0.293563,0.035624,1.80011e-16,58825,ebi-a-GCST011365,rs11591147,T,G,0.015973,Myocardial infarction,PCSK9
1,55505647,-0.124929,0.0153466,3.90032e-16,115082,ebi-a-GCST90093016,rs11591147,T,G,0.017457,Cholesterol levels in very large VLDL,PCSK9
1,55505647,-0.124988,0.015403,4.90004e-16,115082,ebi-a-GCST90092866,rs11591147,T,G,0.017457,Triglyceride levels in large LDL,PCSK9
1,55505647,0.118904,0.0146813,5.50047e-16,115082,ebi-a-GCST90092900,rs11591147,T,G,0.017457,Phospholipid levels in medium HDL,PCSK9
1,55505647,0.117819,0.0147126,5.70033e-16,,met-d-M_HDL_PL,rs11591147,T,G,0.017458,Phospholipids in medium HDL,PCSK9
1,55505647,-0.0446779,0.00820706,6.79986e-16,348806,ebi-a-GCST90025993,rs11591147,T,G,0.0176251,Lipoprotein (a) levels,PCSK9
1,55505647,0.0445405,0.00554118,9.09913e-16,209638,ukb-b-12014,rs11591147,T,G,0.017316,"Medication for cholesterol, blood pressure or diabetes: None of the above",PCSK9
1,55505647,-0.3692,0.0461,1.21899e-15,,finn-b-I9_REVASC,rs11591147,T,G,0.03629,Coronary revascularization (ANGIO or CABG),PCSK9
1,55505647,-0.115757,0.0154276,1.9002e-15,,met-d-VLDL_L,rs11591147,T,G,0.017458,Total lipids in VLDL,PCSK9
1,55505647,0.0509638,0.00647002,3.37754e-15,154702,ukb-a-489,rs11591147,T,G,0.0174556,Medication for cholesterol  blood pressure or diabetes: None of the above,PCSK9
1,55505647,-0.106757,0.0141384,3.50026e-15,,met-d-XL_HDL_L,rs11591147,T,G,0.017458,Total lipids in very large HDL,PCSK9
1,55505647,-0.276735,0.03487,4.6505e-15,15985,met-c-928,rs11591147,T,G,0.030715,Free cholesterol in small VLDL,PCSK9
1,55505647,-0.314397,0.039922,5.31986e-15,13525,met-c-893,rs11591147,T,G,0.028751,"18:2, linoleic acid (LA)",PCSK9
1,55505647,-0.110337,0.0147962,6.09958e-15,,met-d-Cholines,rs11591147,T,G,0.017465,Total cholines,PCSK9
1,55505647,-0.0132784,0.00170505,6.79986e-15,463010,ukb-b-12651,rs11591147,T,G,0.017453,Diagnoses - secondary ICD10: E78.0 Pure hypercholesterolaemia,PCSK9
1,55505647,-0.309146,0.039917,1.11995e-14,13502,met-c-856,rs11591147,T,G,0.028839,Omega-6 fatty acids,PCSK9
1,55505647,-0.266021,0.0345274,1.3122e-14,352063,ebi-a-GCST90013868,rs11591147,T,G,,Coronary artery disease (SPA correction),PCSK9
1,55505647,-0.283544,0.03813,1.41514e-14,352063,ebi-a-GCST90013864,rs11591147,T,G,,Coronary artery disease (Firth correction),PCSK9
1,55505647,-0.341,0.0448,2.73023e-14,,finn-b-I9_REVACS_EXNONE,rs11591147,T,G,0.03609,Emergency coronary revascularization (for ACS) (no controls excluded),PCSK9
1,55505647,-0.341,0.0448,2.73023e-14,,finn-b-I9_REVASC_EXNONE,rs11591147,T,G,0.03609,Coronary revascularization (ANGIO or CABG) (no controls excluded),PCSK9
1,55505647,-0.2269,0.0299,2.93495e-14,,finn-b-I9_IHD,rs11591147,T,G,0.03609,"Ischaemic heart disease, wide definition",PCSK9
1,55505647,-0.107163,0.0141363,3.40017e-14,115082,ebi-a-GCST90093010,rs11591147,T,G,0.017457,Total lipid levels in very large HDL,PCSK9
1,55505647,-0.116113,0.0153886,4.49987e-14,115082,ebi-a-GCST90092999,rs11591147,T,G,0.017457,Total lipid levels in VLDL,PCSK9
1,55505647,-0.111414,0.0152101,5.30029e-14,,met-d-DHA,rs11591147,T,G,0.017465,Docosahexaenoic acid,PCSK9
1,55505647,-0.0317505,0.00422207,5.49794e-14,180203,ukb-a-448,rs11591147,T,G,0.0174556,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: Cholesterol lowering medication,PCSK9
1,55505647,-0.0119231,0.00158604,5.595e-14,337159,ukb-a-176,rs11591147,T,G,0.0174556,Treatment/medication code: atorvastatin,PCSK9
1,55505647,-0.112079,0.0149419,6.29941e-14,115006,ebi-a-GCST90092816,rs11591147,T,G,0.017464,Docosahexaenoic acid levels,PCSK9
1,55505647,-0.109707,0.0147677,1.10002e-13,115006,ebi-a-GCST90092812,rs11591147,T,G,0.017464,Total cholines levels,PCSK9
1,55505647,-0.108737,0.0156074,1.29987e-13,,met-d-Total_FA,rs11591147,T,G,0.017465,Total fatty acids,PCSK9
1,55505647,-0.1094,0.0155616,2.39994e-13,,met-d-LDL_TG,rs11591147,T,G,0.017458,Triglycerides in LDL,PCSK9
1,55505647,-0.109936,0.0150744,3.40017e-13,,met-d-M_LDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.108907,0.0149868,3.69999e-13,115082,ebi-a-GCST90092909,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in medium LDL,PCSK9
1,55505647,-0.676738,0.103738,3.81944e-13,349222,ebi-a-GCST90104007,rs11591147,T,G,0.017589,Familial combined hyperlipidemia defined by Mexico criteria,PCSK9
1,55505647,0.104648,0.0145847,7.19946e-13,115082,ebi-a-GCST90092898,rs11591147,T,G,0.017457,Total lipid levels in medium HDL,PCSK9
1,55505647,0.10342,0.0146073,7.39946e-13,,met-d-M_HDL_L,rs11591147,T,G,0.017458,Total lipids in medium HDL,PCSK9
1,55505647,0.0519075,0.00802549,8.10028e-13,372420,ebi-a-GCST90025983,rs11591147,T,G,0.0179398,Direct bilirubin levels,PCSK9
1,55505647,0.0533183,0.00747617,9.8992e-13,,ieu-b-107,rs11591147,T,G,0.017412,apolipoprotein A-I,PCSK9
1,55505647,-0.109059,0.0153884,1.39991e-12,115082,ebi-a-GCST90092890,rs11591147,T,G,0.017457,Triglyceride levels in LDL,PCSK9
1,55505647,-0.249193,0.034882,1.75995e-12,15985,met-c-931,rs11591147,T,G,0.030715,Phospholipids in small VLDL,PCSK9
1,55505647,-0.2103,0.0299,2.16721e-12,,finn-b-I9_ISCHHEART,rs11591147,T,G,0.03609,Ischemic heart diseases,PCSK9
1,55505647,-0.10863,0.0155184,2.60016e-12,115006,ebi-a-GCST90092987,rs11591147,T,G,0.017464,Total fatty acid levels,PCSK9
1,55505647,-0.0245794,0.00349628,2.70023e-12,484598,ebi-a-GCST90038595,rs11591147,T,G,0.016707,Cardiovascular disease,PCSK9
1,55505647,-0.2971,0.0428,3.85567e-12,,finn-b-I9_MI,rs11591147,T,G,0.03635,Myocardial infarction,PCSK9
1,55505647,-0.2179,0.0316,5.83311e-12,470931,ebi-a-GCST90018793,rs11591147,T,G,0.0230188,Angina pectoris,PCSK9
1,55505647,-0.102911,0.0155512,6.59933e-12,,met-d-IDL_TG,rs11591147,T,G,0.017458,Triglycerides in IDL,PCSK9
1,55505647,-0.023651,0.00347203,8.99912e-12,477807,ebi-a-GCST90029019,rs11591147,T,G,0.017467,Cardiovascular disease,PCSK9
1,55505647,-0.2388,0.0352,1.2471e-11,,finn-b-I9_CHD,rs11591147,T,G,0.03609,Major coronary heart disease event,PCSK9
1,55505647,-0.2309,0.0341,1.26794e-11,,finn-b-I9_CORATHER,rs11591147,T,G,0.03619,Coronary atherosclerosis,PCSK9
1,55505647,-0.238982,0.034886,1.48013e-11,15985,met-c-929,rs11591147,T,G,0.030715,Total lipids in small VLDL,PCSK9
1,55505647,-0.102722,0.0153527,2.19989e-11,115082,ebi-a-GCST90092841,rs11591147,T,G,0.017457,Triglyceride levels in IDL,PCSK9
1,55505647,-0.2491,0.0373,2.37301e-11,,finn-b-I9_ANGINA,rs11591147,T,G,0.03631,Angina pectoris,PCSK9
1,55505647,-0.4103,0.0619,3.26889e-11,,finn-b-I9_CABG,rs11591147,T,G,0.03658,Coronary artery bypass grafting,PCSK9
1,55505647,-0.233824,0.034908,3.95003e-11,15985,met-c-910,rs11591147,T,G,0.030715,Cholesterol esters in medium VLDL,PCSK9
1,55505647,-0.233711,0.034934,4.40961e-11,15985,met-c-956,rs11591147,T,G,0.030715,Triglycerides in very small VLDL,PCSK9
1,55505647,0.0508823,0.00772472,4.48952e-11,355859,ebi-a-GCST90013993,rs11591147,T,G,,Apolipoprotein A levels (UKB data field 30630),PCSK9
1,55505647,-0.2204,0.0337,6.33432e-11,,finn-b-I9_CORATHER_EXNONE,rs11591147,T,G,0.03609,Coronary atherosclerosis (no controls excluded),PCSK9
1,55505647,-0.0971407,0.0149204,7.50067e-11,115006,ebi-a-GCST90092994,rs11591147,T,G,0.017464,Degree of unsaturation,PCSK9
1,55505647,0.0925982,0.0145337,8.00018e-11,,met-d-M_HDL_CE,rs11591147,T,G,0.017458,Cholesteryl esters in medium HDL,PCSK9
1,55505647,-0.270964,0.0416959,8.10028e-11,17505,ebi-a-GCST011364,rs11591147,T,G,0.016784,Myocardial infarction,PCSK9
1,55505647,-0.260498,0.039856,8.61986e-11,13539,met-c-918,rs11591147,T,G,0.029011,Phosphatidylcholine and other cholines,PCSK9
1,55505647,0.0939653,0.0145279,9.8992e-11,115082,ebi-a-GCST90092894,rs11591147,T,G,0.017457,Cholesteryl ester levels in medium HDL,PCSK9
1,55505647,-0.0948857,0.0149712,1.2e-10,,met-d-Unsaturation,rs11591147,T,G,0.017465,Degree of unsaturation,PCSK9
1,55505647,-0.2843,0.0444,1.48799e-10,,finn-b-I9_MI_STRICT,rs11591147,T,G,0.03642,"Myocardial infarction, strict",PCSK9
1,55505647,-0.0130493,0.00203782,1.51981e-10,361194,ukb-d-I9_IHD,rs11591147,T,G,0.0176733,"Ischaemic heart disease, wide definition",PCSK9
1,55505647,0.046744,0.007316,1.66663e-10,,ieu-b-4812,rs11591147,T,G,0.01799,25 hydroxyvitamin D level,PCSK9
1,55505647,-0.0940748,0.0155034,1.7e-10,,met-d-M_LDL_TG,rs11591147,T,G,0.017458,Triglycerides in medium LDL,PCSK9
1,55505647,0.0466153,0.00736394,2.44833e-10,417580,ebi-a-GCST90000615,rs11591147,T,G,0.018031,Serum 25-Hydroxyvitamin D levels,PCSK9
1,55505647,-0.0938102,0.0150545,2.80001e-10,,met-d-L_HDL_CE_pct,rs11591147,T,G,0.017458,Cholesteryl esters to total lipids ratio in large HDL,PCSK9
1,55505647,-0.23639,0.0374874,2.86622e-10,397554,ebi-a-GCST90013936,rs11591147,T,G,,Angina (SPA correction),PCSK9
1,55505647,-0.25172,0.0413597,3.08638e-10,397554,ebi-a-GCST90013886,rs11591147,T,G,,Angina (Firth correction),PCSK9
1,55505647,-0.207321,0.0329668,3.2e-10,13814,ebi-a-GCST90060507,rs11591147,T,G,0.0181376,Sphingomyelin_42:2_[M+OAc]1- levels,PCSK9
1,55505647,-0.252215,0.039851,3.22003e-10,13517,met-c-937,rs11591147,T,G,0.028809,Total phosphoglycerides,PCSK9
1,55505647,0.0461643,0.00736307,3.61735e-10,417580,ebi-a-GCST90000616,rs11591147,T,G,0.018041,Serum 25-Hydroxyvitamin D levels,PCSK9
1,55505647,-0.0941458,0.0150761,4.20001e-10,115006,ebi-a-GCST90092931,rs11591147,T,G,0.017464,Omega-3 fatty acid levels,PCSK9
1,55505647,-0.0922144,0.0154873,4.30002e-10,,met-d-Omega_3,rs11591147,T,G,0.017465,Omega-3 fatty acids,PCSK9
1,55505647,-0.0823232,0.0139511,4.70002e-10,,met-d-M_HDL_FC_pct,rs11591147,T,G,0.017458,Free cholesterol to total lipids ratio in medium HDL,PCSK9
1,55505647,-0.0927373,0.0149606,5.69994e-10,115082,ebi-a-GCST90092847,rs11591147,T,G,0.017457,Cholesteryl esters to total lipids ratio in large HDL,PCSK9
1,55505647,-0.321,0.0519,6.19698e-10,,finn-b-I9_ANGIO,rs11591147,T,G,0.03654,Coronary angiopasty,PCSK9
1,55505647,-0.0876725,0.0152201,7.29995e-10,,met-d-L_VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in large VLDL,PCSK9
1,55505647,-0.2588,0.0421,7.61097e-10,,finn-b-I9_MI_EXNONE,rs11591147,T,G,0.03609,Myocardial infarction (no controls excluded),PCSK9
1,55505647,0.0482586,0.00785293,7.98123e-10,332739,ebi-a-GCST90013997,rs11591147,T,G,,Direct bilirubin levels (UKB data field 30660),PCSK9
1,55505647,-0.0243457,0.00396351,8.10009e-10,407557,ukb-b-18408,rs11591147,T,G,0.017431,Illnesses of father: Heart disease,PCSK9
1,55505647,-0.0938653,0.0153474,9.59997e-10,115082,ebi-a-GCST90092914,rs11591147,T,G,0.017457,Triglyceride levels in medium LDL,PCSK9
1,55505647,-0.3751,0.0614,9.79693e-10,,finn-b-E4_HYPERLIPNAS,rs11591147,T,G,0.03666,"Hyperlipidaemia, other/unspecified",PCSK9
1,55505647,-0.0885619,0.0155929,1.09999e-09,,met-d-SFA,rs11591147,T,G,0.017465,Saturated fatty acids,PCSK9
1,55505647,-0.0842838,0.0147398,1.2e-09,,met-d-Phosphatidylc,rs11591147,T,G,0.017465,Phosphatidylcholines,PCSK9
1,55505647,0.0877732,0.0144766,1.29999e-09,115082,ebi-a-GCST90092899,rs11591147,T,G,0.017457,Concentration of medium HDL particles,PCSK9
1,55505647,0.044772,0.00737972,1.30404e-09,417580,ebi-a-GCST90000617,rs11591147,T,G,0.018031,Serum 25-Hydroxyvitamin D levels,PCSK9
1,55505647,-0.0103698,0.00171027,1.33552e-09,361194,ukb-d-I9_CORATHER,rs11591147,T,G,0.0176733,Coronary atherosclerosis,PCSK9
1,55505647,-0.0968449,0.01581,1.40001e-09,,met-d-XXL_VLDL_C_pct,rs11591147,T,G,0.017428,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PCSK9
1,55505647,0.0865698,0.0144957,1.40001e-09,,met-d-M_HDL_P,rs11591147,T,G,0.017458,Concentration of medium HDL particles,PCSK9
1,55505647,-0.0847428,0.014902,1.40001e-09,,met-d-Phosphoglyc,rs11591147,T,G,0.017465,Phosphoglycerides,PCSK9
1,55505647,-0.0954523,0.0158103,1.6e-09,111638,ebi-a-GCST90093041,rs11591147,T,G,0.017427,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PCSK9
1,55505647,0.0450903,0.00747745,1.63783e-09,417580,ebi-a-GCST90000614,rs11591147,T,G,0.018041,Serum 25-Hydroxyvitamin D levels,PCSK9
1,55505647,0.0852539,0.01448,1.89998e-09,,met-d-M_HDL_C,rs11591147,T,G,0.017458,Cholesterol in medium HDL,PCSK9
1,55505647,0.0866095,0.0144719,2.19999e-09,115082,ebi-a-GCST90092892,rs11591147,T,G,0.017457,Cholesterol levels in medium HDL,PCSK9
1,55505647,-0.3535,0.06,3.90697e-09,,finn-b-I9_CABG_EXNONE,rs11591147,T,G,0.03609,Coronary artery bypass grafting (no controls excluded),PCSK9
1,55505647,-0.2127,0.0361,3.91796e-09,,finn-b-I9_ANGINA_EXNONE,rs11591147,T,G,0.03609,Angina pectoris (no controls excluded),PCSK9
1,55505647,-0.0802104,0.0141434,4.30002e-09,,met-d-XL_HDL_PL,rs11591147,T,G,0.017458,Phospholipids in very large HDL,PCSK9
1,55505647,-0.0814009,0.0139371,5.19996e-09,115082,ebi-a-GCST90092897,rs11591147,T,G,0.017457,Free cholesterol to total lipids ratio in medium HDL,PCSK9
1,55505647,-0.087951,0.0151893,7.00003e-09,115082,ebi-a-GCST90092872,rs11591147,T,G,0.017457,Free cholesterol levels in large VLDL,PCSK9
1,55505647,-0.204644,0.034899,7.52004e-09,15985,met-c-930,rs11591147,T,G,0.030715,Concentration of small VLDL particles,PCSK9
1,55505647,-0.603121,0.115852,1.00083e-08,349222,ebi-a-GCST90104003,rs11591147,T,G,0.017589,Familial combined hyperlipidemia defined by Brunzell criteria,PCSK9
1,55505647,-0.0808208,0.014136,1.09999e-08,115082,ebi-a-GCST90093012,rs11591147,T,G,0.017457,Phospholipid levels in very large HDL,PCSK9
1,55505647,-0.0882842,0.0155031,1.2e-08,115006,ebi-a-GCST90092980,rs11591147,T,G,0.017464,Saturated fatty acid levels,PCSK9
1,55505647,-0.0835336,0.0146982,1.29999e-08,115006,ebi-a-GCST90092937,rs11591147,T,G,0.017464,Phosphatidylcholine levels,PCSK9
1,55505647,-0.0841679,0.0148493,1.40001e-08,115006,ebi-a-GCST90092938,rs11591147,T,G,0.017464,Phosphoglycerides levels,PCSK9
1,55505647,0.049618,0.0087769,1.5759e-08,313387,ukb-d-30630_irnt,rs11591147,T,G,0.017655,Apoliprotein A,PCSK9
1,55505647,-0.0261119,0.00462457,1.64051e-08,292053,ukb-a-201,rs11591147,T,G,0.0174556,Illnesses of father: Heart disease,PCSK9
1,55505647,-0.33,0.06,2.02633e-08,9961,ebi-a-GCST005068,rs11591147,T,G,,LDL cholesterol,PCSK9
1,55505647,-0.224405,0.039904,2.15001e-08,13501,met-c-936,rs11591147,T,G,0.028841,Total fatty acids,PCSK9
1,55505647,-0.189699,0.0338923,2.19999e-08,13814,ebi-a-GCST90060505,rs11591147,T,G,0.0181376,Sphingomyelin_42:3_[M+OAc]1- levels,PCSK9
1,55505647,-0.00766499,0.00137805,2.19999e-08,484598,ebi-a-GCST90038609,rs11591147,T,G,0.016707,Angina,PCSK9
1,55505647,-0.2426,0.0436,2.61102e-08,,finn-b-I9_MI_STRICT_EXNONE,rs11591147,T,G,0.03609,"""Myocardial infarction, strict"" (no controls excluded)",PCSK9
1,55505647,-0.199134,0.0361146,3.50002e-08,13814,ebi-a-GCST90060309,rs11591147,T,G,0.0181376,Sphingomyelin_34:1_[M+OAc]1- levels,PCSK9
1,55505647,0.0432011,0.0079385,5.26926e-08,496946,ebi-a-GCST90000618,rs11591147,T,G,0.016608,Serum 25-Hydroxyvitamin D levels,PCSK9
1,55505647,0.0847817,0.0155807,5.30005e-08,115082,ebi-a-GCST90092952,rs11591147,T,G,0.017457,Phospholipid levels in small HDL,PCSK9
1,55505647,-0.32,0.06,5.44478e-08,9817,ebi-a-GCST005065,rs11591147,T,G,,"Cholesterol, total",PCSK9
1,55505647,-0.0820832,0.0151665,6.19998e-08,115006,ebi-a-GCST90092881,rs11591147,T,G,0.017464,Ratio of linoleic acid to total fatty acids,PCSK9
1,55505647,-0.0108215,0.00200545,6.69993e-08,484598,ebi-a-GCST90038605,rs11591147,T,G,0.016707,Cardiac problem,PCSK9
1,55505647,-0.0763691,0.0152416,6.90001e-08,,met-d-XL_VLDL_FC,rs11591147,T,G,0.017458,Free cholesterol in very large VLDL,PCSK9
1,55505647,0.012804,0.0023804,7.49894e-08,313387,ukb-d-30630_raw,rs11591147,T,G,0.017655,Apoliprotein A,PCSK9
1,55505647,-0.204122,0.0380408,8.09991e-08,13814,ebi-a-GCST90060370,rs11591147,T,G,0.0181376,Phosphatidylglycerol-O_38:0_[M-H]1- levels,PCSK9
1,55505647,0.042911,0.00807024,9.09997e-08,418691,ebi-a-GCST90025967,rs11591147,T,G,0.018058,Vitamin D levels,PCSK9
1,55505647,-0.2705,0.0508,1.01899e-07,,finn-b-I9_ANGIO_EXNONE,rs11591147,T,G,0.03609,Coronary angiopasty (no controls excluded),PCSK9
1,55505647,0.0446852,0.00844748,1.22473e-07,373045,ebi-a-GCST90014016,rs11591147,T,G,,Vitamin D levels (UKB data field 30890),PCSK9
1,55505647,-0.0758756,0.0154595,1.29999e-07,,met-d-XL_HDL_TG,rs11591147,T,G,0.017458,Triglycerides in very large HDL,PCSK9
1,55505647,-0.185063,0.034914,1.54999e-07,15985,met-c-909,rs11591147,T,G,0.030715,Total cholesterol in medium VLDL,PCSK9
1,55505647,-0.184993,0.03498,1.7e-07,15985,met-c-923,rs11591147,T,G,0.030715,Triglycerides in small HDL,PCSK9
1,55505647,-0.174485,0.0333568,1.7e-07,13814,ebi-a-GCST90060464,rs11591147,T,G,0.0181376,Sphingomyelin_40:2_[M+OAc]1- levels,PCSK9
1,55505647,-0.354653,0.0685546,2.30001e-07,171875,ieu-a-798,rs11591147,T,G,0.0151613,Myocardial infarction,PCSK9
1,55505647,-0.0831577,0.0153963,2.80001e-07,,met-d-LA_pct,rs11591147,T,G,0.017465,Ratio of linoleic acid to total fatty acids,PCSK9
1,55505647,-0.2234,0.0436,3.01703e-07,343026,ebi-a-GCST90018915,rs11591147,T,G,0.0178354,Stable angina pectoris,PCSK9
1,55505647,-0.0752634,0.0150339,3.09999e-07,,met-d-XL_HDL_C_pct,rs11591147,T,G,0.017453,Cholesterol to total lipids ratio in very large HDL,PCSK9
1,55505647,-0.5133,0.1005,3.24698e-07,,finn-b-E4_LIPOPROTNAS,rs11591147,T,G,0.03683,"Disorder of lipoprotein metabolism, unspecified",PCSK9
1,55505647,-0.171034,0.0334828,3.29997e-07,13814,ebi-a-GCST90060470,rs11591147,T,G,0.0181376,Phosphatidylglycerol-O_42:0_[M-H]1- levels,PCSK9
1,55505647,-0.0769686,0.0152099,4.20001e-07,115082,ebi-a-GCST90093020,rs11591147,T,G,0.017457,Free cholesterol levels in very large VLDL,PCSK9
1,55505647,-0.20229,0.039883,4.70999e-07,13473,met-c-854,rs11591147,T,G,0.028858,"Description of average fatty acid chain length, not actual carbon number",PCSK9
1,55505647,-0.4711,0.0936,4.7863e-07,3301,prot-a-127,rs11591147,T,G,0.01797,Apolipoprotein B,PCSK9
1,55505647,-0.172535,0.0344312,5.39995e-07,13814,ebi-a-GCST90060419,rs11591147,T,G,0.0181376,Phosphatidylglycerol-O_40:0_[M-H]1- levels,PCSK9
1,55505647,0.0831023,0.0155989,5.49997e-07,,met-d-S_HDL_PL,rs11591147,T,G,0.017458,Phospholipids in small HDL,PCSK9
1,55505647,-0.171084,0.0341527,5.49997e-07,13814,ebi-a-GCST90060467,rs11591147,T,G,0.0181376,Sphingomyelin_40:1_[M+OAc]1- levels,PCSK9
1,55505647,-0.177439,0.0354919,5.80003e-07,13814,ebi-a-GCST90060409,rs11591147,T,G,0.0181376,Sphingomyelin_38:2_[M+OAc]1- levels,PCSK9
1,55505647,-0.0765561,0.0153275,5.89997e-07,115082,ebi-a-GCST90093014,rs11591147,T,G,0.017457,Triglyceride levels in very large HDL,PCSK9
1,55505647,0.0374828,0.00765413,5.99998e-07,437660,ebi-a-GCST90025946,rs11591147,T,G,0.0176535,Creatinine levels,PCSK9
1,55505647,-0.1274,0.0256,6.74994e-07,153639,ebi-a-GCST90018982,rs11591147,T,G,0.0175802,Medication use (antithrombotic agents),PCSK9
1,55505647,-0.074211,0.0149672,7.10003e-07,115056,ebi-a-GCST90093005,rs11591147,T,G,0.017452,Cholesterol to total lipids ratio in very large HDL,PCSK9
1,55505647,-0.0771337,0.0157342,7.49998e-07,,met-d-XL_HDL_CE_pct,rs11591147,T,G,0.017453,Cholesteryl esters to total lipids ratio in very large HDL,PCSK9
1,55505647,-0.00581961,0.00117198,7.59994e-07,484598,ebi-a-GCST90038610,rs11591147,T,G,0.016707,Myocardial infarction,PCSK9
6,161013013,82.857,0.92583,0,273896,ukb-d-30790_raw,rs140570886,C,T,0.0054385,Lipoprotein A,LPA
6,161013013,1.3261,0.018776,0,273896,ukb-d-30790_irnt,rs140570886,C,T,0.0054385,Lipoprotein A,LPA
6,161013013,-0.542266,0.016354,5.19996e-250,,met-d-XXL_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.540016,0.0163392,1.49968e-239,115082,ebi-a-GCST90093050,rs140570886,C,T,0.015486,Triglyceride levels in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.507464,0.016329,1.39959e-220,,met-d-XXL_VLDL_L,rs140570886,C,T,0.015487,Total lipids in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.504926,0.0163071,1.69824e-210,115082,ebi-a-GCST90093046,rs140570886,C,T,0.015486,Total lipid levels in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.476491,0.0163111,3.09742e-195,,met-d-XXL_VLDL_P,rs140570886,C,T,0.015487,Concentration of chylomicrons and extremely large VLDL particles,LPA
6,161013013,-0.46758,0.0162758,4.89779e-189,,met-d-XXL_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.468177,0.01634,4.69894e-188,,met-d-XXL_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.474569,0.0162732,5.79429e-187,115082,ebi-a-GCST90093047,rs140570886,C,T,0.015486,Concentration of chylomicrons and extremely large VLDL particles,LPA
6,161013013,-0.465856,0.0162403,5.79429e-181,115082,ebi-a-GCST90093048,rs140570886,C,T,0.015486,Phospholipid levels in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.46609,0.016303,9.2045e-180,115082,ebi-a-GCST90093044,rs140570886,C,T,0.015486,Free cholesterol levels in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.455181,0.016349,1.90108e-177,,met-d-XXL_VLDL_C,rs140570886,C,T,0.015487,Cholesterol in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.430689,0.0158109,1.90108e-170,,met-d-VLDL_size,rs140570886,C,T,0.015487,Average diameter for VLDL particles,LPA
6,161013013,-0.452956,0.0163227,1.69824e-169,115082,ebi-a-GCST90093040,rs140570886,C,T,0.015486,Cholesterol levels in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.442028,0.0163865,1.39959e-166,,met-d-XXL_VLDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.430514,0.0158101,2.79898e-163,115082,ebi-a-GCST90093002,rs140570886,C,T,0.015486,Average diameter for VLDL particles,LPA
6,161013013,-0.439369,0.0163646,8.70964e-159,115082,ebi-a-GCST90093042,rs140570886,C,T,0.015486,Cholesteryl ester levels in chylomicrons and extremely large VLDL,LPA
6,161013013,0.458375,0.0172414,6.69885e-158,,met-d-XXL_VLDL_FC_pct,rs140570886,C,T,0.014897,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,0.457105,0.0172291,4.29536e-155,111638,ebi-a-GCST90093045,rs140570886,C,T,0.014914,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.419518,0.0162263,3.69828e-152,,met-d-XL_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in very large VLDL,LPA
6,161013013,-0.415393,0.0163274,5.00035e-148,,met-d-VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in VLDL,LPA
6,161013013,0.411372,0.0163505,3.80189e-147,,met-d-XL_VLDL_CE_pct,rs140570886,C,T,0.015328,Cholesteryl esters to total lipids ratio in very large VLDL,LPA
6,161013013,-0.417906,0.0161941,7.60326e-147,115082,ebi-a-GCST90093026,rs140570886,C,T,0.015486,Triglyceride levels in very large VLDL,LPA
6,161013013,0.201667,0.00783463,4.10204e-146,431167,ebi-a-GCST90002412,rs140570886,C,T,0.015599,Low density lipoprotein cholesterol levels,LPA
6,161013013,0.442192,0.0173514,3.89942e-145,,met-d-XXL_VLDL_C_pct,rs140570886,C,T,0.014897,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,0.443976,0.0173412,1.39959e-144,111638,ebi-a-GCST90093041,rs140570886,C,T,0.014914,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.413818,0.0162849,1.90108e-142,115082,ebi-a-GCST90093003,rs140570886,C,T,0.015486,Triglyceride levels in VLDL,LPA
6,161013013,0.410528,0.0162941,4.4978e-140,114160,ebi-a-GCST90093019,rs140570886,C,T,0.015328,Cholesteryl esters to total lipids ratio in very large VLDL,LPA
6,161013013,-0.402211,0.0163268,9.50605e-139,,met-d-L_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in large VLDL,LPA
6,161013013,-0.402211,0.0163264,3.49945e-138,,met-d-XL_VLDL_L,rs140570886,C,T,0.015487,Total lipids in very large VLDL,LPA
6,161013013,-0.430636,0.0174675,5.10505e-136,,met-d-XXL_VLDL_TG_pct,rs140570886,C,T,0.014897,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.433094,0.0174485,5.29663e-136,111638,ebi-a-GCST90093051,rs140570886,C,T,0.014914,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.396433,0.0163762,1.1995e-133,,met-d-XL_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in very large VLDL,LPA
6,161013013,-0.400876,0.0162977,1.39959e-133,115082,ebi-a-GCST90093022,rs140570886,C,T,0.015486,Total lipid levels in very large VLDL,LPA
6,161013013,-0.400688,0.0163025,2.19786e-133,115082,ebi-a-GCST90092878,rs140570886,C,T,0.015486,Triglyceride levels in large VLDL,LPA
6,161013013,0.390675,0.0163452,2.89734e-132,,met-d-XL_VLDL_C_pct,rs140570886,C,T,0.015328,Cholesterol to total lipids ratio in very large VLDL,LPA
6,161013013,-0.393949,0.0164379,5.10505e-131,,met-d-XL_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in very large VLDL,LPA
6,161013013,-0.390676,0.0165567,4.19759e-129,,met-d-S_LDL_TG,rs140570886,C,T,0.015487,Triglycerides in small LDL,LPA
6,161013013,-0.394924,0.0163436,5.29663e-129,115082,ebi-a-GCST90093024,rs140570886,C,T,0.015486,Phospholipid levels in very large VLDL,LPA
6,161013013,-0.387763,0.0164284,6.69885e-128,,met-d-Total_TG,rs140570886,C,T,0.015487,Total triglycerides,LPA
6,161013013,-0.385149,0.0163114,4.60257e-127,,met-d-XL_VLDL_P,rs140570886,C,T,0.015487,Concentration of very large VLDL particles,LPA
6,161013013,0.390119,0.0162974,1.1995e-126,114160,ebi-a-GCST90093017,rs140570886,C,T,0.015328,Cholesterol to total lipids ratio in very large VLDL,LPA
6,161013013,-0.392592,0.0164031,1.39959e-126,115082,ebi-a-GCST90093020,rs140570886,C,T,0.015486,Free cholesterol levels in very large VLDL,LPA
6,161013013,-0.388295,0.0164452,2.89734e-123,115082,ebi-a-GCST90092966,rs140570886,C,T,0.015486,Triglyceride levels in small LDL,LPA
6,161013013,-0.385782,0.0163555,5.19996e-123,115082,ebi-a-GCST90092992,rs140570886,C,T,0.015486,Total triglycerides levels,LPA
6,161013013,-0.383784,0.0162739,5.79429e-123,115082,ebi-a-GCST90093023,rs140570886,C,T,0.015486,Concentration of very large VLDL particles,LPA
6,161013013,0.373007,0.0162421,3.80189e-122,,met-d-L_VLDL_CE_pct,rs140570886,C,T,0.015484,Cholesteryl esters to total lipids ratio in large VLDL,LPA
6,161013013,0.36427,0.0164545,4.60257e-117,,met-d-S_LDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in small LDL,LPA
6,161013013,0.370934,0.0162438,1.99986e-115,115071,ebi-a-GCST90092871,rs140570886,C,T,0.015483,Cholesteryl esters to total lipids ratio in large VLDL,LPA
6,161013013,-0.367012,0.0164031,1.99986e-114,,met-d-L_VLDL_L,rs140570886,C,T,0.015487,Total lipids in large VLDL,LPA
6,161013013,-0.365486,0.0163896,8.60994e-114,,met-d-L_VLDL_P,rs140570886,C,T,0.015487,Concentration of large VLDL particles,LPA
6,161013013,-0.349717,0.0157491,1.09901e-113,,met-d-TG_by_PG,rs140570886,C,T,0.015497,Ratio of triglycerides to phosphoglycerides,LPA
6,161013013,-0.365599,0.0163725,1.90108e-110,115082,ebi-a-GCST90092874,rs140570886,C,T,0.015486,Total lipid levels in large VLDL,LPA
6,161013013,-0.36418,0.0163523,7.09578e-110,115082,ebi-a-GCST90092875,rs140570886,C,T,0.015486,Concentration of large VLDL particles,LPA
6,161013013,-0.348643,0.0157234,6.19441e-109,115006,ebi-a-GCST90092983,rs140570886,C,T,0.015497,Ratio of triglycerides to phosphoglycerides,LPA
6,161013013,-0.363676,0.0166435,1.09901e-108,,met-d-VLDL_L,rs140570886,C,T,0.015487,Total lipids in VLDL,LPA
6,161013013,0.36176,0.0163477,1.69824e-108,115082,ebi-a-GCST90092961,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in small LDL,LPA
6,161013013,-0.361954,0.016601,2.19786e-105,115082,ebi-a-GCST90092999,rs140570886,C,T,0.015486,Total lipid levels in VLDL,LPA
6,161013013,0.375971,0.017452,3.99945e-105,,met-d-XXL_VLDL_CE_pct,rs140570886,C,T,0.014897,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,0.378786,0.01744,1.30017e-104,111638,ebi-a-GCST90093043,rs140570886,C,T,0.014914,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.352425,0.0165807,1e-102,,met-d-XL_VLDL_C,rs140570886,C,T,0.015487,Cholesterol in very large VLDL,LPA
6,161013013,-0.346605,0.0163793,1.39959e-102,,met-d-L_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in large VLDL,LPA
6,161013013,0.338397,0.0162646,1.09901e-101,,met-d-M_LDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in medium LDL,LPA
6,161013013,-0.345174,0.0164944,1e-100,,met-d-M_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in medium VLDL,LPA
6,161013013,-0.351188,0.016557,7.59976e-100,115082,ebi-a-GCST90093016,rs140570886,C,T,0.015486,Cholesterol levels in very large VLDL,LPA
6,161013013,0.341558,0.0165875,4.00037e-99,,met-d-L_VLDL_C_pct,rs140570886,C,T,0.015484,Cholesterol to total lipids ratio in large VLDL,LPA
6,161013013,-0.345393,0.016349,4.60045e-99,115082,ebi-a-GCST90092876,rs140570886,C,T,0.015486,Phospholipid levels in large VLDL,LPA
6,161013013,-0.339805,0.0164215,6.09958e-98,,met-d-L_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in large VLDL,LPA
6,161013013,-0.343342,0.0164532,1.10002e-96,115082,ebi-a-GCST90092926,rs140570886,C,T,0.015486,Triglyceride levels in medium VLDL,LPA
6,161013013,-0.336359,0.0165347,2.90001e-96,,met-d-XL_VLDL_TG_pct,rs140570886,C,T,0.015328,Triglycerides to total lipids ratio in very large VLDL,LPA
6,161013013,0.336135,0.0161697,5.60015e-96,115082,ebi-a-GCST90092909,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in medium LDL,LPA
6,161013013,-0.338454,0.0163879,9.20026e-95,115082,ebi-a-GCST90092872,rs140570886,C,T,0.015486,Free cholesterol levels in large VLDL,LPA
6,161013013,-0.324563,0.0164549,2.49977e-94,,met-d-S_LDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in small LDL,LPA
6,161013013,0.33949,0.0165921,4.79954e-93,115071,ebi-a-GCST90092869,rs140570886,C,T,0.015483,Cholesterol to total lipids ratio in large VLDL,LPA
6,161013013,-0.337242,0.0168025,2.80027e-92,,met-d-MUFA,rs140570886,C,T,0.015497,Monounsaturated fatty acids,LPA
6,161013013,-0.336247,0.0165083,3.19963e-92,114160,ebi-a-GCST90093027,rs140570886,C,T,0.015328,Triglycerides to total lipids ratio in very large VLDL,LPA
6,161013013,0.4778,0.0236,2.06016e-91,296525,ebi-a-GCST005194,rs140570886,C,T,0.0167,Coronary artery disease,LPA
6,161013013,-0.337178,0.0169118,3.40017e-90,,met-d-M_LDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in medium LDL,LPA
6,161013013,-0.333148,0.0169568,1.69981e-89,,met-d-S_LDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in small LDL,LPA
6,161013013,-0.334628,0.0167181,4.00037e-89,115006,ebi-a-GCST90092928,rs140570886,C,T,0.015497,Monounsaturated fatty acid levels,LPA
6,161013013,-0.334312,0.0168953,3.80014e-87,115082,ebi-a-GCST90092907,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in medium LDL,LPA
6,161013013,-0.322349,0.016335,1.10002e-86,115082,ebi-a-GCST90092967,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in small LDL,LPA
6,161013013,0.327498,0.0169546,2.09991e-86,,met-d-S_LDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in small LDL,LPA
6,161013013,-0.331403,0.0169658,5.70033e-85,115082,ebi-a-GCST90092959,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in small LDL,LPA
6,161013013,-0.323946,0.0167719,1.29987e-84,,met-d-VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in VLDL,LPA
6,161013013,-0.322319,0.0167307,1.10002e-82,115082,ebi-a-GCST90093001,rs140570886,C,T,0.015486,Phospholipid levels in VLDL,LPA
6,161013013,0.326024,0.0169669,2.80027e-82,115082,ebi-a-GCST90092965,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in small LDL,LPA
6,161013013,-0.307391,0.0164795,4.49987e-82,,met-d-S_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in small VLDL,LPA
6,161013013,-0.31241,0.0166079,6.59933e-81,,met-d-L_VLDL_C,rs140570886,C,T,0.015487,Cholesterol in large VLDL,LPA
6,161013013,-0.31452,0.0168413,2.99985e-80,,met-d-Total_FA,rs140570886,C,T,0.015497,Total fatty acids,LPA
6,161013013,-0.312211,0.0168244,9.49948e-79,,met-d-SFA,rs140570886,C,T,0.015497,Saturated fatty acids,LPA
6,161013013,-0.311148,0.016575,1.29987e-78,115082,ebi-a-GCST90092868,rs140570886,C,T,0.015486,Cholesterol levels in large VLDL,LPA
6,161013013,0.553822,0.029707,1.39991e-77,547261,ebi-a-GCST005195,rs140570886,C,T,,Coronary artery disease,LPA
6,161013013,-0.312199,0.0167454,1.39991e-77,115006,ebi-a-GCST90092987,rs140570886,C,T,0.015497,Total fatty acid levels,LPA
6,161013013,-0.309148,0.0167139,1.50003e-77,,met-d-XL_VLDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in very large VLDL,LPA
6,161013013,-0.305108,0.0163666,1.50003e-77,115082,ebi-a-GCST90092978,rs140570886,C,T,0.015486,Triglyceride levels in small VLDL,LPA
6,161013013,-0.309662,0.0167279,1.69981e-76,115006,ebi-a-GCST90092980,rs140570886,C,T,0.015497,Saturated fatty acid levels,LPA
6,161013013,-0.307962,0.0166967,5.79963e-76,115082,ebi-a-GCST90093018,rs140570886,C,T,0.015486,Cholesteryl ester levels in very large VLDL,LPA
6,161013013,0.306803,0.0169805,6.20012e-76,,met-d-M_LDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in medium LDL,LPA
6,161013013,-0.306831,0.0168544,4.90004e-75,,met-d-VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in VLDL,LPA
6,161013013,-0.305256,0.0168191,1.29987e-73,115082,ebi-a-GCST90092998,rs140570886,C,T,0.015486,Free cholesterol levels in VLDL,LPA
6,161013013,-0.289936,0.0166884,4.20049e-73,,met-d-XL_HDL_TG,rs140570886,C,T,0.015487,Triglycerides in very large HDL,LPA
6,161013013,0.303051,0.0168969,6.29941e-72,115082,ebi-a-GCST90092913,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in medium LDL,LPA
6,161013013,-0.287645,0.0165462,1.10002e-67,115082,ebi-a-GCST90093014,rs140570886,C,T,0.015486,Triglyceride levels in very large HDL,LPA
6,161013013,0.268511,0.0159481,5.30029e-67,,met-d-M_VLDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in medium VLDL,LPA
6,161013013,-0.281896,0.0167336,6.29941e-67,,met-d-M_LDL_TG,rs140570886,C,T,0.015487,Triglycerides in medium LDL,LPA
6,161013013,0.276773,0.0162814,2.29985e-66,,met-d-PUFA_by_MUFA,rs140570886,C,T,0.015497,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,LPA
6,161013013,0.277664,0.0165227,2.49977e-65,,met-d-Omega_6_pct,rs140570886,C,T,0.015497,Ratio of omega-6 fatty acids to total fatty acids,LPA
6,161013013,-0.284372,0.0168659,1.29987e-64,,met-d-M_VLDL_L,rs140570886,C,T,0.015487,Total lipids in medium VLDL,LPA
6,161013013,-0.279594,0.0165654,6.4998e-64,115082,ebi-a-GCST90092914,rs140570886,C,T,0.015486,Triglyceride levels in medium LDL,LPA
6,161013013,0.274318,0.0162531,6.4998e-64,115006,ebi-a-GCST90092940,rs140570886,C,T,0.015497,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,LPA
6,161013013,0.274338,0.0162805,1e-63,115006,ebi-a-GCST90092935,rs140570886,C,T,0.015497,Ratio of omega-6 fatty acids to total fatty acids,LPA
6,161013013,0.267261,0.0158915,1.80011e-63,115082,ebi-a-GCST90092919,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in medium VLDL,LPA
6,161013013,-0.283011,0.0168436,2.29985e-63,115082,ebi-a-GCST90092922,rs140570886,C,T,0.015486,Total lipid levels in medium VLDL,LPA
6,161013013,-0.26775,0.0162777,1.10002e-62,,met-d-MUFA_pct,rs140570886,C,T,0.015497,Ratio of monounsaturated fatty acids to total fatty acids,LPA
6,161013013,-0.277888,0.0167797,1.20005e-62,,met-d-L_VLDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in large VLDL,LPA
6,161013013,0.26817,0.0163397,2.19989e-61,,met-d-PUFA_pct,rs140570886,C,T,0.015497,Ratio of polyunsaturated fatty acids to total fatty acids,LPA
6,161013013,0.256854,0.0159916,2.39994e-61,,met-d-M_VLDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in medium VLDL,LPA
6,161013013,-0.276728,0.0167484,2.49977e-61,115082,ebi-a-GCST90092870,rs140570886,C,T,0.015486,Cholesteryl ester levels in large VLDL,LPA
6,161013013,-0.265675,0.016259,5.10035e-60,115006,ebi-a-GCST90092929,rs140570886,C,T,0.015497,Ratio of monounsaturated fatty acids to total fatty acids,LPA
6,161013013,0.265398,0.0163063,1.50003e-59,115006,ebi-a-GCST90092941,rs140570886,C,T,0.015497,Ratio of polyunsaturated fatty acids to total fatty acids,LPA
6,161013013,0.25574,0.0159561,8.19974e-58,115082,ebi-a-GCST90092917,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in medium VLDL,LPA
6,161013013,-0.253243,0.0167667,2.70023e-53,,met-d-S_VLDL_P,rs140570886,C,T,0.015487,Concentration of small VLDL particles,LPA
6,161013013,0.249563,0.016547,5.79963e-53,,met-d-XL_VLDL_FC_pct,rs140570886,C,T,0.015328,Free cholesterol to total lipids ratio in very large VLDL,LPA
6,161013013,-0.237386,0.016047,1.10002e-52,,met-d-M_VLDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in medium VLDL,LPA
6,161013013,-0.25574,0.0168918,1.39991e-52,,met-d-VLDL_P,rs140570886,C,T,0.015487,Concentration of VLDL particles,LPA
6,161013013,-0.257785,0.0169426,1.80011e-52,,met-d-M_VLDL_P,rs140570886,C,T,0.015487,Concentration of medium VLDL particles,LPA
6,161013013,-0.256707,0.0169244,5.79963e-52,115082,ebi-a-GCST90092923,rs140570886,C,T,0.015486,Concentration of medium VLDL particles,LPA
6,161013013,0.0406507,0.00271735,1.50003e-51,464736,ebi-a-GCST90029021,rs140570886,C,T,0.015536,High cholesterol,LPA
6,161013013,0.249675,0.0165277,1.50003e-51,114160,ebi-a-GCST90093021,rs140570886,C,T,0.015328,Free cholesterol to total lipids ratio in very large VLDL,LPA
6,161013013,-0.253981,0.0168352,1.99986e-51,115082,ebi-a-GCST90093000,rs140570886,C,T,0.015486,Concentration of VLDL particles,LPA
6,161013013,0.0399649,0.00268178,2.29985e-51,484598,ebi-a-GCST90038690,rs140570886,C,T,0.015371,High cholesterol,LPA
6,161013013,-0.251367,0.0166908,2.99985e-51,115082,ebi-a-GCST90092975,rs140570886,C,T,0.015486,Concentration of small VLDL particles,LPA
6,161013013,-0.249071,0.0168161,4.70002e-51,,met-d-S_VLDL_L,rs140570886,C,T,0.015487,Total lipids in small VLDL,LPA
6,161013013,-0.252182,0.0169614,3.80014e-50,,met-d-VLDL_C,rs140570886,C,T,0.015487,VLDL cholesterol,LPA
6,161013013,-0.250826,0.0169372,1.29987e-49,115082,ebi-a-GCST90092996,rs140570886,C,T,0.015486,VLDL cholesterol levels,LPA
6,161013013,-0.24716,0.0167453,2.70023e-49,115082,ebi-a-GCST90092974,rs140570886,C,T,0.015486,Total lipid levels in small VLDL,LPA
6,161013013,-0.236004,0.0160166,3.80014e-49,115082,ebi-a-GCST90092927,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in medium VLDL,LPA
6,161013013,-0.241623,0.0166561,6.00067e-49,,met-d-LA,rs140570886,C,T,0.015497,Linoleic acid,LPA
6,161013013,-0.241198,0.0166622,1.69981e-47,115006,ebi-a-GCST90092880,rs140570886,C,T,0.015497,Linoleic acid levels,LPA
6,161013013,0.446228,0.030858,2.38013e-47,58825,ebi-a-GCST011365,rs140570886,C,T,0.017372,Myocardial infarction,LPA
6,161013013,-0.232539,0.0164752,6.79986e-47,,met-d-S_HDL_TG,rs140570886,C,T,0.015487,Triglycerides in small HDL,LPA
6,161013013,0.0400483,0.00278955,9.70063e-47,462933,ukb-b-10912,rs140570886,C,T,0.015491,"Non-cancer illness code, self-reported: high cholesterol",LPA
6,161013013,-0.232005,0.0165634,1.69981e-46,,met-d-PUFA,rs140570886,C,T,0.015497,Polyunsaturated fatty acids,LPA
6,161013013,0.381153,0.025859,4.6849e-46,407746,ebi-a-GCST90013882,rs140570886,C,T,,High cholesterol (Firth correction),LPA
6,161013013,-0.241617,0.0169591,4.70002e-46,,met-d-M_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in medium VLDL,LPA
6,161013013,0.222885,0.0165309,4.90004e-46,,met-d-S_VLDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in small VLDL,LPA
6,161013013,0.410431,0.028819,5.04778e-46,407746,ebi-a-GCST90013932,rs140570886,C,T,,High cholesterol (SPA correction),LPA
6,161013013,0.22426,0.0167627,6.09958e-46,,met-d-S_VLDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in small VLDL,LPA
6,161013013,-0.240559,0.0169423,9.30037e-46,115082,ebi-a-GCST90092924,rs140570886,C,T,0.015486,Phospholipid levels in medium VLDL,LPA
6,161013013,-0.232671,0.0167987,1.29987e-45,,met-d-LDL_TG,rs140570886,C,T,0.015487,Triglycerides in LDL,LPA
6,161013013,0.22098,0.0161936,1.80011e-45,,met-d-L_LDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in large LDL,LPA
6,161013013,0.031048,0.00220359,4.51336e-45,361194,ukb-d-I9_IHD,rs140570886,C,T,0.0156259,"Ischaemic heart disease, wide definition",LPA
6,161013013,-0.230749,0.0163911,5.19996e-45,115082,ebi-a-GCST90092954,rs140570886,C,T,0.015486,Triglyceride levels in small HDL,LPA
6,161013013,-0.220182,0.0161647,1.10002e-44,,met-d-S_HDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in small HDL,LPA
6,161013013,-0.2308,0.0164808,1.50003e-44,115006,ebi-a-GCST90092939,rs140570886,C,T,0.015497,Polyunsaturated fatty acid levels,LPA
6,161013013,0.464151,0.0319615,8.90841e-44,352063,ebi-a-GCST90013864,rs140570886,C,T,,Coronary artery disease (Firth correction),LPA
6,161013013,0.512626,0.0369615,9.73868e-44,352063,ebi-a-GCST90013868,rs140570886,C,T,,Coronary artery disease (SPA correction),LPA
6,161013013,-0.230292,0.0166122,1.10002e-43,115082,ebi-a-GCST90092890,rs140570886,C,T,0.015486,Triglyceride levels in LDL,LPA
6,161013013,0.0256197,0.00184941,1.25314e-43,361194,ukb-d-I9_CORATHER,rs140570886,C,T,0.0156259,Coronary atherosclerosis,LPA
6,161013013,0.237299,0.0174352,1.39991e-43,,met-d-XXL_VLDL_PL_pct,rs140570886,C,T,0.014897,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.225635,0.0165858,1.99986e-43,,met-d-Omega_6,rs140570886,C,T,0.015497,Omega-6 fatty acids,LPA
6,161013013,0.23933,0.0173314,2.19989e-43,111638,ebi-a-GCST90093049,rs140570886,C,T,0.014914,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,161013013,-0.214403,0.0164402,4.40048e-43,,met-d-S_VLDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in small VLDL,LPA
6,161013013,-0.115052,0.00838781,8.07421e-43,389562,ebi-a-GCST90014014,rs140570886,C,T,,Triglyceride levels (UKB data field 30870),LPA
6,161013013,-0.111912,0.00815915,8.10028e-43,,ieu-b-111,rs140570886,C,T,0.015534,triglycerides,LPA
6,161013013,0.21223,0.0161589,2.19989e-42,,met-d-M_VLDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in medium VLDL,LPA
6,161013013,-0.221076,0.0167265,2.90001e-42,,met-d-XS_VLDL_TG,rs140570886,C,T,0.015487,Triglycerides in very small VLDL,LPA
6,161013013,-0.225739,0.0167139,3.19963e-42,,met-d-Total_L,rs140570886,C,T,0.015487,Total lipids in lipoprotein particles,LPA
6,161013013,-0.218847,0.0160925,4.00037e-42,115082,ebi-a-GCST90092955,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in small HDL,LPA
6,161013013,0.218881,0.0161122,4.90004e-42,115082,ebi-a-GCST90092861,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in large LDL,LPA
6,161013013,-0.224634,0.0165741,7.59976e-42,115006,ebi-a-GCST90092933,rs140570886,C,T,0.015497,Omega-6 fatty acid levels,LPA
6,161013013,-0.224284,0.0166887,3.59998e-41,115082,ebi-a-GCST90092989,rs140570886,C,T,0.015486,Total lipid levels in lipoprotein particles,LPA
6,161013013,0.221287,0.0164807,4.19952e-41,115082,ebi-a-GCST90092969,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in small VLDL,LPA
6,161013013,-0.217419,0.0167563,9.20026e-41,,met-d-HDL_TG,rs140570886,C,T,0.015487,Triglycerides in HDL,LPA
6,161013013,-0.208514,0.01601,2.19989e-40,,met-d-XL_HDL_TG_pct,rs140570886,C,T,0.01549,Triglycerides to total lipids ratio in very large HDL,LPA
6,161013013,0.222575,0.0167416,2.49977e-40,115082,ebi-a-GCST90092971,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in small VLDL,LPA
6,161013013,0.11299,0.00853511,5.30029e-40,,ieu-b-108,rs140570886,C,T,0.015533,apolipoprotein B,LPA
6,161013013,-0.218483,0.016527,6.79986e-40,115082,ebi-a-GCST90093038,rs140570886,C,T,0.015486,Triglyceride levels in very small VLDL,LPA
6,161013013,0.112158,0.00851115,1.17896e-39,388022,ebi-a-GCST90013994,rs140570886,C,T,,Apolipoprotein B levels (UKB data field 30640),LPA
6,161013013,0.21135,0.0161589,4.30031e-39,115082,ebi-a-GCST90092921,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in medium VLDL,LPA
6,161013013,-0.21295,0.0163777,1.20005e-38,115082,ebi-a-GCST90092979,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in small VLDL,LPA
6,161013013,-0.206589,0.0159466,2.19989e-38,115056,ebi-a-GCST90093015,rs140570886,C,T,0.01549,Triglycerides to total lipids ratio in very large HDL,LPA
6,161013013,-0.215029,0.0166063,2.39994e-38,115082,ebi-a-GCST90092829,rs140570886,C,T,0.015486,Triglyceride levels in HDL,LPA
6,161013013,0.109693,0.00856691,1.59993e-37,,ieu-b-110,rs140570886,C,T,0.015529,LDL cholesterol,LPA
6,161013013,0.461672,0.0346406,1.34246e-36,397554,ebi-a-GCST90013886,rs140570886,C,T,,Angina (Firth correction),LPA
6,161013013,0.51771,0.040999,1.49142e-36,397554,ebi-a-GCST90013936,rs140570886,C,T,,Angina (SPA correction),LPA
6,161013013,0.0449768,0.0035663,1.80011e-36,426240,ukb-b-12477,rs140570886,C,T,0.015497,Illnesses of mother: Heart disease,LPA
6,161013013,0.108663,0.00862968,2.34207e-36,389189,ebi-a-GCST90013871,rs140570886,C,T,,Direct low density lipoprotein levels (UKB data field 30780),LPA
6,161013013,0.108662,0.00864279,2.98813e-36,389189,ebi-a-GCST90014009,rs140570886,C,T,,Direct low density lipoprotein levels (UKB data field 30780),LPA
6,161013013,0.191934,0.0162271,1.80011e-35,,met-d-S_VLDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in small VLDL,LPA
6,161013013,0.0195776,0.00157844,2.55976e-35,337199,ukb-a-534,rs140570886,C,T,0.0157148,Diagnoses - main ICD10: I25 Chronic ischaemic heart disease,LPA
6,161013013,-0.11677,0.0095035,1.08193e-34,343992,ukb-d-30870_irnt,rs140570886,C,T,0.015643,Triglycerides,LPA
6,161013013,0.0225885,0.00183927,1.10002e-34,463010,ukb-b-12651,rs140570886,C,T,0.015491,Diagnoses - secondary ICD10: E78.0 Pure hypercholesterolaemia,LPA
6,161013013,0.186871,0.0160209,1.39991e-34,,met-d-XS_VLDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in very small VLDL,LPA
6,161013013,0.039615,0.00326149,6.1038e-34,337159,ukb-a-108,rs140570886,C,T,0.0157148,Non-cancer illness code  self-reported: high cholesterol,LPA
6,161013013,-0.198109,0.0167831,8.4004e-34,,met-d-M_HDL_TG,rs140570886,C,T,0.015487,Triglycerides in medium HDL,LPA
6,161013013,0.0516166,0.00426698,1.10002e-33,407557,ukb-b-18408,rs140570886,C,T,0.015543,Illnesses of father: Heart disease,LPA
6,161013013,0.540966,0.0448584,1.69981e-33,17505,ebi-a-GCST011364,rs140570886,C,T,0.015159,Myocardial infarction,LPA
6,161013013,-0.204743,0.0169764,1.69981e-33,115082,ebi-a-GCST90092997,rs140570886,C,T,0.015486,Cholesteryl ester levels in VLDL,LPA
6,161013013,-0.205882,0.0169931,1.80011e-33,,met-d-VLDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in VLDL,LPA
6,161013013,-0.193447,0.0165003,3.40017e-33,,met-d-L_VLDL_PL_pct,rs140570886,C,T,0.015484,Phospholipids to total lipids ratio in large VLDL,LPA
6,161013013,0.19205,0.0167957,5.30029e-33,,met-d-S_HDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in small HDL,LPA
6,161013013,-0.202058,0.0169542,6.00067e-33,,met-d-S_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in small VLDL,LPA
6,161013013,0.5625,0.0472,8.25848e-33,,finn-b-RX_STATIN,rs140570886,C,T,0.009302,Statin medication,LPA
6,161013013,0.10003,0.0083843,8.26609e-33,343621,ukb-d-30780_raw,rs140570886,C,T,0.015641,LDL direct,LPA
6,161013013,0.183684,0.0162611,9.09913e-33,,met-d-S_VLDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in small VLDL,LPA
6,161013013,-0.202078,0.0169703,1.10002e-32,115082,ebi-a-GCST90092920,rs140570886,C,T,0.015486,Free cholesterol levels in medium VLDL,LPA
6,161013013,0.0275,0.002315,1.54383e-32,342590,ukb-d-30640_raw,rs140570886,C,T,0.015647,Apoliprotein B,LPA
6,161013013,0.18179,0.0161046,1.59993e-32,,met-d-XS_VLDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in very small VLDL,LPA
6,161013013,-0.203046,0.0169851,1.59993e-32,,met-d-M_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in medium VLDL,LPA
6,161013013,-0.182772,0.0161427,1.69981e-32,,met-d-XS_VLDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in very small VLDL,LPA
6,161013013,-0.200553,0.0169164,1.99986e-32,115082,ebi-a-GCST90092976,rs140570886,C,T,0.015486,Phospholipid levels in small VLDL,LPA
6,161013013,0.190682,0.0161382,3.19963e-32,115082,ebi-a-GCST90092973,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in small VLDL,LPA
6,161013013,-0.200744,0.0169934,3.29989e-32,115082,ebi-a-GCST90092958,rs140570886,C,T,0.015486,Cholesteryl ester levels in small LDL,LPA
6,161013013,-0.200518,0.0169902,3.80014e-32,115082,ebi-a-GCST90092963,rs140570886,C,T,0.015486,Concentration of small LDL particles,LPA
6,161013013,-0.201816,0.0169982,4.70002e-32,,met-d-S_LDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in small LDL,LPA
6,161013013,-0.201621,0.0170044,5.00035e-32,,met-d-S_LDL_P,rs140570886,C,T,0.015487,Concentration of small LDL particles,LPA
6,161013013,0.11437,0.0097224,6.09116e-32,342590,ukb-d-30640_irnt,rs140570886,C,T,0.015647,Apoliprotein B,LPA
6,161013013,-0.195677,0.0166597,7.39946e-32,115082,ebi-a-GCST90092902,rs140570886,C,T,0.015486,Triglyceride levels in medium HDL,LPA
6,161013013,-0.19345,0.0164777,7.89951e-32,115071,ebi-a-GCST90092877,rs140570886,C,T,0.015483,Phospholipids to total lipids ratio in large VLDL,LPA
6,161013013,0.11299,0.0096474,1.11661e-31,343621,ukb-d-30780_irnt,rs140570886,C,T,0.015641,LDL direct,LPA
6,161013013,-0.185234,0.0163016,1.20005e-31,,met-d-M_HDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in medium HDL,LPA
6,161013013,0.186099,0.015921,1.50003e-31,115082,ebi-a-GCST90093031,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in very small VLDL,LPA
6,161013013,0.183505,0.0164807,3.29989e-30,,met-d-M_HDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in medium HDL,LPA
6,161013013,0.190017,0.0166925,5.10035e-30,115082,ebi-a-GCST90092945,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in small HDL,LPA
6,161013013,0.182253,0.0167567,6.4998e-30,,met-d-S_HDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in small HDL,LPA
6,161013013,-0.181523,0.0160567,1.20005e-29,115082,ebi-a-GCST90093039,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in very small VLDL,LPA
6,161013013,-0.18341,0.0162352,1.39991e-29,115082,ebi-a-GCST90092903,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in medium HDL,LPA
6,161013013,0.180994,0.0160265,1.39991e-29,115082,ebi-a-GCST90093029,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in very small VLDL,LPA
6,161013013,0.182483,0.0161725,1.59993e-29,115082,ebi-a-GCST90092977,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in small VLDL,LPA
6,161013013,0.179134,0.0161616,2.49977e-29,,met-d-Unsaturation,rs140570886,C,T,0.015497,Degree of unsaturation,LPA
6,161013013,0.35806,0.0313668,3.24564e-29,407746,ebi-a-GCST90013919,rs140570886,C,T,,Cholesterol lowering medication use (UKB data field 6177_1) (Firth correction),LPA
6,161013013,0.372623,0.0332194,3.36357e-29,407746,ebi-a-GCST90013969,rs140570886,C,T,,Cholesterol lowering medication use (UKB data field 6177_1) (SPA correction),LPA
6,161013013,-0.180704,0.0169154,3.50026e-29,,met-d-L_VLDL_TG_pct,rs140570886,C,T,0.015484,Triglycerides to total lipids ratio in large VLDL,LPA
6,161013013,-0.186955,0.0170368,5.19996e-29,,met-d-L_LDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in large LDL,LPA
6,161013013,0.0238479,0.00213667,7.29962e-29,484598,ebi-a-GCST90038605,rs140570886,C,T,0.015371,Cardiac problem,LPA
6,161013013,0.177925,0.0161063,2.29985e-28,115006,ebi-a-GCST90092994,rs140570886,C,T,0.015497,Degree of unsaturation,LPA
6,161013013,0.180908,0.0163979,2.70023e-28,115082,ebi-a-GCST90092895,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in medium HDL,LPA
6,161013013,0.0586892,0.00533058,3.40017e-28,209638,ukb-b-11740,rs140570886,C,T,0.015523,"Medication for cholesterol, blood pressure or diabetes: Cholesterol lowering medication",LPA
6,161013013,-0.186529,0.0170222,6.09958e-28,115082,ebi-a-GCST90092859,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in large LDL,LPA
6,161013013,0.0227681,0.00208793,1.10002e-27,445693,ukb-b-20300,rs140570886,C,T,0.015501,Treatment speciality of consultant (recoded): Cardiology,LPA
6,161013013,0.179832,0.0166027,2.39994e-27,115082,ebi-a-GCST90092947,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in small HDL,LPA
6,161013013,0.173502,0.0166114,9.09913e-27,,met-d-LDL_size,rs140570886,C,T,0.015487,Average diameter for LDL particles,LPA
6,161013013,-0.174807,0.0168337,1.80011e-26,,met-d-L_LDL_TG,rs140570886,C,T,0.015487,Triglycerides in large LDL,LPA
6,161013013,-0.179292,0.0169103,2.90001e-26,115071,ebi-a-GCST90092879,rs140570886,C,T,0.015483,Triglycerides to total lipids ratio in large VLDL,LPA
6,161013013,0.043456,0.00410647,3.6358e-26,308780,ukb-a-209,rs140570886,C,T,0.0157148,Illnesses of mother: Heart disease,LPA
6,161013013,-0.164503,0.0167785,1.29987e-25,,met-d-M_LDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in medium LDL,LPA
6,161013013,0.16542,0.016181,1.99986e-25,,met-d-M_HDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in medium HDL,LPA
6,161013013,-0.169787,0.0167892,2.39994e-25,,met-d-IDL_TG,rs140570886,C,T,0.015487,Triglycerides in IDL,LPA
6,161013013,-0.176612,0.0170286,3.29989e-25,115082,ebi-a-GCST90092911,rs140570886,C,T,0.015486,Concentration of medium LDL particles,LPA
6,161013013,-0.172442,0.0166301,3.40017e-25,115082,ebi-a-GCST90092866,rs140570886,C,T,0.015486,Triglyceride levels in large LDL,LPA
6,161013013,0.0382977,0.00372828,4.40048e-25,484598,ebi-a-GCST90038595,rs140570886,C,T,0.015371,Cardiovascular disease,LPA
6,161013013,-0.178319,0.0170402,4.79954e-25,,met-d-M_LDL_P,rs140570886,C,T,0.015487,Concentration of medium LDL particles,LPA
6,161013013,-0.175081,0.0170056,7.39946e-25,115082,ebi-a-GCST90092906,rs140570886,C,T,0.015486,Cholesteryl ester levels in medium LDL,LPA
6,161013013,0.170446,0.0165651,7.89951e-25,115082,ebi-a-GCST90092889,rs140570886,C,T,0.015486,Average diameter for LDL particles,LPA
6,161013013,-0.176435,0.0170146,1e-24,,met-d-M_LDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in medium LDL,LPA
6,161013013,0.0150388,0.0014682,1e-24,484598,ebi-a-GCST90038609,rs140570886,C,T,0.015371,Angina,LPA
6,161013013,0.0360844,0.0035348,1.83443e-24,361194,ukb-d-IX_CIRCULATORY,rs140570886,C,T,0.0156259,Diseases of the circulatory system,LPA
6,161013013,0.0160921,0.00157961,2.2751e-24,361194,ukb-d-I9_CHD_NOREV,rs140570886,C,T,0.0156259,Major coronary heart disease event excluding revascularizations,LPA
6,161013013,0.0160921,0.00157961,2.2751e-24,361194,ukb-d-I9_CHD,rs140570886,C,T,0.0156259,Major coronary heart disease event,LPA
6,161013013,-0.16139,0.0161824,2.90001e-24,,met-d-Total_PL,rs140570886,C,T,0.015487,Total phospholipids in lipoprotein particles,LPA
6,161013013,0.163479,0.0161434,4.19952e-24,115082,ebi-a-GCST90092893,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in medium HDL,LPA
6,161013013,0.0376033,0.00374735,4.40048e-24,477807,ebi-a-GCST90029019,rs140570886,C,T,0.015536,Cardiovascular disease,LPA
6,161013013,-0.0781,0.0077,6.43873e-24,343992,ebi-a-GCST90018975,rs140570886,C,T,0.0186017,Triglycerides,LPA
6,161013013,-0.167114,0.0165753,6.59933e-24,115082,ebi-a-GCST90092841,rs140570886,C,T,0.015486,Triglyceride levels in IDL,LPA
6,161013013,0.162514,0.0170012,8.49963e-24,,met-d-L_LDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in large LDL,LPA
6,161013013,0.0192662,0.00191559,8.49963e-24,461416,ukb-b-16376,rs140570886,C,T,0.015496,Main speciality of consultant (recoded): Cardiology,LPA
6,161013013,0.1833,0.0183,1.00207e-23,290385,ebi-a-GCST90018989,rs140570886,C,T,0.0202628,Medication use (HMG CoA reductase inhibitors),LPA
6,161013013,-0.15999,0.0161522,4.00037e-23,115082,ebi-a-GCST90092991,rs140570886,C,T,0.015486,Total phospholipid levels in lipoprotein particles,LPA
6,161013013,0.154309,0.0165935,4.40048e-23,,met-d-IDL_C_pct,rs140570886,C,T,0.015487,Cholesterol to total lipids ratio in IDL,LPA
6,161013013,0.0842058,0.00853395,5.7783e-23,389864,ebi-a-GCST90014000,rs140570886,C,T,,Cholesterol levels (UKB data field 30690),LPA
6,161013013,0.012201,0.00124854,9.70063e-23,484598,ebi-a-GCST90038610,rs140570886,C,T,0.015371,Myocardial infarction,LPA
6,161013013,-0.162782,0.0166307,1.29987e-22,115082,ebi-a-GCST90092915,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in medium LDL,LPA
6,161013013,0.10593,0.010849,1.60805e-22,344278,ukb-d-30690_raw,rs140570886,C,T,0.015639,Cholesterol,LPA
6,161013013,0.158489,0.0164112,4.60045e-22,115006,ebi-a-GCST90092817,rs140570886,C,T,0.015497,Ratio of docosahexaenoic acid to total fatty acid levels,LPA
6,161013013,0.0479643,0.00497083,4.99459e-22,292053,ukb-a-201,rs140570886,C,T,0.0157148,Illnesses of father: Heart disease,LPA
6,161013013,0.160304,0.0165348,5.79963e-22,,met-d-DHA_pct,rs140570886,C,T,0.015497,Ratio of docosahexaenoic acid to total fatty acids,LPA
6,161013013,-0.094095,0.0098199,9.56753e-22,343992,ukb-d-30870_raw,rs140570886,C,T,0.015643,Triglycerides,LPA
6,161013013,0.147817,0.0163086,9.79941e-22,,met-d-M_VLDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in medium VLDL,LPA
6,161013013,0.162224,0.016958,1.10002e-21,115082,ebi-a-GCST90092865,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in large LDL,LPA
6,161013013,0.016234,0.00170433,1.65844e-21,337159,ukb-a-176,rs140570886,C,T,0.0157148,Treatment/medication code: atorvastatin,LPA
6,161013013,0.089962,0.009495,2.69339e-21,344278,ukb-d-30690_irnt,rs140570886,C,T,0.015639,Cholesterol,LPA
6,161013013,0.358095,0.0378144,2.80027e-21,42457,ebi-a-GCST003116,rs140570886,C,T,0.020084,Coronary artery disease,LPA
6,161013013,0.358095,0.0378144,2.80027e-21,184305,ieu-a-7,rs140570886,C,T,0.020084,Coronary heart disease,LPA
6,161013013,0.0363949,0.00386381,4.49987e-21,249710,ukb-b-17805,rs140570886,C,T,0.015514,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Cholesterol lowering medication",LPA
6,161013013,-0.14615,0.016418,4.60045e-21,,met-d-IDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in IDL,LPA
6,161013013,-0.155807,0.0169144,6.59933e-21,,met-d-GlycA,rs140570886,C,T,0.015487,Glycoprotein acetyls,LPA
6,161013013,-0.158915,0.0169795,8.00018e-21,115082,ebi-a-GCST90092962,rs140570886,C,T,0.015486,Total lipid levels in small LDL,LPA
6,161013013,0.146351,0.0166786,1.59993e-20,,met-d-IDL_CE_pct,rs140570886,C,T,0.015487,Cholesteryl esters to total lipids ratio in IDL,LPA
6,161013013,0.153163,0.0164987,1.59993e-20,115082,ebi-a-GCST90092832,rs140570886,C,T,0.015486,Cholesterol to total lipids ratio in IDL,LPA
6,161013013,0.617,0.0666,2.01883e-20,,finn-b-I9_CORATHER_EXNONE,rs140570886,C,T,0.009302,Coronary atherosclerosis (no controls excluded),LPA
6,161013013,-0.159717,0.0169864,2.09991e-20,,met-d-S_LDL_L,rs140570886,C,T,0.015487,Total lipids in small LDL,LPA
6,161013013,0.6196,0.067,2.42773e-20,,finn-b-I9_CORATHER,rs140570886,C,T,0.009286,Coronary atherosclerosis,LPA
6,161013013,0.148374,0.0168374,2.60016e-20,,met-d-L_VLDL_FC_pct,rs140570886,C,T,0.015484,Free cholesterol to total lipids ratio in large VLDL,LPA
6,161013013,0.0576132,0.00623819,2.60016e-20,154702,ukb-a-488,rs140570886,C,T,0.0157148,Medication for cholesterol  blood pressure or diabetes: Cholesterol lowering medication,LPA
6,161013013,-0.156631,0.0169671,4.19952e-20,,met-d-S_VLDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in small VLDL,LPA
6,161013013,-0.155411,0.0169302,4.30031e-20,115082,ebi-a-GCST90092970,rs140570886,C,T,0.015486,Cholesteryl ester levels in small VLDL,LPA
6,161013013,-0.154996,0.0169573,6.20012e-20,115082,ebi-a-GCST90092968,rs140570886,C,T,0.015486,Cholesterol levels in small VLDL,LPA
6,161013013,0.0135807,0.00148642,6.48485e-20,337159,ukb-a-63,rs140570886,C,T,0.0157148,Non-cancer illness code  self-reported: heart attack/myocardial infarction,LPA
6,161013013,-0.141198,0.0160933,8.19974e-20,,met-d-Phosphoglyc,rs140570886,C,T,0.015497,Phosphoglycerides,LPA
6,161013013,-0.15619,0.0169874,8.30042e-20,,met-d-S_VLDL_C,rs140570886,C,T,0.015487,Cholesterol in small VLDL,LPA
6,161013013,-0.143479,0.0167178,1.10002e-19,,met-d-Omega_3,rs140570886,C,T,0.015497,Omega-3 fatty acids,LPA
6,161013013,0.0157683,0.00173745,1.13737e-19,337159,ukb-a-62,rs140570886,C,T,0.0157148,Non-cancer illness code  self-reported: angina,LPA
6,161013013,-0.151061,0.0167939,2.39994e-19,115082,ebi-a-GCST90092821,rs140570886,C,T,0.015486,Glycoprotein acetyls levels,LPA
6,161013013,0.0134246,0.00149322,2.47571e-19,336683,ukb-a-434,rs140570886,C,T,0.0157148,Vascular/heart problems diagnosed by doctor: Heart attack,LPA
6,161013013,-0.138564,0.0160474,2.90001e-19,,met-d-L_HDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in large HDL,LPA
6,161013013,0.146292,0.0163067,2.90001e-19,115082,ebi-a-GCST90092925,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in medium VLDL,LPA
6,161013013,-0.144472,0.0162891,7.39946e-19,115082,ebi-a-GCST90092842,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in IDL,LPA
6,161013013,-0.150084,0.0169752,9.49948e-19,115082,ebi-a-GCST90092972,rs140570886,C,T,0.015486,Free cholesterol levels in small VLDL,LPA
6,161013013,0.517,0.0587,1.27997e-18,,finn-b-I9_ISCHHEART,rs140570886,C,T,0.009302,Ischemic heart diseases,LPA
6,161013013,-0.149359,0.0169706,1.39991e-18,115082,ebi-a-GCST90092887,rs140570886,C,T,0.015486,Concentration of LDL particles,LPA
6,161013013,-0.149502,0.0170043,1.50003e-18,115082,ebi-a-GCST90092956,rs140570886,C,T,0.015486,Cholesterol levels in small LDL,LPA
6,161013013,0.145389,0.0165367,1.50003e-18,115082,ebi-a-GCST90092834,rs140570886,C,T,0.015486,Cholesteryl esters to total lipids ratio in IDL,LPA
6,161013013,-0.151149,0.016993,1.69981e-18,,met-d-S_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in small VLDL,LPA
6,161013013,-0.142069,0.0162737,2.49977e-18,115006,ebi-a-GCST90092931,rs140570886,C,T,0.015497,Omega-3 fatty acid levels,LPA
6,161013013,0.146753,0.0168243,2.70023e-18,115071,ebi-a-GCST90092873,rs140570886,C,T,0.015483,Free cholesterol to total lipids ratio in large VLDL,LPA
6,161013013,-0.139681,0.0160371,2.99985e-18,115006,ebi-a-GCST90092938,rs140570886,C,T,0.015497,Phosphoglycerides levels,LPA
6,161013013,-0.150085,0.0169779,3.19963e-18,,met-d-LDL_P,rs140570886,C,T,0.015487,Concentration of LDL particles,LPA
6,161013013,0.508,0.0584,3.31971e-18,,finn-b-I9_IHD,rs140570886,C,T,0.009302,"Ischaemic heart disease, wide definition",LPA
6,161013013,0.0151256,0.00174011,3.56615e-18,336683,ukb-a-436,rs140570886,C,T,0.0157148,Vascular/heart problems diagnosed by doctor: Angina,LPA
6,161013013,-0.150213,0.0170082,5.00035e-18,,met-d-S_LDL_C,rs140570886,C,T,0.015487,Cholesterol in small LDL,LPA
6,161013013,0.0713,0.0082,5.67545e-18,343621,ebi-a-GCST90018961,rs140570886,C,T,0.0177835,LDL cholesterol,LPA
6,161013013,0.7729,0.0897,6.9199e-18,,finn-b-I9_REVASC,rs140570886,C,T,0.009177,Coronary revascularization (ANGIO or CABG),LPA
6,161013013,0.0767766,0.00894062,1.10002e-17,415311,ebi-a-GCST006701,rs140570886,C,T,0.015533,Parental longevity (father's attained age),LPA
6,161013013,-0.136412,0.0159798,1.39991e-17,115082,ebi-a-GCST90092855,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in large HDL,LPA
6,161013013,0.36113,0.0425148,1.99297e-17,171875,ieu-a-798,rs140570886,C,T,0.0195859,Myocardial infarction,LPA
6,161013013,0.0111585,0.00132215,3.19521e-17,361194,ukb-d-I9_MI_STRICT,rs140570886,C,T,0.0156259,"Myocardial infarction, strict",LPA
6,161013013,0.0111585,0.00132215,3.19521e-17,361194,ukb-d-I9_MI,rs140570886,C,T,0.0156259,Myocardial infarction,LPA
6,161013013,-0.130946,0.0163233,3.19963e-17,,met-d-L_HDL_TG,rs140570886,C,T,0.015487,Triglycerides in large HDL,LPA
6,161013013,-0.141251,0.0167607,3.50026e-17,,met-d-SFA_pct,rs140570886,C,T,0.015497,Ratio of saturated fatty acids to total fatty acids,LPA
6,161013013,-0.143112,0.0170094,4.00037e-17,115082,ebi-a-GCST90092910,rs140570886,C,T,0.015486,Total lipid levels in medium LDL,LPA
6,161013013,-0.141754,0.0169604,6.4003e-17,115082,ebi-a-GCST90092809,rs140570886,C,T,0.015486,Apolipoprotein B levels,LPA
6,161013013,-0.140572,0.0168751,8.10028e-17,115082,ebi-a-GCST90092943,rs140570886,C,T,0.015486,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",LPA
6,161013013,-0.144158,0.0170165,9.20026e-17,,met-d-M_LDL_L,rs140570886,C,T,0.015487,Total lipids in medium LDL,LPA
6,161013013,0.717,0.0863,9.43626e-17,,finn-b-I9_REVACS_EXNONE,rs140570886,C,T,0.009302,Emergency coronary revascularization (for ACS) (no controls excluded),LPA
6,161013013,0.717,0.0863,9.43626e-17,,finn-b-I9_REVASC_EXNONE,rs140570886,C,T,0.009302,Coronary revascularization (ANGIO or CABG) (no controls excluded),LPA
6,161013013,-0.138841,0.016743,1.10002e-16,115006,ebi-a-GCST90092981,rs140570886,C,T,0.015497,Ratio of saturated fatty acids to total fatty acids,LPA
6,161013013,0.0374116,0.00451453,1.17004e-16,180203,ukb-a-448,rs140570886,C,T,0.0157148,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: Cholesterol lowering medication,LPA
6,161013013,0.0762979,0.00920285,1.20005e-16,389166,ebi-a-GCST006697,rs140570886,C,T,0.015518,"Parental longevity (combined parental attained age, Martingale residuals)",LPA
6,161013013,-0.142552,0.0169689,1.69981e-16,,met-d-ApoB,rs140570886,C,T,0.015487,Apolipoprotein B,LPA
6,161013013,-0.141531,0.016883,2.39994e-16,,met-d-Remnant_C,rs140570886,C,T,0.015487,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",LPA
6,161013013,0.02413,0.00297048,4.49987e-16,457547,ukb-b-7137,rs140570886,C,T,0.015484,"Medication for pain relief, constipation, heartburn: Aspirin",LPA
6,161013013,0.023384,0.00288446,5.19996e-16,462933,ukb-b-8755,rs140570886,C,T,0.015491,Treatment/medication code: aspirin,LPA
6,161013013,-0.137847,0.0170191,5.50047e-16,115082,ebi-a-GCST90092904,rs140570886,C,T,0.015486,Cholesterol levels in medium LDL,LPA
6,161013013,-0.0480879,0.00594943,6.29941e-16,209638,ukb-b-12014,rs140570886,C,T,0.015523,"Medication for cholesterol, blood pressure or diabetes: None of the above",LPA
6,161013013,-0.133922,0.0165949,7.00003e-16,115082,ebi-a-GCST90092988,rs140570886,C,T,0.015486,Total free cholesterol levels,LPA
6,161013013,0.5541,0.0687,7.49031e-16,,finn-b-I9_CHD,rs140570886,C,T,0.009302,Major coronary heart disease event,LPA
6,161013013,-0.12372,0.0159797,1.39991e-15,,met-d-Cholines,rs140570886,C,T,0.015497,Total cholines,LPA
6,161013013,-0.138874,0.0170242,1.50003e-15,,met-d-M_LDL_C,rs140570886,C,T,0.015487,Cholesterol in medium LDL,LPA
6,161013013,-0.128745,0.0161453,1.50003e-15,115082,ebi-a-GCST90092854,rs140570886,C,T,0.015486,Triglyceride levels in large HDL,LPA
6,161013013,-0.134826,0.0166007,1.59993e-15,,met-d-Total_FC,rs140570886,C,T,0.015487,Total free cholesterol,LPA
6,161013013,0.0212012,0.00269375,3.50026e-15,462933,ukb-b-11268,rs140570886,C,T,0.015491,Treatment/medication code: simvastatin,LPA
6,161013013,0.233944,0.0290095,3.71706e-15,349222,ebi-a-GCST90104006,rs140570886,C,T,0.015739,Familial combined hyperlipidemia defined by Consensus criteria,LPA
6,161013013,-0.122482,0.0159495,1.59993e-14,115006,ebi-a-GCST90092812,rs140570886,C,T,0.015497,Total cholines levels,LPA
6,161013013,0.2353,0.0308,2.13501e-14,470931,ebi-a-GCST90018793,rs140570886,C,T,0.0174012,Angina pectoris,LPA
6,161013013,-0.121561,0.0161214,4.79954e-14,,met-d-M_HDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in medium HDL,LPA
6,161013013,-0.0734269,0.00979131,6.4003e-14,341118,ukb-b-11303,rs140570886,C,T,0.015769,Father's age at death,LPA
6,161013013,-0.113051,0.0159214,1.10002e-13,,met-d-Phosphatidylc,rs140570886,C,T,0.015497,Phosphatidylcholines,LPA
6,161013013,-0.1234,0.0167542,1.10002e-13,,met-d-XS_VLDL_PL,rs140570886,C,T,0.015487,Phospholipids in very small VLDL,LPA
6,161013013,-0.119577,0.016116,1.20005e-13,115082,ebi-a-GCST90092901,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in medium HDL,LPA
6,161013013,-0.12462,0.0169417,1.9002e-13,115082,ebi-a-GCST90092916,rs140570886,C,T,0.015486,Cholesterol levels in medium VLDL,LPA
6,161013013,0.00560813,0.000766184,2.49345e-13,337159,ukb-a-191,rs140570886,C,T,0.0157148,Treatment/medication code: ezetimibe,LPA
6,161013013,-0.121545,0.0166599,2.99985e-13,115082,ebi-a-GCST90093036,rs140570886,C,T,0.015486,Phospholipid levels in very small VLDL,LPA
6,161013013,0.7689,0.1057,3.43005e-13,,finn-b-I9_ANGIO,rs140570886,C,T,0.00906,Coronary angiopasty,LPA
6,161013013,0.5194,0.0717,4.30031e-13,,finn-b-E4_LIPOPROT,rs140570886,C,T,0.009337,Disorders of lipoprotein metabolism and other lipidaemias,LPA
6,161013013,-0.318196,0.0439376,4.42079e-13,19757,eqtl-a-ENSG00000175003,rs140570886,C,T,0.0186283,ENSG00000175003,LPA
6,161013013,0.0241125,0.00336806,8.13205e-13,337159,ukb-a-132,rs140570886,C,T,0.0157148,Treatment/medication code: aspirin,LPA
6,161013013,-0.124896,0.0169447,1.29987e-12,,met-d-M_VLDL_C,rs140570886,C,T,0.015487,Cholesterol in medium VLDL,LPA
6,161013013,-0.120175,0.0169268,1.29987e-12,115082,ebi-a-GCST90092863,rs140570886,C,T,0.015486,Concentration of large LDL particles,LPA
6,161013013,0.5185,0.0734,1.60805e-12,,finn-b-I9_ANGINA,rs140570886,C,T,0.009151,Angina pectoris,LPA
6,161013013,-0.11202,0.0158771,1.69981e-12,115006,ebi-a-GCST90092937,rs140570886,C,T,0.015497,Phosphatidylcholine levels,LPA
6,161013013,0.8499,0.121,2.15576e-12,,finn-b-I9_CABG,rs140570886,C,T,0.009048,Coronary artery bypass grafting,LPA
6,161013013,-0.108732,0.0166631,2.39994e-12,,met-d-L_LDL_TG_pct,rs140570886,C,T,0.015487,Triglycerides to total lipids ratio in large LDL,LPA
6,161013013,-0.119707,0.0170949,2.49977e-12,114160,ebi-a-GCST90093025,rs140570886,C,T,0.015328,Phospholipids to total lipids ratio in very large VLDL,LPA
6,161013013,0.0240973,0.00346013,3.30674e-12,333581,ukb-a-452,rs140570886,C,T,0.0157148,Medication for pain relief  constipation  heartburn: Aspirin,LPA
6,161013013,-0.120392,0.0169325,3.40017e-12,,met-d-L_LDL_P,rs140570886,C,T,0.015487,Concentration of large LDL particles,LPA
6,161013013,-0.116375,0.0169448,6.4998e-12,115082,ebi-a-GCST90092884,rs140570886,C,T,0.015486,Cholesteryl ester levels in LDL,LPA
6,161013013,-0.119214,0.0171068,7.39946e-12,,met-d-XL_VLDL_PL_pct,rs140570886,C,T,0.015328,Phospholipids to total lipids ratio in very large VLDL,LPA
6,161013013,-0.115284,0.0168976,8.9002e-12,115082,ebi-a-GCST90092930,rs140570886,C,T,0.015486,Total cholesterol minus HDL-C levels,LPA
6,161013013,0.00808334,0.00118606,9.42323e-12,337199,ukb-a-532,rs140570886,C,T,0.0157148,Diagnoses - main ICD10: I20 Angina pectoris,LPA
6,161013013,-0.113233,0.016703,1e-11,,met-d-XS_VLDL_L,rs140570886,C,T,0.015487,Total lipids in very small VLDL,LPA
6,161013013,0.7725,0.1149,1.74703e-11,,finn-b-I9_CABG_EXNONE,rs140570886,C,T,0.009302,Coronary artery bypass grafting (no controls excluded),LPA
6,161013013,-0.11714,0.0169484,1.80011e-11,,met-d-LDL_CE,rs140570886,C,T,0.015487,Cholesteryl esters in LDL,LPA
6,161013013,-0.111392,0.0166216,2.09991e-11,115082,ebi-a-GCST90093034,rs140570886,C,T,0.015486,Total lipid levels in very small VLDL,LPA
6,161013013,0.0196688,0.00295018,2.60016e-11,363542,ukb-b-14371,rs140570886,C,T,0.015467,Illnesses of siblings: Heart disease,LPA
6,161013013,0.0209651,0.00315582,3.07185e-11,337159,ukb-a-121,rs140570886,C,T,0.0157148,Treatment/medication code: simvastatin,LPA
6,161013013,-0.116004,0.0169011,3.50026e-11,,met-d-non_HDL_C,rs140570886,C,T,0.015487,Total cholesterol minus HDL-C,LPA
6,161013013,-0.0293054,0.00443348,3.80014e-11,402586,ukb-b-15169,rs140570886,C,T,0.015487,Illnesses of father: None of the above (group 1),LPA
6,161013013,-0.11245,0.0170141,3.90032e-11,115082,ebi-a-GCST90092912,rs140570886,C,T,0.015486,Phospholipid levels in medium LDL,LPA
6,161013013,0.00616127,0.000935124,4.44222e-11,361194,ukb-d-I9_UAP,rs140570886,C,T,0.0156259,Unstable angina pectoris,LPA
6,161013013,0.2136,0.0328,7.68776e-11,977323,ebi-a-GCST009541,rs140570886,C,T,,Heart failure,LPA
6,161013013,-0.106725,0.0164973,9.8992e-11,115082,ebi-a-GCST90092867,rs140570886,C,T,0.015486,Triglycerides to total lipids ratio in large LDL,LPA
6,161013013,-0.113099,0.0170178,1.2e-10,,met-d-M_LDL_PL,rs140570886,C,T,0.015487,Phospholipids in medium LDL,LPA
6,161013013,0.4485,0.0698,1.32501e-10,,finn-b-I9_ANGINA_EXNONE,rs140570886,C,T,0.009302,Angina pectoris (no controls excluded),LPA
6,161013013,-0.0246208,0.00384575,1.5e-10,461880,ukb-b-13352,rs140570886,C,T,0.015495,Vascular/heart problems diagnosed by doctor: None of the above,LPA
6,161013013,0.5695,0.0895,1.97102e-10,,finn-b-E4_HYPERCHOL,rs140570886,C,T,0.009242,Pure hypercholesterolaemia,LPA
6,161013013,-0.106013,0.0167177,2.30001e-10,115082,ebi-a-GCST90092810,rs140570886,C,T,0.015486,Ratio of apolipoprotein B to apolipoprotein A1 levels,LPA
6,161013013,0.6252,0.0988,2.48399e-10,,finn-b-I9_ANGIO_EXNONE,rs140570886,C,T,0.009302,Coronary angiopasty (no controls excluded),LPA
6,161013013,0.042793,0.0068161,3.40001e-10,462933,ukb-b-3656,rs140570886,C,T,0.015491,Number of treatments/medications taken,LPA
6,161013013,-0.103716,0.0168491,4.39997e-10,,met-d-S_HDL_PL,rs140570886,C,T,0.015487,Phospholipids in small HDL,LPA
6,161013013,-0.0432385,0.00697571,5.71729e-10,154702,ukb-a-489,rs140570886,C,T,0.0157148,Medication for cholesterol  blood pressure or diabetes: None of the above,LPA
6,161013013,-0.106134,0.0167325,8.9e-10,,met-d-ApoB_by_ApoA1,rs140570886,C,T,0.015487,Ratio of apolipoprotein B to apolipoprotein A1,LPA
6,161013013,0.0167809,0.00274082,9.20005e-10,463010,ukb-b-12493,rs140570886,C,T,0.015491,Diagnoses - secondary ICD10: I10 Essential (primary) hypertension,LPA
6,161013013,-0.0972576,0.016588,9.69996e-10,,met-d-XS_VLDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in very small VLDL,LPA
6,161013013,-0.103182,0.0167674,1.2e-09,,met-d-XS_VLDL_P,rs140570886,C,T,0.015487,Concentration of very small VLDL particles,LPA
6,161013013,-0.101428,0.0166968,1.2e-09,115082,ebi-a-GCST90093035,rs140570886,C,T,0.015486,Concentration of very small VLDL particles,LPA
6,161013013,0.0414834,0.00685029,1.40001e-09,144817,ukb-b-19722,rs140570886,C,T,0.015292,Non-accidental death in close genetic family,LPA
6,161013013,-0.101877,0.0168306,1.40001e-09,115082,ebi-a-GCST90092952,rs140570886,C,T,0.015486,Phospholipid levels in small HDL,LPA
6,161013013,-0.068364,0.0114253,2.18625e-09,248726,ukb-a-41,rs140570886,C,T,0.0157148,Father's age at death,LPA
6,161013013,0.1996,0.0336,2.75899e-09,461823,ebi-a-GCST90018877,rs140570886,C,T,0.0174133,Myocardial infarction,LPA
6,161013013,0.1122,0.0189,2.81903e-09,153639,ebi-a-GCST90018982,rs140570886,C,T,0.022302,Medication use (antithrombotic agents),LPA
6,161013013,0.1823,0.0307,2.87601e-09,343026,ebi-a-GCST90018915,rs140570886,C,T,0.0195515,Stable angina pectoris,LPA
6,161013013,0.00633358,0.00106805,3.03131e-09,337199,ukb-a-533,rs140570886,C,T,0.0157148,Diagnoses - main ICD10: I21 Acute myocardial infarction,LPA
6,161013013,0.04709,0.00798182,3.64594e-09,337159,ukb-a-24,rs140570886,C,T,0.0157148,Number of treatments/medications taken,LPA
6,161013013,0.3375,0.0572,3.69301e-09,,finn-b-I9_CVD_HARD,rs140570886,C,T,0.009302,Hard cardiovascular diseases,LPA
6,161013013,-0.0972608,0.016565,4.30002e-09,115082,ebi-a-GCST90093037,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in very small VLDL,LPA
6,161013013,0.0943897,0.016617,5.49997e-09,,met-d-LA_pct,rs140570886,C,T,0.015497,Ratio of linoleic acid to total fatty acids,LPA
6,161013013,-0.0987788,0.0169383,6.69993e-09,,met-d-S_HDL_L,rs140570886,C,T,0.015487,Total lipids in small HDL,LPA
6,161013013,0.137,0.0239,9.60904e-09,64115,ieu-b-4846,rs140570886,C,T,,LDL cholesterol,LPA
6,161013013,-0.0970752,0.0169289,9.80009e-09,115082,ebi-a-GCST90092950,rs140570886,C,T,0.015486,Total lipid levels in small HDL,LPA
6,161013013,0.6262,0.1094,1.05599e-08,,finn-b-I9_UAP,rs140570886,C,T,0.009098,Unstable angina pectoris,LPA
6,161013013,0.019054,0.00333943,1.15936e-08,259921,ukb-a-217,rs140570886,C,T,0.0157148,Illnesses of siblings: Heart disease,LPA
6,161013013,-0.0906038,0.0170669,1.29999e-08,,met-d-IDL_PL_pct,rs140570886,C,T,0.015487,Phospholipids to total lipids ratio in IDL,LPA
6,161013013,0.00450095,0.000792446,1.34946e-08,337159,ukb-a-180,rs140570886,C,T,0.0157148,Treatment/medication code: clopidogrel,LPA
6,161013013,-0.0959864,0.016933,1.40001e-08,115082,ebi-a-GCST90092886,rs140570886,C,T,0.015486,Total lipid levels in LDL,LPA
6,161013013,-0.0921012,0.0164515,2.19999e-08,115082,ebi-a-GCST90092985,rs140570886,C,T,0.015486,Total cholesterol levels,LPA
6,161013013,0.0912621,0.0163692,2.5e-08,115006,ebi-a-GCST90092881,rs140570886,C,T,0.015497,Ratio of linoleic acid to total fatty acids,LPA
6,161013013,0.0390258,0.00702621,2.80001e-08,462933,ukb-b-4063,rs140570886,C,T,0.015491,Number of self-reported non-cancer illnesses,LPA
6,161013013,0.0698637,0.0127565,3.40001e-08,,ieu-b-5089,rs140570886,C,T,0.015546,LDL cholesterol,LPA
6,161013013,-0.0737751,0.0133774,3.40001e-08,208118,ebi-a-GCST006702,rs140570886,C,T,0.015677,Parental longevity (combined parental age at death),LPA
6,161013013,0.0408,0.0074,3.71903e-08,344278,ebi-a-GCST90018974,rs140570886,C,T,0.0191264,Total cholesterol levels,LPA
6,161013013,-0.0966358,0.0169367,4.49997e-08,,met-d-LDL_L,rs140570886,C,T,0.015487,Total lipids in LDL,LPA
6,161013013,0.3102,0.0568,4.78002e-08,,finn-b-E4_METABOLIA,rs140570886,C,T,0.009302,Metabolic disorders,LPA
6,161013013,-0.0928091,0.0164522,4.90004e-08,,met-d-Total_C,rs140570886,C,T,0.015487,Total cholesterol,LPA
6,161013013,-0.0896717,0.0166259,6.90001e-08,115082,ebi-a-GCST90093032,rs140570886,C,T,0.015486,Free cholesterol levels in very small VLDL,LPA
6,161013013,-0.0912306,0.0166981,8.30004e-08,,met-d-XS_VLDL_FC,rs140570886,C,T,0.015487,Free cholesterol in very small VLDL,LPA
6,161013013,0.0833542,0.016984,8.60003e-08,,met-d-XL_HDL_CE_pct,rs140570886,C,T,0.01549,Cholesteryl esters to total lipids ratio in very large HDL,LPA
6,161013013,0.2444,0.0457,9.1791e-08,465527,ebi-a-GCST90018811,rs140570886,C,T,0.0178597,Cardiac valvular disease,LPA
6,161013013,0.0867101,0.0168673,9.29994e-08,,met-d-IDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in IDL,LPA
6,161013013,0.4925,0.0924,9.75192e-08,,finn-b-Z21_PRESENCE_CARDIAC_VASCULAR_IMPLANTNTS_GRAFTS,rs140570886,C,T,0.00933,Presence of cardiac and vascular implants and grafts,LPA
6,161013013,0.0478619,0.00899005,1e-07,412937,ebi-a-GCST006696,rs140570886,C,T,0.015527,Parental longevity (mother's attained age),LPA
6,161013013,-0.276967,0.051494,1.01e-07,19267,met-c-941,rs140570886,C,T,0.011813,Mean diameter for VLDL particles,LPA
6,161013013,-0.0906281,0.0170573,1.09999e-07,115082,ebi-a-GCST90092840,rs140570886,C,T,0.015486,Phospholipids to total lipids ratio in IDL,LPA
6,161013013,-0.0897061,0.0169419,1.2e-07,115082,ebi-a-GCST90092964,rs140570886,C,T,0.015486,Phospholipid levels in small LDL,LPA
6,161013013,0.5678,0.1078,1.37101e-07,,finn-b-DM_PERIPHATHERO,rs140570886,C,T,0.009139,Peripheral atherosclerosis,LPA
6,161013013,0.5345,0.1021,1.63099e-07,,finn-b-I9_ATHSCLE,rs140570886,C,T,0.009286,"Atherosclerosis, excluding cerebral, coronary and PAD",LPA
6,161013013,0.5222,0.1,1.74401e-07,,finn-b-I9_UAP_EXNONE,rs140570886,C,T,0.009302,Unstable angina pectoris (no controls excluded),LPA
6,161013013,0.5287,0.1017,2.00401e-07,,finn-b-I9_ATHSCLE_EXNONE,rs140570886,C,T,0.009302,"""Atherosclerosis, excluding cerebral, coronary and PAD"" (no controls excluded)",LPA
6,161013013,-0.022075,0.00426276,2.19999e-07,457547,ukb-b-11085,rs140570886,C,T,0.015484,"Medication for pain relief, constipation, heartburn: None of the above",LPA
6,161013013,-0.0875568,0.0169196,2.30001e-07,115082,ebi-a-GCST90092883,rs140570886,C,T,0.015486,LDL cholesterol levels,LPA
6,161013013,-0.0275738,0.00537735,2.90001e-07,249710,ukb-b-20379,rs140570886,C,T,0.015514,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: None of the above",LPA
6,161013013,0.0767918,0.0162343,3.29997e-07,,met-d-XL_HDL_C_pct,rs140570886,C,T,0.01549,Cholesterol to total lipids ratio in very large HDL,LPA
6,161013013,0.0808447,0.0168727,3.40001e-07,,met-d-XS_VLDL_FC_pct,rs140570886,C,T,0.015487,Free cholesterol to total lipids ratio in very small VLDL,LPA
6,161013013,-0.0553559,0.0109152,3.89996e-07,317652,ebi-a-GCST006700,rs140570886,C,T,0.015458,Parental longevity (father's age at death),LPA
6,161013013,-0.0900508,0.0169504,4.30002e-07,,met-d-S_LDL_PL,rs140570886,C,T,0.015487,Phospholipids in small LDL,LPA
6,161013013,0.0844812,0.0168692,5.49997e-07,115082,ebi-a-GCST90092836,rs140570886,C,T,0.015486,Free cholesterol to total lipids ratio in IDL,LPA
6,161013013,0.2468,0.0496,6.37705e-07,456468,ebi-a-GCST90018932,rs140570886,C,T,0.017174,Unstable angina pectoris,LPA
6,161013013,0.0407556,0.00822133,7.15122e-07,337159,ukb-a-22,rs140570886,C,T,0.0157148,Number of self-reported non-cancer illnesses,LPA
6,161013013,-0.022508,0.00454532,7.35258e-07,336683,ukb-a-435,rs140570886,C,T,0.0157148,Vascular/heart problems diagnosed by doctor: None of the above,LPA
6,161013013,-0.0880547,0.0169204,7.49998e-07,,met-d-LDL_C,rs140570886,C,T,0.015487,LDL cholesterol,LPA
6,161013013,-0.0245653,0.00498328,8.2467e-07,333581,ukb-a-453,rs140570886,C,T,0.0157148,Medication for pain relief  constipation  heartburn: None of the above,LPA
6,160911596,1.249,0.014905,0,273896,ukb-d-30790_irnt,rs147555597,A,G,0.0083353,Lipoprotein A,LPA
6,160911596,77.334,0.73362,0,273896,ukb-d-30790_raw,rs147555597,A,G,0.0083353,Lipoprotein A,LPA
6,160911596,-0.305124,0.0207157,4.19952e-49,115082,ebi-a-GCST90093050,rs147555597,A,G,0.00955,Triglyceride levels in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.302438,0.0207344,9.20026e-49,,met-d-XXL_VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in chylomicrons and extremely large VLDL,LPA
6,160911596,0.303606,0.0215559,4.70002e-45,111638,ebi-a-GCST90093045,rs147555597,A,G,0.009435,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,0.302602,0.0215582,5.19996e-45,,met-d-XXL_VLDL_FC_pct,rs147555597,A,G,0.009435,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,0.300691,0.0216958,4.30031e-44,,met-d-XXL_VLDL_C_pct,rs147555597,A,G,0.009435,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,0.301692,0.0216961,5.90065e-44,111638,ebi-a-GCST90093041,rs147555597,A,G,0.009435,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.280595,0.0206749,5.90065e-42,115082,ebi-a-GCST90093046,rs147555597,A,G,0.00955,Total lipid levels in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.277884,0.0207027,1.80011e-41,,met-d-XXL_VLDL_L,rs147555597,A,G,0.00955,Total lipids in chylomicrons and extremely large VLDL,LPA
6,160911596,0.132494,0.00998585,3.50026e-40,431167,ebi-a-GCST90002412,rs147555597,A,G,0.009507,Low density lipoprotein cholesterol levels,LPA
6,160911596,-0.283237,0.021841,7.19946e-39,,met-d-XXL_VLDL_TG_pct,rs147555597,A,G,0.009435,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.283966,0.0218303,1.10002e-38,111638,ebi-a-GCST90093051,rs147555597,A,G,0.009435,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.264004,0.020632,1.69981e-37,115082,ebi-a-GCST90093047,rs147555597,A,G,0.00955,Concentration of chylomicrons and extremely large VLDL particles,LPA
6,160911596,-0.261108,0.02068,6.70039e-37,,met-d-XXL_VLDL_P,rs147555597,A,G,0.00955,Concentration of chylomicrons and extremely large VLDL particles,LPA
6,160911596,0.26147,0.0206175,7.39946e-37,114160,ebi-a-GCST90093019,rs147555597,A,G,0.009493,Cholesteryl esters to total lipids ratio in very large VLDL,LPA
6,160911596,0.2578,0.020689,3.10027e-36,,met-d-XL_VLDL_CE_pct,rs147555597,A,G,0.009493,Cholesteryl esters to total lipids ratio in very large VLDL,LPA
6,160911596,-0.256145,0.0205903,1.59993e-35,115082,ebi-a-GCST90093048,rs147555597,A,G,0.00955,Phospholipid levels in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.25347,0.0206354,4.00037e-35,,met-d-XXL_VLDL_PL,rs147555597,A,G,0.00955,Phospholipids in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.253305,0.0206698,1.59993e-34,115082,ebi-a-GCST90093044,rs147555597,A,G,0.00955,Free cholesterol levels in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.25008,0.0207167,6.29941e-34,,met-d-XXL_VLDL_FC,rs147555597,A,G,0.00955,Free cholesterol in chylomicrons and extremely large VLDL,LPA
6,160911596,0.248312,0.0206217,2.19989e-33,114160,ebi-a-GCST90093017,rs147555597,A,G,0.009493,Cholesterol to total lipids ratio in very large VLDL,LPA
6,160911596,-0.237535,0.0200458,2.90001e-33,,met-d-VLDL_size,rs147555597,A,G,0.00955,Average diameter for VLDL particles,LPA
6,160911596,-0.239665,0.0200448,6.00067e-33,115082,ebi-a-GCST90093002,rs147555597,A,G,0.00955,Average diameter for VLDL particles,LPA
6,160911596,0.245076,0.0206823,6.4998e-33,,met-d-XL_VLDL_C_pct,rs147555597,A,G,0.009493,Cholesterol to total lipids ratio in very large VLDL,LPA
6,160911596,0.3864,0.0326,1.74301e-32,296525,ebi-a-GCST005194,rs147555597,A,G,0.0088,Coronary artery disease,LPA
6,160911596,-0.244317,0.0206948,3.59998e-32,115082,ebi-a-GCST90093040,rs147555597,A,G,0.00955,Cholesterol levels in chylomicrons and extremely large VLDL,LPA
6,160911596,0.240404,0.0205897,1.9002e-31,,met-d-L_VLDL_CE_pct,rs147555597,A,G,0.009551,Cholesteryl esters to total lipids ratio in large VLDL,LPA
6,160911596,-0.24084,0.0207281,1.9002e-31,,met-d-XXL_VLDL_C,rs147555597,A,G,0.00955,Cholesterol in chylomicrons and extremely large VLDL,LPA
6,160911596,0.240007,0.0205919,2.19989e-31,115071,ebi-a-GCST90092871,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in large VLDL,LPA
6,160911596,0.252496,0.0218197,5.70033e-31,111638,ebi-a-GCST90093043,rs147555597,A,G,0.009435,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,0.251828,0.0218216,7.59976e-31,,met-d-XXL_VLDL_CE_pct,rs147555597,A,G,0.009435,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.237583,0.0207479,2.29985e-30,115082,ebi-a-GCST90093042,rs147555597,A,G,0.00955,Cholesteryl ester levels in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.233395,0.0205317,6.09958e-30,115082,ebi-a-GCST90093026,rs147555597,A,G,0.00955,Triglyceride levels in very large VLDL,LPA
6,160911596,-0.234275,0.0207757,1.20005e-29,,met-d-XXL_VLDL_CE,rs147555597,A,G,0.00955,Cholesteryl esters in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.230345,0.0205725,2.19989e-29,,met-d-XL_VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in very large VLDL,LPA
6,160911596,0.421726,0.0374705,2.19989e-29,547261,ebi-a-GCST005195,rs147555597,A,G,,Coronary artery disease,LPA
6,160911596,0.22848,0.0210276,2.19989e-27,,met-d-L_VLDL_C_pct,rs147555597,A,G,0.009551,Cholesterol to total lipids ratio in large VLDL,LPA
6,160911596,-0.223901,0.0206691,2.39994e-27,115082,ebi-a-GCST90092878,rs147555597,A,G,0.00955,Triglyceride levels in large VLDL,LPA
6,160911596,-0.223319,0.0206468,2.90001e-27,115082,ebi-a-GCST90093003,rs147555597,A,G,0.00955,Triglyceride levels in VLDL,LPA
6,160911596,0.227398,0.0210334,2.99985e-27,115071,ebi-a-GCST90092869,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in large VLDL,LPA
6,160911596,-0.221282,0.0207,5.50047e-27,,met-d-L_VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in large VLDL,LPA
6,160911596,-0.220269,0.0207008,9.8992e-27,,met-d-VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in VLDL,LPA
6,160911596,-0.218791,0.020663,3.40017e-26,115082,ebi-a-GCST90093022,rs147555597,A,G,0.00955,Total lipid levels in very large VLDL,LPA
6,160911596,-0.220922,0.0208886,3.80014e-26,114160,ebi-a-GCST90093027,rs147555597,A,G,0.009493,Triglycerides to total lipids ratio in very large VLDL,LPA
6,160911596,-0.219055,0.020922,1.10002e-25,,met-d-XL_VLDL_TG_pct,rs147555597,A,G,0.009493,Triglycerides to total lipids ratio in very large VLDL,LPA
6,160911596,-0.215647,0.0206994,1.59993e-25,,met-d-XL_VLDL_L,rs147555597,A,G,0.00955,Total lipids in very large VLDL,LPA
6,160911596,-0.213262,0.0207212,7.70016e-25,115082,ebi-a-GCST90093024,rs147555597,A,G,0.00955,Phospholipid levels in very large VLDL,LPA
6,160911596,-0.211045,0.0207967,3.40017e-24,115082,ebi-a-GCST90093020,rs147555597,A,G,0.00955,Free cholesterol levels in very large VLDL,LPA
6,160911596,-0.21017,0.0207627,4.90004e-24,,met-d-XL_VLDL_PL,rs147555597,A,G,0.00955,Phospholipids in very large VLDL,LPA
6,160911596,-0.206515,0.0206329,1.39991e-23,115082,ebi-a-GCST90093023,rs147555597,A,G,0.00955,Concentration of very large VLDL particles,LPA
6,160911596,-0.207977,0.0208408,1.69981e-23,,met-d-XL_VLDL_FC,rs147555597,A,G,0.00955,Free cholesterol in very large VLDL,LPA
6,160911596,-0.198435,0.0199348,2.39994e-23,115006,ebi-a-GCST90092983,rs147555597,A,G,0.009556,Ratio of triglycerides to phosphoglycerides,LPA
6,160911596,0.206195,0.0207264,2.60016e-23,115082,ebi-a-GCST90092961,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in small LDL,LPA
6,160911596,-0.205928,0.0207363,3.10027e-23,115082,ebi-a-GCST90092992,rs147555597,A,G,0.00955,Total triglycerides levels,LPA
6,160911596,-0.205897,0.0208501,5.30029e-23,115082,ebi-a-GCST90092966,rs147555597,A,G,0.00955,Triglyceride levels in small LDL,LPA
6,160911596,0.202137,0.0208618,5.50047e-23,,met-d-S_LDL_FC_pct,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in small LDL,LPA
6,160911596,-0.195793,0.0199675,5.50047e-23,,met-d-TG_by_PG,rs147555597,A,G,0.009556,Ratio of triglycerides to phosphoglycerides,LPA
6,160911596,-0.203504,0.0206805,7.00003e-23,,met-d-XL_VLDL_P,rs147555597,A,G,0.00955,Concentration of very large VLDL particles,LPA
6,160911596,-0.202608,0.0208288,1e-22,,met-d-Total_TG,rs147555597,A,G,0.00955,Total triglycerides,LPA
6,160911596,-0.203206,0.0209915,1.59993e-22,,met-d-S_LDL_TG,rs147555597,A,G,0.00955,Triglycerides in small LDL,LPA
6,160911596,0.407205,0.0412613,2.66993e-21,352063,ebi-a-GCST90013864,rs147555597,A,G,,Coronary artery disease (Firth correction),LPA
6,160911596,0.444466,0.0469523,2.89868e-21,352063,ebi-a-GCST90013868,rs147555597,A,G,,Coronary artery disease (SPA correction),LPA
6,160911596,-0.195946,0.0207579,3.69999e-21,115082,ebi-a-GCST90092874,rs147555597,A,G,0.00955,Total lipid levels in large VLDL,LPA
6,160911596,-0.192996,0.0207323,1.29987e-20,115082,ebi-a-GCST90092875,rs147555597,A,G,0.00955,Concentration of large VLDL particles,LPA
6,160911596,-0.193067,0.0207966,1.9002e-20,,met-d-L_VLDL_L,rs147555597,A,G,0.00955,Total lipids in large VLDL,LPA
6,160911596,-0.190178,0.0207796,6.20012e-20,,met-d-L_VLDL_P,rs147555597,A,G,0.00955,Concentration of large VLDL particles,LPA
6,160911596,-0.186016,0.0208624,7.00003e-20,,met-d-S_LDL_TG_pct,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small LDL,LPA
6,160911596,-0.188998,0.0207103,7.10068e-20,115082,ebi-a-GCST90092967,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small LDL,LPA
6,160911596,-0.186839,0.0210476,6.90081e-19,115082,ebi-a-GCST90092999,rs147555597,A,G,0.00955,Total lipid levels in VLDL,LPA
6,160911596,-0.181866,0.0207281,1.69981e-18,115082,ebi-a-GCST90092876,rs147555597,A,G,0.00955,Phospholipid levels in large VLDL,LPA
6,160911596,-0.183607,0.0209918,2.19989e-18,115082,ebi-a-GCST90093016,rs147555597,A,G,0.00955,Cholesterol levels in very large VLDL,LPA
6,160911596,0.0204914,0.00234362,2.26934e-18,361194,ukb-d-I9_CORATHER,rs147555597,A,G,0.00962662,Coronary atherosclerosis,LPA
6,160911596,0.178533,0.0205007,3.10027e-18,115082,ebi-a-GCST90092909,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in medium LDL,LPA
6,160911596,-0.183743,0.0211015,3.19963e-18,,met-d-VLDL_L,rs147555597,A,G,0.00955,Total lipids in VLDL,LPA
6,160911596,-0.179883,0.0208602,6.4998e-18,115082,ebi-a-GCST90092926,rs147555597,A,G,0.00955,Triglyceride levels in medium VLDL,LPA
6,160911596,-0.180916,0.0210219,6.70039e-18,,met-d-XL_VLDL_C,rs147555597,A,G,0.00955,Cholesterol in very large VLDL,LPA
6,160911596,-0.179087,0.0207666,6.79986e-18,,met-d-L_VLDL_PL,rs147555597,A,G,0.00955,Phospholipids in large VLDL,LPA
6,160911596,0.173977,0.0206211,1e-17,,met-d-M_LDL_FC_pct,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in medium LDL,LPA
6,160911596,-0.177218,0.0209125,2.39994e-17,,met-d-M_VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in medium VLDL,LPA
6,160911596,-0.174726,0.0207774,4.10015e-17,115082,ebi-a-GCST90092872,rs147555597,A,G,0.00955,Free cholesterol levels in large VLDL,LPA
6,160911596,0.0233883,0.00279249,5.52205e-17,361194,ukb-d-I9_IHD,rs147555597,A,G,0.00962662,"Ischaemic heart disease, wide definition",LPA
6,160911596,-0.171821,0.02082,1.69981e-16,,met-d-L_VLDL_FC,rs147555597,A,G,0.00955,Free cholesterol in large VLDL,LPA
6,160911596,0.361361,0.043867,1.85012e-16,58825,ebi-a-GCST011365,rs147555597,A,G,0.008833,Myocardial infarction,LPA
6,160911596,0.163565,0.0201481,4.70002e-16,115082,ebi-a-GCST90092919,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in medium VLDL,LPA
6,160911596,0.160691,0.0202198,4.79954e-16,,met-d-M_VLDL_CE_pct,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in medium VLDL,LPA
6,160911596,0.028193,0.00354576,1.80011e-15,462933,ukb-b-10912,rs147555597,A,G,0.00951,"Non-cancer illness code, self-reported: high cholesterol",LPA
6,160911596,0.0266413,0.00345658,2.39994e-15,464736,ebi-a-GCST90029021,rs147555597,A,G,0.009523,High cholesterol,LPA
6,160911596,0.157535,0.020275,2.60016e-15,,met-d-M_VLDL_C_pct,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in medium VLDL,LPA
6,160911596,0.159744,0.02023,2.90001e-15,115082,ebi-a-GCST90092917,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in medium VLDL,LPA
6,160911596,-0.160957,0.0211584,4.40048e-15,,met-d-XL_HDL_TG,rs147555597,A,G,0.00955,Triglycerides in very large HDL,LPA
6,160911596,-0.164426,0.0209782,4.60045e-15,115082,ebi-a-GCST90093014,rs147555597,A,G,0.00955,Triglyceride levels in very large HDL,LPA
6,160911596,0.0153082,0.00200567,2.3094e-14,337199,ukb-a-534,rs147555597,A,G,0.0096234,Diagnoses - main ICD10: I25 Chronic ischaemic heart disease,LPA
6,160911596,-0.161768,0.021212,2.39994e-14,115082,ebi-a-GCST90093001,rs147555597,A,G,0.00955,Phospholipid levels in VLDL,LPA
6,160911596,-0.162316,0.0214208,3.50026e-14,115082,ebi-a-GCST90092907,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in medium LDL,LPA
6,160911596,-0.1626,0.0215101,4.10015e-14,115082,ebi-a-GCST90092959,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in small LDL,LPA
6,160911596,0.6585,0.0871,4.12857e-14,,finn-b-I9_REVASC,rs147555597,A,G,0.009283,Coronary revascularization (ANGIO or CABG),LPA
6,160911596,-0.160054,0.0214987,5.00035e-14,,met-d-S_LDL_CE_pct,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in small LDL,LPA
6,160911596,-0.157803,0.0210146,5.90065e-14,115082,ebi-a-GCST90092868,rs147555597,A,G,0.00955,Cholesterol levels in large VLDL,LPA
6,160911596,-0.158843,0.0212643,8.69961e-14,,met-d-VLDL_PL,rs147555597,A,G,0.00955,Phospholipids in VLDL,LPA
6,160911596,-0.157101,0.0211689,1.20005e-13,115082,ebi-a-GCST90093018,rs147555597,A,G,0.00955,Cholesteryl ester levels in very large VLDL,LPA
6,160911596,-0.15693,0.021196,1.29987e-13,115006,ebi-a-GCST90092928,rs147555597,A,G,0.009556,Monounsaturated fatty acid levels,LPA
6,160911596,0.156018,0.0214959,1.50003e-13,,met-d-S_LDL_PL_pct,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in small LDL,LPA
6,160911596,0.152949,0.0209376,1.59993e-13,,met-d-XL_VLDL_FC_pct,rs147555597,A,G,0.009493,Free cholesterol to total lipids ratio in very large VLDL,LPA
6,160911596,-0.1478,0.0203452,1.80011e-13,,met-d-M_VLDL_TG_pct,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in medium VLDL,LPA
6,160911596,0.158411,0.0215115,1.80011e-13,115082,ebi-a-GCST90092965,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in small LDL,LPA
6,160911596,-0.149533,0.0203066,1.80011e-13,115082,ebi-a-GCST90092927,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in medium VLDL,LPA
6,160911596,-0.154834,0.0210563,2.09991e-13,,met-d-L_VLDL_C,rs147555597,A,G,0.00955,Cholesterol in large VLDL,LPA
6,160911596,-0.15476,0.0211907,2.70023e-13,,met-d-XL_VLDL_CE,rs147555597,A,G,0.00955,Cholesteryl esters in very large VLDL,LPA
6,160911596,0.152825,0.0209131,2.70023e-13,114160,ebi-a-GCST90093021,rs147555597,A,G,0.009493,Free cholesterol to total lipids ratio in very large VLDL,LPA
6,160911596,-0.158438,0.0214417,2.80027e-13,,met-d-M_LDL_CE_pct,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in medium LDL,LPA
6,160911596,-0.153686,0.021303,4.30031e-13,,met-d-MUFA,rs147555597,A,G,0.009556,Monounsaturated fatty acids,LPA
6,160911596,-0.149914,0.0207504,5.00035e-13,115082,ebi-a-GCST90092978,rs147555597,A,G,0.00955,Triglyceride levels in small VLDL,LPA
6,160911596,0.40968,0.0571742,7.8001e-13,17505,ebi-a-GCST011364,rs147555597,A,G,0.009182,Myocardial infarction,LPA
6,160911596,-0.146674,0.0208936,1.29987e-12,,met-d-S_VLDL_TG,rs147555597,A,G,0.00955,Triglycerides in small VLDL,LPA
6,160911596,-0.15125,0.0213241,1.29987e-12,115082,ebi-a-GCST90092998,rs147555597,A,G,0.00955,Free cholesterol levels in VLDL,LPA
6,160911596,0.153638,0.0216838,1.39991e-12,111638,ebi-a-GCST90093049,rs147555597,A,G,0.009435,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,0.243915,0.0337786,1.71672e-12,407746,ebi-a-GCST90013882,rs147555597,A,G,,High cholesterol (Firth correction),LPA
6,160911596,0.255963,0.0363114,1.80094e-12,407746,ebi-a-GCST90013932,rs147555597,A,G,,High cholesterol (SPA correction),LPA
6,160911596,0.149502,0.0212258,1.9002e-12,115082,ebi-a-GCST90092971,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in small VLDL,LPA
6,160911596,0.333591,0.045574,2.02675e-12,397554,ebi-a-GCST90013886,rs147555597,A,G,,Angina (Firth correction),LPA
6,160911596,0.362641,0.0516482,2.19735e-12,397554,ebi-a-GCST90013936,rs147555597,A,G,,Angina (SPA correction),LPA
6,160911596,0.3538,0.0506,2.7077e-12,470931,ebi-a-GCST90018793,rs147555597,A,G,0.00943318,Angina pectoris,LPA
6,160911596,0.5849,0.0838,2.88403e-12,,finn-b-I9_REVACS_EXNONE,rs147555597,A,G,0.009326,Emergency coronary revascularization (for ACS) (no controls excluded),LPA
6,160911596,0.5849,0.0838,2.88403e-12,,finn-b-I9_REVASC_EXNONE,rs147555597,A,G,0.009326,Coronary revascularization (ANGIO or CABG) (no controls excluded),LPA
6,160911596,0.152605,0.0218006,3.10027e-12,,met-d-XXL_VLDL_PL_pct,rs147555597,A,G,0.009435,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,LPA
6,160911596,-0.148439,0.0213689,5.50047e-12,,met-d-VLDL_FC,rs147555597,A,G,0.00955,Free cholesterol in VLDL,LPA
6,160911596,0.149043,0.0212526,7.10068e-12,,met-d-S_VLDL_CE_pct,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in small VLDL,LPA
6,160911596,-0.144904,0.0212085,8.4004e-12,115006,ebi-a-GCST90092980,rs147555597,A,G,0.009556,Saturated fatty acid levels,LPA
6,160911596,0.139344,0.020487,1e-11,115082,ebi-a-GCST90092921,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in medium VLDL,LPA
6,160911596,-0.144379,0.0212306,1e-11,115006,ebi-a-GCST90092987,rs147555597,A,G,0.009556,Total fatty acid levels,LPA
6,160911596,0.139169,0.0204871,1.10002e-11,,met-d-M_VLDL_FC_pct,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in medium VLDL,LPA
6,160911596,0.144687,0.0214228,1.39991e-11,115082,ebi-a-GCST90092913,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in medium LDL,LPA
6,160911596,0.4094,0.0608,1.6531e-11,461823,ebi-a-GCST90018877,rs147555597,A,G,0.00940855,Myocardial infarction,LPA
6,160911596,0.8187,0.1217,1.69395e-11,,finn-b-I9_CABG,rs147555597,A,G,0.009153,Coronary artery bypass grafting,LPA
6,160911596,0.4592,0.0683,1.74301e-11,,finn-b-I9_CHD,rs147555597,A,G,0.009326,Major coronary heart disease event,LPA
6,160911596,0.4866,0.0726,2.0179e-11,,finn-b-I9_ANGINA,rs147555597,A,G,0.009265,Angina pectoris,LPA
6,160911596,-0.141662,0.0213521,2.29985e-11,,met-d-Total_FA,rs147555597,A,G,0.009556,Total fatty acids,LPA
6,160911596,0.137532,0.0206412,2.70023e-11,115006,ebi-a-GCST90092935,rs147555597,A,G,0.009556,Ratio of omega-6 fatty acids to total fatty acids,LPA
6,160911596,-0.141391,0.0213307,2.80027e-11,,met-d-SFA,rs147555597,A,G,0.009556,Saturated fatty acids,LPA
6,160911596,0.583,0.0883,3.99025e-11,456468,ebi-a-GCST90018932,rs147555597,A,G,0.00934708,Unstable angina pectoris,LPA
6,160911596,0.137633,0.020895,4.49987e-11,115082,ebi-a-GCST90092969,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in small VLDL,LPA
6,160911596,-0.137898,0.0210025,5.19996e-11,115082,ebi-a-GCST90092914,rs147555597,A,G,0.00955,Triglyceride levels in medium LDL,LPA
6,160911596,0.136201,0.0209587,6.09958e-11,,met-d-S_VLDL_C_pct,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in small VLDL,LPA
6,160911596,-0.139456,0.0213552,6.59933e-11,115082,ebi-a-GCST90092922,rs147555597,A,G,0.00955,Total lipid levels in medium VLDL,LPA
6,160911596,0.139493,0.0215288,7.8001e-11,,met-d-M_LDL_PL_pct,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in medium LDL,LPA
6,160911596,-0.137933,0.0212344,8.30042e-11,115082,ebi-a-GCST90092870,rs147555597,A,G,0.00955,Cholesteryl ester levels in large VLDL,LPA
6,160911596,0.132893,0.0206065,1.09999e-10,115006,ebi-a-GCST90092940,rs147555597,A,G,0.009556,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,LPA
6,160911596,-0.137904,0.0214433,1.2e-10,,met-d-L_VLDL_TG_pct,rs147555597,A,G,0.009551,Triglycerides to total lipids ratio in large VLDL,LPA
6,160911596,-0.135224,0.0212157,1.29999e-10,,met-d-M_LDL_TG,rs147555597,A,G,0.00955,Triglycerides in medium LDL,LPA
6,160911596,0.131665,0.0206738,1.89998e-10,115006,ebi-a-GCST90092941,rs147555597,A,G,0.009556,Ratio of polyunsaturated fatty acids to total fatty acids,LPA
6,160911596,-0.134965,0.0212741,2.19999e-10,,met-d-L_VLDL_CE,rs147555597,A,G,0.00955,Cholesteryl esters in large VLDL,LPA
6,160911596,-0.137141,0.0213835,2.30001e-10,,met-d-M_VLDL_L,rs147555597,A,G,0.00955,Total lipids in medium VLDL,LPA
6,160911596,-0.135964,0.0214368,2.30001e-10,115071,ebi-a-GCST90092879,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in large VLDL,LPA
6,160911596,0.129207,0.0206422,2.59998e-10,,met-d-PUFA_by_MUFA,rs147555597,A,G,0.009556,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,LPA
6,160911596,0.068716,0.0108737,2.59998e-10,,ieu-b-108,rs147555597,A,G,0.009501,apolipoprotein B,LPA
6,160911596,0.131776,0.0209483,2.99999e-10,,met-d-Omega_6_pct,rs147555597,A,G,0.009556,Ratio of omega-6 fatty acids to total fatty acids,LPA
6,160911596,0.0679604,0.0108109,3.2517e-10,388022,ebi-a-GCST90013994,rs147555597,A,G,,Apolipoprotein B levels (UKB data field 30640),LPA
6,160911596,-0.129834,0.0207645,4e-10,115082,ebi-a-GCST90092979,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small VLDL,LPA
6,160911596,-0.128016,0.0208437,4.49997e-10,,met-d-S_VLDL_TG_pct,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small VLDL,LPA
6,160911596,0.127281,0.0207163,5.39995e-10,,met-d-PUFA_pct,rs147555597,A,G,0.009556,Ratio of polyunsaturated fatty acids to total fatty acids,LPA
6,160911596,-0.127452,0.0206139,6.29999e-10,115006,ebi-a-GCST90092929,rs147555597,A,G,0.009556,Ratio of monounsaturated fatty acids to total fatty acids,LPA
6,160911596,0.4006,0.0648,6.33797e-10,,finn-b-I9_CORATHER,rs147555597,A,G,0.009318,Coronary atherosclerosis,LPA
6,160911596,0.012269,0.00200158,8.81617e-10,361194,ukb-d-I9_CHD_NOREV,rs147555597,A,G,0.00962662,Major coronary heart disease event excluding revascularizations,LPA
6,160911596,0.012269,0.00200158,8.81617e-10,361194,ukb-d-I9_CHD,rs147555597,A,G,0.00962662,Major coronary heart disease event,LPA
6,160911596,0.0348987,0.00572519,1.09219e-09,180203,ukb-a-448,rs147555597,A,G,0.0096234,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: Cholesterol lowering medication,LPA
6,160911596,0.6886,0.1133,1.214e-09,,finn-b-I9_CABG_EXNONE,rs147555597,A,G,0.009326,Coronary artery bypass grafting (no controls excluded),LPA
6,160911596,0.3933,0.065,1.42502e-09,,finn-b-I9_CORATHER_EXNONE,rs147555597,A,G,0.009326,Coronary atherosclerosis (no controls excluded),LPA
6,160911596,0.0250795,0.00414521,1.44777e-09,337159,ukb-a-108,rs147555597,A,G,0.0096234,Non-cancer illness code  self-reported: high cholesterol,LPA
6,160911596,-0.12452,0.0206376,1.7e-09,,met-d-MUFA_pct,rs147555597,A,G,0.009556,Ratio of monounsaturated fatty acids to total fatty acids,LPA
6,160911596,0.3449,0.0574,1.85102e-09,,finn-b-I9_ISCHHEART,rs147555597,A,G,0.009326,Ischemic heart diseases,LPA
6,160911596,0.4153,0.0693,2.07601e-09,,finn-b-I9_ANGINA_EXNONE,rs147555597,A,G,0.009326,Angina pectoris (no controls excluded),LPA
6,160911596,0.3414,0.0574,2.79898e-09,,finn-b-I9_CVD_HARD,rs147555597,A,G,0.009326,Hard cardiovascular diseases,LPA
6,160911596,0.0636049,0.0109157,5.60003e-09,,ieu-b-110,rs147555597,A,G,0.009495,LDL cholesterol,LPA
6,160911596,-0.0617565,0.0106564,6.82229e-09,389562,ebi-a-GCST90014014,rs147555597,A,G,,Triglyceride levels (UKB data field 30870),LPA
6,160911596,-0.122997,0.0214576,9.90011e-09,115082,ebi-a-GCST90092923,rs147555597,A,G,0.00955,Concentration of medium VLDL particles,LPA
6,160911596,0.3271,0.0572,1.05201e-08,,finn-b-I9_IHD,rs147555597,A,G,0.009326,"Ischaemic heart disease, wide definition",LPA
6,160911596,0.062637,0.0109592,1.09388e-08,389189,ebi-a-GCST90013871,rs147555597,A,G,,Direct low density lipoprotein levels (UKB data field 30780),LPA
6,160911596,0.6325,0.1112,1.276e-08,,finn-b-I9_UAP,rs147555597,A,G,0.009133,Unstable angina pectoris,LPA
6,160911596,0.0618723,0.0109758,1.7289e-08,389189,ebi-a-GCST90014009,rs147555597,A,G,,Direct low density lipoprotein levels (UKB data field 30780),LPA
6,160911596,0.23123,0.0405769,1.79436e-08,407746,ebi-a-GCST90013919,rs147555597,A,G,,Cholesterol lowering medication use (UKB data field 6177_1) (Firth correction),LPA
6,160911596,0.237295,0.0421761,1.84137e-08,407746,ebi-a-GCST90013969,rs147555597,A,G,,Cholesterol lowering medication use (UKB data field 6177_1) (SPA correction),LPA
6,160911596,-0.058181,0.0103993,2.19999e-08,,ieu-b-111,rs147555597,A,G,0.009494,triglycerides,LPA
6,160911596,0.567,0.1015,2.31601e-08,,finn-b-I9_ANGIO,rs147555597,A,G,0.009149,Coronary angiopasty,LPA
6,160911596,-0.1209,0.0214806,2.39999e-08,,met-d-M_VLDL_P,rs147555597,A,G,0.00955,Concentration of medium VLDL particles,LPA
6,160911596,0.0380533,0.0068156,2.39999e-08,209638,ukb-b-11740,rs147555597,A,G,0.009417,"Medication for cholesterol, blood pressure or diabetes: Cholesterol lowering medication",LPA
6,160911596,0.0650625,0.0116789,2.39999e-08,389166,ebi-a-GCST006697,rs147555597,A,G,0.00956,"Parental longevity (combined parental attained age, Martingale residuals)",LPA
6,160911596,-0.117354,0.021125,2.80001e-08,115006,ebi-a-GCST90092880,rs147555597,A,G,0.009556,Linoleic acid levels,LPA
6,160911596,-0.119242,0.0214738,2.80001e-08,115082,ebi-a-GCST90092996,rs147555597,A,G,0.00955,VLDL cholesterol levels,LPA
6,160911596,-0.118077,0.0213445,3.2e-08,115082,ebi-a-GCST90093000,rs147555597,A,G,0.00955,Concentration of VLDL particles,LPA
6,160911596,-0.118532,0.0211174,3.50002e-08,,met-d-LA,rs147555597,A,G,0.009556,Linoleic acid,LPA
6,160911596,0.11241,0.0204278,3.69999e-08,115082,ebi-a-GCST90092861,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in large LDL,LPA
6,160911596,-0.112166,0.0204028,3.89996e-08,115082,ebi-a-GCST90092955,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small HDL,LPA
6,160911596,0.0257405,0.00476679,3.89996e-08,477807,ebi-a-GCST90029019,rs147555597,A,G,0.009523,Cardiovascular disease,LPA
6,160911596,0.0298602,0.00543982,4e-08,407557,ukb-b-18408,rs147555597,A,G,0.009478,Illnesses of father: Heart disease,LPA
6,160911596,0.117527,0.0213444,4.60002e-08,,met-d-L_VLDL_FC_pct,rs147555597,A,G,0.009551,Free cholesterol to total lipids ratio in large VLDL,LPA
6,160911596,0.115882,0.0213277,5.49997e-08,115071,ebi-a-GCST90092873,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in large VLDL,LPA
6,160911596,-0.108857,0.0204945,5.60003e-08,,met-d-S_HDL_TG_pct,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in small HDL,LPA
6,160911596,-0.114874,0.0211614,5.69994e-08,115082,ebi-a-GCST90092975,rs147555597,A,G,0.00955,Concentration of small VLDL particles,LPA
6,160911596,-0.116751,0.0215046,6.19998e-08,,met-d-VLDL_C,rs147555597,A,G,0.00955,VLDL cholesterol,LPA
6,160911596,0.109992,0.0205311,6.80002e-08,,met-d-L_LDL_FC_pct,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in large LDL,LPA
6,160911596,0.0241539,0.00447914,6.95168e-08,361194,ukb-d-IX_CIRCULATORY,rs147555597,A,G,0.00962662,Diseases of the circulatory system,LPA
6,160911596,-0.115768,0.0214803,7.10003e-08,115082,ebi-a-GCST90092924,rs147555597,A,G,0.00955,Phospholipid levels in medium VLDL,LPA
6,160911596,0.00902545,0.00167529,7.15369e-08,361194,ukb-d-I9_MI_STRICT,rs147555597,A,G,0.00962662,"Myocardial infarction, strict",LPA
6,160911596,0.00902545,0.00167529,7.15369e-08,361194,ukb-d-I9_MI,rs147555597,A,G,0.00962662,Myocardial infarction,LPA
6,160911596,-0.115091,0.0214163,9.29994e-08,,met-d-VLDL_P,rs147555597,A,G,0.00955,Concentration of VLDL particles,LPA
6,160911596,-0.113765,0.0215016,1.5e-07,,met-d-M_VLDL_PL,rs147555597,A,G,0.00955,Phospholipids in medium VLDL,LPA
6,160911596,0.103465,0.0206167,1.5e-07,,met-d-S_VLDL_PL_pct,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in small VLDL,LPA
6,160911596,-0.111909,0.0212577,1.5e-07,,met-d-S_VLDL_P,rs147555597,A,G,0.00955,Concentration of small VLDL particles,LPA
6,160911596,0.3176,0.0607,1.65501e-07,343026,ebi-a-GCST90018915,rs147555597,A,G,0.00946866,Stable angina pectoris,LPA
6,160911596,0.0584798,0.0113373,2.1e-07,415311,ebi-a-GCST006701,rs147555597,A,G,0.009574,Parental longevity (father's attained age),LPA
6,160911596,-0.0352536,0.00680786,2.19999e-07,249710,ukb-b-20379,rs147555597,A,G,0.009601,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: None of the above",LPA
6,160911596,0.102385,0.0205736,2.30001e-07,,met-d-S_VLDL_FC_pct,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in small VLDL,LPA
6,160911596,0.106031,0.0205043,2.30001e-07,115082,ebi-a-GCST90092977,rs147555597,A,G,0.00955,Phospholipids to total lipids ratio in small VLDL,LPA
6,160911596,-0.108104,0.0208951,2.30001e-07,115006,ebi-a-GCST90092939,rs147555597,A,G,0.009556,Polyunsaturated fatty acid levels,LPA
6,160911596,-0.108967,0.0212305,2.90001e-07,115082,ebi-a-GCST90092974,rs147555597,A,G,0.00955,Total lipid levels in small VLDL,LPA
6,160911596,0.104856,0.0204609,2.99999e-07,115082,ebi-a-GCST90092973,rs147555597,A,G,0.00955,Free cholesterol to total lipids ratio in small VLDL,LPA
6,160911596,-0.10689,0.0209999,3.09999e-07,,met-d-PUFA,rs147555597,A,G,0.009556,Polyunsaturated fatty acids,LPA
6,160911596,0.10312,0.0201855,3.2e-07,115082,ebi-a-GCST90093031,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in very small VLDL,LPA
6,160911596,-0.107113,0.0210853,3.79997e-07,115082,ebi-a-GCST90092915,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in medium LDL,LPA
6,160911596,0.10129,0.0203121,4.39997e-07,,met-d-XS_VLDL_CE_pct,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in very small VLDL,LPA
6,160911596,-0.105999,0.0210618,4.79999e-07,115082,ebi-a-GCST90092890,rs147555597,A,G,0.00955,Triglyceride levels in LDL,LPA
6,160911596,-0.104563,0.0212726,5.49997e-07,,met-d-M_LDL_TG_pct,rs147555597,A,G,0.00955,Triglycerides to total lipids ratio in medium LDL,LPA
6,160911596,0.105315,0.0211637,6.49995e-07,115082,ebi-a-GCST90092945,rs147555597,A,G,0.00955,Cholesterol to total lipids ratio in small HDL,LPA
6,160911596,0.0186186,0.00375168,6.9536e-07,360294,ukb-d-1538_1,rs147555597,A,G,0.00963039,"Major dietary changes in the last 5 years: Yes, because of illness",LPA
6,160911596,0.4193,0.0847,7.35902e-07,,finn-b-I9_MI_STRICT,rs147555597,A,G,0.00917,"Myocardial infarction, strict",LPA
6,160911596,-0.106049,0.0213203,7.39997e-07,,met-d-S_VLDL_L,rs147555597,A,G,0.00955,Total lipids in small VLDL,LPA
6,160911596,0.103508,0.0210497,8.79995e-07,115082,ebi-a-GCST90092947,rs147555597,A,G,0.00955,Cholesteryl esters to total lipids ratio in small HDL,LPA
6,160911596,0.4826,0.0984,9.38296e-07,,finn-b-I9_UAP_EXNONE,rs147555597,A,G,0.009326,Unstable angina pectoris (no controls excluded),LPA
6,161123451,0.96969,0.004557,0,273896,ukb-d-30790_irnt,rs4252185,C,T,0.090323,Lipoprotein A,PLG
6,161123451,64.358,0.21059,0,273896,ukb-d-30790_raw,rs4252185,C,T,0.090323,Lipoprotein A,PLG
6,161123451,0.667347,0.00317574,0,348806,ebi-a-GCST90025993,rs4252185,C,T,0.0888956,Lipoprotein (a) levels,PLG
6,161123451,0.102979,0.00329108,6.29506e-215,431167,ebi-a-GCST90002412,rs4252185,C,T,0.099252,Low density lipoprotein cholesterol levels,PLG
6,161123451,-0.19523,0.00682706,6.29506e-183,,met-d-XXL_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.194565,0.00682085,5.70164e-179,115082,ebi-a-GCST90093050,rs4252185,C,T,0.099677,Triglyceride levels in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.181972,0.00681662,4.69894e-160,,met-d-XXL_VLDL_L,rs4252185,C,T,0.099681,Total lipids in chylomicrons and extremely large VLDL,PLG
6,161123451,0.190843,0.00713266,8.20352e-159,,met-d-XXL_VLDL_C_pct,rs4252185,C,T,0.098759,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,0.190319,0.00713306,7.7983e-157,111638,ebi-a-GCST90093041,rs4252185,C,T,0.09874,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.18118,0.00680743,4.4978e-156,115082,ebi-a-GCST90093046,rs4252185,C,T,0.099677,Total lipid levels in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.169744,0.00680913,7.19449e-140,,met-d-XXL_VLDL_P,rs4252185,C,T,0.099681,Concentration of chylomicrons and extremely large VLDL particles,PLG
6,161123451,-0.179872,0.00718039,4.39542e-139,,met-d-XXL_VLDL_TG_pct,rs4252185,C,T,0.098759,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.179886,0.00717718,1.1995e-138,111638,ebi-a-GCST90093051,rs4252185,C,T,0.09874,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.16801,0.00679444,1.49968e-137,,met-d-XXL_VLDL_PL,rs4252185,C,T,0.099681,Phospholipids in chylomicrons and extremely large VLDL,PLG
6,161123451,0.176681,0.00708744,4.89779e-137,,met-d-XXL_VLDL_FC_pct,rs4252185,C,T,0.098759,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.168406,0.00682123,5.59758e-137,,met-d-XXL_VLDL_FC,rs4252185,C,T,0.099681,Free cholesterol in chylomicrons and extremely large VLDL,PLG
6,161123451,0.176145,0.00708696,2.30144e-136,111638,ebi-a-GCST90093045,rs4252185,C,T,0.09874,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.168814,0.0067933,2.60016e-136,115082,ebi-a-GCST90093047,rs4252185,C,T,0.099677,Concentration of chylomicrons and extremely large VLDL particles,PLG
6,161123451,0.166004,0.00679548,2.69774e-134,,met-d-XL_VLDL_CE_pct,rs4252185,C,T,0.099524,Cholesteryl esters to total lipids ratio in very large VLDL,PLG
6,161123451,-0.167069,0.00677956,4.39542e-134,115082,ebi-a-GCST90093048,rs4252185,C,T,0.099677,Phospholipid levels in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.167484,0.00680574,1e-133,115082,ebi-a-GCST90093044,rs4252185,C,T,0.099677,Free cholesterol levels in chylomicrons and extremely large VLDL,PLG
6,161123451,0.164936,0.00677211,5.10505e-131,114160,ebi-a-GCST90093019,rs4252185,C,T,0.099515,Cholesteryl esters to total lipids ratio in very large VLDL,PLG
6,161123451,0.160373,0.00677997,3.09742e-128,,met-d-L_VLDL_CE_pct,rs4252185,C,T,0.099669,Cholesteryl esters to total lipids ratio in large VLDL,PLG
6,161123451,0.172096,0.00717402,3.39625e-128,,met-d-XXL_VLDL_CE_pct,rs4252185,C,T,0.098759,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,0.171542,0.00717372,2.30144e-126,111638,ebi-a-GCST90093043,rs4252185,C,T,0.09874,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,0.160283,0.00678065,1.59956e-123,115071,ebi-a-GCST90092871,rs4252185,C,T,0.099665,Cholesteryl esters to total lipids ratio in large VLDL,PLG
6,161123451,0.158104,0.00679326,4.4978e-122,,met-d-XL_VLDL_C_pct,rs4252185,C,T,0.099524,Cholesterol to total lipids ratio in very large VLDL,PLG
6,161123451,-0.158314,0.00682497,7.49894e-121,,met-d-XXL_VLDL_C,rs4252185,C,T,0.099681,Cholesterol in chylomicrons and extremely large VLDL,PLG
6,161123451,0.15719,0.00677349,3.89942e-119,114160,ebi-a-GCST90093017,rs4252185,C,T,0.099515,Cholesterol to total lipids ratio in very large VLDL,PLG
6,161123451,-0.157646,0.00681397,1.99986e-118,115082,ebi-a-GCST90093040,rs4252185,C,T,0.099677,Cholesterol levels in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.149348,0.00660032,1.30017e-115,,met-d-VLDL_size,rs4252185,C,T,0.099681,Average diameter for VLDL particles,PLG
6,161123451,-0.14907,0.00659995,5.90201e-113,115082,ebi-a-GCST90093002,rs4252185,C,T,0.099677,Average diameter for VLDL particles,PLG
6,161123451,0.149126,0.00692418,1.90108e-107,,met-d-L_VLDL_C_pct,rs4252185,C,T,0.099669,Cholesterol to total lipids ratio in large VLDL,PLG
6,161123451,-0.148913,0.00684064,1.79887e-106,,met-d-XXL_VLDL_CE,rs4252185,C,T,0.099681,Cholesteryl esters in chylomicrons and extremely large VLDL,PLG
6,161123451,0.2463,0.0112,1.84077e-106,296525,ebi-a-GCST005194,rs4252185,C,T,0.0853,Coronary artery disease,PLG
6,161123451,-0.148305,0.00683145,1.69824e-104,115082,ebi-a-GCST90093042,rs4252185,C,T,0.099677,Cholesteryl ester levels in chylomicrons and extremely large VLDL,PLG
6,161123451,0.0720807,0.00344602,4.69894e-104,435744,ebi-a-GCST90025952,rs4252185,C,T,0.0999567,Apolipoprotein B levels,PLG
6,161123451,0.149394,0.00692603,3.39625e-103,115071,ebi-a-GCST90092869,rs4252185,C,T,0.099665,Cholesterol to total lipids ratio in large VLDL,PLG
6,161123451,-0.142166,0.00687201,7.89951e-97,,met-d-XL_VLDL_TG_pct,rs4252185,C,T,0.099524,Triglycerides to total lipids ratio in very large VLDL,PLG
6,161123451,-0.139467,0.00677373,4.60045e-96,,met-d-XL_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in very large VLDL,PLG
6,161123451,-0.141839,0.00686114,6.09958e-95,114160,ebi-a-GCST90093027,rs4252185,C,T,0.099515,Triglycerides to total lipids ratio in very large VLDL,PLG
6,161123451,-0.138781,0.00676028,1.20005e-93,115082,ebi-a-GCST90093026,rs4252185,C,T,0.099677,Triglyceride levels in very large VLDL,PLG
6,161123451,0.0696693,0.0035015,6.29941e-92,437068,ebi-a-GCST90025954,rs4252185,C,T,0.099939,Direct low density lipoprotein cholesterol levels,PLG
6,161123451,0.13768,0.006869,1.39991e-91,,met-d-S_LDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in small LDL,PLG
6,161123451,0.136885,0.00682437,1.69981e-89,115082,ebi-a-GCST90092961,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in small LDL,PLG
6,161123451,-0.133328,0.00681597,6.09958e-87,,met-d-VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in VLDL,PLG
6,161123451,-0.132776,0.00679816,6.00067e-85,115082,ebi-a-GCST90093003,rs4252185,C,T,0.099677,Triglyceride levels in VLDL,PLG
6,161123451,-0.130292,0.0068692,5.19996e-82,,met-d-S_LDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in small LDL,PLG
6,161123451,-0.129128,0.00681553,3.19963e-81,,met-d-XL_VLDL_L,rs4252185,C,T,0.099681,Total lipids in very large VLDL,PLG
6,161123451,0.0681795,0.00358143,8.4004e-81,,ieu-b-108,rs4252185,C,T,0.098942,apolipoprotein B,PLG
6,161123451,0.0673744,0.00354476,1.49968e-80,388022,ebi-a-GCST90013994,rs4252185,C,T,,Apolipoprotein B levels (UKB data field 30640),PLG
6,161123451,-0.129251,0.00681908,4.10015e-80,115082,ebi-a-GCST90092967,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in small LDL,PLG
6,161123451,-0.128478,0.00680352,1.50003e-79,115082,ebi-a-GCST90093022,rs4252185,C,T,0.099677,Total lipid levels in very large VLDL,PLG
6,161123451,0.233929,0.0124348,6.00067e-79,547261,ebi-a-GCST005195,rs4252185,C,T,,Coronary artery disease,PLG
6,161123451,-0.125902,0.00683635,5.00035e-77,,met-d-XL_VLDL_PL,rs4252185,C,T,0.099681,Phospholipids in very large VLDL,PLG
6,161123451,-0.124744,0.00681571,1e-75,,met-d-L_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in large VLDL,PLG
6,161123451,-0.125069,0.00682266,4.60045e-75,115082,ebi-a-GCST90093024,rs4252185,C,T,0.099677,Phospholipid levels in very large VLDL,PLG
6,161123451,-0.124373,0.00680551,1.29987e-74,115082,ebi-a-GCST90092878,rs4252185,C,T,0.099677,Triglyceride levels in large VLDL,PLG
6,161123451,0.0629057,0.00349298,4.20049e-74,437878,ebi-a-GCST90025953,rs4252185,C,T,0.0999404,Total cholesterol levels,PLG
6,161123451,0.0653621,0.00359532,7.50067e-74,,ieu-b-110,rs4252185,C,T,0.098912,LDL cholesterol,PLG
6,161123451,-0.117587,0.00657631,1.50003e-73,,met-d-TG_by_PG,rs4252185,C,T,0.099687,Ratio of triglycerides to phosphoglycerides,PLG
6,161123451,-0.122506,0.00680929,2.39994e-73,,met-d-XL_VLDL_P,rs4252185,C,T,0.099681,Concentration of very large VLDL particles,PLG
6,161123451,-0.122647,0.00685813,2.80027e-73,,met-d-Total_TG,rs4252185,C,T,0.099681,Total triglycerides,PLG
6,161123451,0.121112,0.00678973,1.59993e-72,,met-d-M_LDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in medium LDL,PLG
6,161123451,-0.122424,0.0069117,3.10027e-72,,met-d-S_LDL_TG,rs4252185,C,T,0.099681,Triglycerides in small LDL,PLG
6,161123451,-0.122082,0.00686209,4.30031e-72,,met-d-XL_VLDL_FC,rs4252185,C,T,0.099681,Free cholesterol in very large VLDL,PLG
6,161123451,-0.121825,0.0067936,6.59933e-72,115082,ebi-a-GCST90093023,rs4252185,C,T,0.099677,Concentration of very large VLDL particles,PLG
6,161123451,-0.121922,0.00682763,2.49977e-71,115082,ebi-a-GCST90092992,rs4252185,C,T,0.099677,Total triglycerides levels,PLG
6,161123451,0.064124,0.00359407,3.3597e-71,389189,ebi-a-GCST90013871,rs4252185,C,T,,Direct low density lipoprotein levels (UKB data field 30780),PLG
6,161123451,0.064202,0.00359953,3.70084e-71,389189,ebi-a-GCST90014009,rs4252185,C,T,,Direct low density lipoprotein levels (UKB data field 30780),PLG
6,161123451,0.12039,0.00675007,3.80014e-71,115082,ebi-a-GCST90092909,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in medium LDL,PLG
6,161123451,-0.116988,0.00656541,5.00035e-71,115006,ebi-a-GCST90092983,rs4252185,C,T,0.099686,Ratio of triglycerides to phosphoglycerides,PLG
6,161123451,-0.121404,0.00684751,2.49977e-70,115082,ebi-a-GCST90093020,rs4252185,C,T,0.099677,Free cholesterol levels in very large VLDL,PLG
6,161123451,-0.121399,0.0068651,5.60015e-70,115082,ebi-a-GCST90092966,rs4252185,C,T,0.099677,Triglyceride levels in small LDL,PLG
6,161123451,0.107503,0.00665762,4.19952e-60,,met-d-M_VLDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in medium VLDL,PLG
6,161123451,0.107327,0.00667578,4.70002e-60,,met-d-M_VLDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in medium VLDL,PLG
6,161123451,0.066073,0.0040517,9.22359e-60,342590,ukb-d-30640_irnt,rs4252185,C,T,0.10123,Apoliprotein B,PLG
6,161123451,0.250143,0.015491,1.33015e-58,58825,ebi-a-GCST011365,rs4252185,C,T,0.076246,Myocardial infarction,PLG
6,161123451,0.106978,0.00663397,1.69981e-58,115082,ebi-a-GCST90092919,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in medium VLDL,PLG
6,161123451,0.106976,0.00666093,4.79954e-58,115082,ebi-a-GCST90092917,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in medium VLDL,PLG
6,161123451,-0.108788,0.00684193,6.59933e-58,,met-d-L_VLDL_P,rs4252185,C,T,0.099681,Concentration of large VLDL particles,PLG
6,161123451,-0.108537,0.00684754,1.59993e-57,,met-d-L_VLDL_L,rs4252185,C,T,0.099681,Total lipids in large VLDL,PLG
6,161123451,0.015398,0.0009648,2.57513e-57,342590,ukb-d-30640_raw,rs4252185,C,T,0.10123,Apoliprotein B,PLG
6,161123451,0.055712,0.0034945,3.35815e-57,343621,ukb-d-30780_raw,rs4252185,C,T,0.1012,LDL direct,PLG
6,161123451,0.108339,0.00699766,8.10028e-57,,met-d-S_VLDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in small VLDL,PLG
6,161123451,0.0638,0.004,8.9454e-57,343621,ebi-a-GCST90018961,rs4252185,C,T,0.1012,LDL cholesterol,PLG
6,161123451,0.063847,0.004021,9.35406e-57,343621,ukb-d-30780_irnt,rs4252185,C,T,0.1012,LDL direct,PLG
6,161123451,-0.10821,0.0068263,1.39991e-56,115082,ebi-a-GCST90092875,rs4252185,C,T,0.099677,Concentration of large VLDL particles,PLG
6,161123451,0.10738,0.00690091,1.99986e-56,,met-d-S_VLDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in small VLDL,PLG
6,161123451,-0.108045,0.00683476,2.70023e-56,115082,ebi-a-GCST90092874,rs4252185,C,T,0.099677,Total lipid levels in large VLDL,PLG
6,161123451,0.055987,0.00355366,6.37089e-56,389864,ebi-a-GCST90014000,rs4252185,C,T,,Cholesterol levels (UKB data field 30690),PLG
6,161123451,-0.103222,0.0066989,1.20005e-55,,met-d-M_VLDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in medium VLDL,PLG
6,161123451,0.107042,0.0068799,1.39991e-54,115082,ebi-a-GCST90092969,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in small VLDL,PLG
6,161123451,0.1084,0.00698882,2.90001e-54,115082,ebi-a-GCST90092971,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in small VLDL,PLG
6,161123451,0.102149,0.00674562,9.09913e-54,,met-d-M_VLDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in medium VLDL,PLG
6,161123451,-0.102919,0.00668616,1.80011e-53,115082,ebi-a-GCST90092927,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in medium VLDL,PLG
6,161123451,-0.10482,0.00694793,4.49987e-53,,met-d-VLDL_L,rs4252185,C,T,0.099681,Total lipids in VLDL,PLG
6,161123451,-0.103481,0.00686305,5.79963e-53,,met-d-S_VLDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in small VLDL,PLG
6,161123451,0.104236,0.00687711,1.20005e-52,,met-d-XL_VLDL_FC_pct,rs4252185,C,T,0.099524,Free cholesterol to total lipids ratio in very large VLDL,PLG
6,161123451,-0.107168,0.00707871,2.60016e-52,,met-d-S_LDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in small LDL,PLG
6,161123451,0.104556,0.0068692,2.60016e-52,114160,ebi-a-GCST90093021,rs4252185,C,T,0.099515,Free cholesterol to total lipids ratio in very large VLDL,PLG
6,161123451,-0.107685,0.00708242,3.29989e-52,115082,ebi-a-GCST90092959,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in small LDL,PLG
6,161123451,-0.102928,0.00683764,4.60045e-52,,met-d-L_VLDL_PL,rs4252185,C,T,0.099681,Phospholipids in large VLDL,PLG
6,161123451,0.10223,0.00674556,7.00003e-52,115082,ebi-a-GCST90092921,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in medium VLDL,PLG
6,161123451,0.107263,0.00708286,8.30042e-52,115082,ebi-a-GCST90092965,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in small LDL,PLG
6,161123451,0.10682,0.00707777,2.29985e-51,,met-d-S_LDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in small LDL,PLG
6,161123451,-0.10299,0.00683693,2.80027e-51,115082,ebi-a-GCST90092979,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in small VLDL,PLG
6,161123451,-0.104144,0.00693014,4.79954e-51,115082,ebi-a-GCST90092999,rs4252185,C,T,0.099677,Total lipid levels in VLDL,PLG
6,161123451,-0.102322,0.00682495,8.19974e-51,115082,ebi-a-GCST90092876,rs4252185,C,T,0.099677,Phospholipid levels in large VLDL,PLG
6,161123451,-0.101992,0.00692171,2.90001e-50,,met-d-XL_VLDL_C,rs4252185,C,T,0.099681,Cholesterol in very large VLDL,PLG
6,161123451,0.220037,0.0145118,5.22878e-50,352063,ebi-a-GCST90013864,rs4252185,C,T,,Coronary artery disease (Firth correction),PLG
6,161123451,0.228819,0.0154033,6.44169e-50,352063,ebi-a-GCST90013868,rs4252185,C,T,,Coronary artery disease (SPA correction),PLG
6,161123451,-0.103707,0.00705992,2.19989e-49,,met-d-M_LDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in medium LDL,PLG
6,161123451,-0.102139,0.00701617,2.80027e-49,,met-d-MUFA,rs4252185,C,T,0.099687,Monounsaturated fatty acids,PLG
6,161123451,-0.103949,0.007053,3.69999e-49,115082,ebi-a-GCST90092907,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in medium LDL,PLG
6,161123451,-0.101387,0.00691176,1e-48,115082,ebi-a-GCST90093016,rs4252185,C,T,0.099677,Cholesterol levels in very large VLDL,PLG
6,161123451,0.026214,0.0017899,1.39991e-48,407557,ukb-b-18408,rs4252185,C,T,0.099175,Illnesses of father: Heart disease,PLG
6,161123451,-0.101318,0.00698075,9.8992e-48,115006,ebi-a-GCST90092928,rs4252185,C,T,0.099686,Monounsaturated fatty acid levels,PLG
6,161123451,0.0982119,0.00679804,2.60016e-47,115006,ebi-a-GCST90092935,rs4252185,C,T,0.099686,Ratio of omega-6 fatty acids to total fatty acids,PLG
6,161123451,-0.0980271,0.00685523,2.80027e-47,,met-d-L_VLDL_FC,rs4252185,C,T,0.099681,Free cholesterol in large VLDL,PLG
6,161123451,0.2527,0.0176,5.53605e-47,470931,ebi-a-GCST90018793,rs4252185,C,T,0.090254,Angina pectoris,PLG
6,161123451,0.011078,0.000770213,6.81397e-47,361194,ukb-d-I9_CORATHER,rs4252185,C,T,0.101344,Coronary atherosclerosis,PLG
6,161123451,0.0993743,0.00689934,7.8001e-47,,met-d-Omega_6_pct,rs4252185,C,T,0.099687,Ratio of omega-6 fatty acids to total fatty acids,PLG
6,161123451,-0.0974326,0.00684116,5.00035e-46,115082,ebi-a-GCST90092872,rs4252185,C,T,0.099677,Free cholesterol levels in large VLDL,PLG
6,161123451,-0.0960497,0.00688568,2.09991e-45,,met-d-M_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in medium VLDL,PLG
6,161123451,0.063652,0.0045212,5.2881e-45,344278,ukb-d-30690_raw,rs4252185,C,T,0.10121,Cholesterol,PLG
6,161123451,0.0128408,0.000917739,1.79763e-44,361194,ukb-d-I9_IHD,rs4252185,C,T,0.101344,"Ischaemic heart disease, wide definition",PLG
6,161123451,-0.0956439,0.00686844,4.49987e-44,115082,ebi-a-GCST90092926,rs4252185,C,T,0.099677,Triglyceride levels in medium VLDL,PLG
6,161123451,-0.0933523,0.00696666,9.3994e-44,,met-d-XL_HDL_TG,rs4252185,C,T,0.099681,Triglycerides in very large HDL,PLG
6,161123451,0.0548,0.004,1.16011e-43,344278,ebi-a-GCST90018974,rs4252185,C,T,0.10121,Total cholesterol levels,PLG
6,161123451,0.054832,0.0039571,1.19069e-43,344278,ukb-d-30690_irnt,rs4252185,C,T,0.10121,Cholesterol,PLG
6,161123451,0.0936393,0.00679854,2.70023e-43,,met-d-PUFA_by_MUFA,rs4252185,C,T,0.099687,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,PLG
6,161123451,0.0927062,0.0067866,1.80011e-42,115006,ebi-a-GCST90092940,rs4252185,C,T,0.099686,Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,PLG
6,161123451,0.0913898,0.00677409,2.80027e-42,,met-d-S_VLDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in small VLDL,PLG
6,161123451,0.0929084,0.00682292,3.80014e-42,,met-d-PUFA_pct,rs4252185,C,T,0.099687,Ratio of polyunsaturated fatty acids to total fatty acids,PLG
6,161123451,0.0919625,0.00680879,1.39991e-41,115006,ebi-a-GCST90092941,rs4252185,C,T,0.099686,Ratio of polyunsaturated fatty acids to total fatty acids,PLG
6,161123451,-0.0913694,0.00687947,2.09991e-41,,met-d-S_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in small VLDL,PLG
6,161123451,0.0905504,0.00673695,3.50026e-41,115082,ebi-a-GCST90092973,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in small VLDL,PLG
6,161123451,0.217291,0.0158577,6.18586e-41,397554,ebi-a-GCST90013886,rs4252185,C,T,,Angina (Firth correction),PLG
6,161123451,-0.0925323,0.00690727,6.4003e-41,115082,ebi-a-GCST90093014,rs4252185,C,T,0.099677,Triglyceride levels in very large HDL,PLG
6,161123451,0.227188,0.0169741,7.46105e-41,397554,ebi-a-GCST90013936,rs4252185,C,T,,Angina (SPA correction),PLG
6,161123451,-0.0934541,0.0070253,9.3994e-41,,met-d-SFA,rs4252185,C,T,0.099687,Saturated fatty acids,PLG
6,161123451,-0.0901218,0.00679703,1.10002e-40,,met-d-MUFA_pct,rs4252185,C,T,0.099687,Ratio of monounsaturated fatty acids to total fatty acids,PLG
6,161123451,-0.0921709,0.00706106,1.20005e-40,,met-d-L_VLDL_TG_pct,rs4252185,C,T,0.099669,Triglycerides to total lipids ratio in large VLDL,PLG
6,161123451,-0.0927417,0.00698486,3.10027e-40,115006,ebi-a-GCST90092980,rs4252185,C,T,0.099686,Saturated fatty acid levels,PLG
6,161123451,0.0892416,0.00678828,3.50026e-40,,met-d-S_VLDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in small VLDL,PLG
6,161123451,-0.0905087,0.00683228,4.70002e-40,115082,ebi-a-GCST90092978,rs4252185,C,T,0.099677,Triglyceride levels in small VLDL,PLG
6,161123451,-0.0892871,0.00678905,1.69981e-39,115006,ebi-a-GCST90092929,rs4252185,C,T,0.099686,Ratio of monounsaturated fatty acids to total fatty acids,PLG
6,161123451,-0.09273,0.00705887,1.99986e-39,115071,ebi-a-GCST90092879,rs4252185,C,T,0.099665,Triglycerides to total lipids ratio in large VLDL,PLG
6,161123451,0.0907966,0.00691515,2.19989e-39,115082,ebi-a-GCST90092889,rs4252185,C,T,0.099677,Average diameter for LDL particles,PLG
6,161123451,0.0926689,0.0070886,2.80027e-39,,met-d-M_LDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in medium LDL,PLG
6,161123451,-0.0910781,0.00703235,2.90001e-39,,met-d-Total_FA,rs4252185,C,T,0.099687,Total fatty acids,PLG
6,161123451,0.0149307,0.00113961,2.90001e-39,464736,ebi-a-GCST90029021,rs4252185,C,T,0.099417,High cholesterol,PLG
6,161123451,0.0924677,0.00705366,2.90001e-39,115082,ebi-a-GCST90092913,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in medium LDL,PLG
6,161123451,0.0884678,0.00675126,3.10027e-39,115082,ebi-a-GCST90092977,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in small VLDL,PLG
6,161123451,0.0149157,0.0011362,3.80014e-39,484598,ebi-a-GCST90038690,rs4252185,C,T,0.095418,High cholesterol,PLG
6,161123451,0.0908469,0.00693451,5.19996e-39,,met-d-LDL_size,rs4252185,C,T,0.099681,Average diameter for LDL particles,PLG
6,161123451,-0.0903929,0.00699215,3.10027e-38,115006,ebi-a-GCST90092987,rs4252185,C,T,0.099686,Total fatty acid levels,PLG
6,161123451,0.00734879,0.000569883,4.79954e-38,463010,ukb-b-1668,rs4252185,C,T,0.099094,Diagnoses - main ICD10: I25.1 Atherosclerotic heart disease,PLG
6,161123451,0.2676,0.0208,5.7306e-38,461823,ebi-a-GCST90018877,rs4252185,C,T,0.0900652,Myocardial infarction,PLG
6,161123451,0.0149967,0.00116831,1e-37,462933,ukb-b-10912,rs4252185,C,T,0.099101,"Non-cancer illness code, self-reported: high cholesterol",PLG
6,161123451,0.240018,0.0189318,7.8001e-37,17505,ebi-a-GCST011364,rs4252185,C,T,0.094657,Myocardial infarction,PLG
6,161123451,0.2544,0.0201,7.9506e-37,343026,ebi-a-GCST90018915,rs4252185,C,T,0.100901,Stable angina pectoris,PLG
6,161123451,0.0886989,0.00716712,2.80027e-36,,met-d-XXL_VLDL_PL_pct,rs4252185,C,T,0.098759,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,0.0892841,0.00712901,5.50047e-36,111638,ebi-a-GCST90093049,rs4252185,C,T,0.09874,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,PLG
6,161123451,-0.0858698,0.00700151,6.89922e-36,,met-d-VLDL_PL,rs4252185,C,T,0.099681,Phospholipids in VLDL,PLG
6,161123451,0.0834601,0.00676009,1.29987e-35,,met-d-L_LDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in large LDL,PLG
6,161123451,0.1231,0.0099,2.69526e-35,290385,ebi-a-GCST90018989,rs4252185,C,T,0.0913332,Medication use (HMG CoA reductase inhibitors),PLG
6,161123451,0.0826424,0.00672607,1.10002e-34,115082,ebi-a-GCST90092861,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in large LDL,PLG
6,161123451,0.14301,0.0115204,1.28558e-34,407746,ebi-a-GCST90013882,rs4252185,C,T,,High cholesterol (Firth correction),PLG
6,161123451,0.146328,0.0119313,1.41026e-34,407746,ebi-a-GCST90013932,rs4252185,C,T,,High cholesterol (SPA correction),PLG
6,161123451,-0.0851734,0.00698427,3.29989e-34,115082,ebi-a-GCST90093001,rs4252185,C,T,0.099677,Phospholipid levels in VLDL,PLG
6,161123451,0.0846493,0.00701147,4.90004e-34,,met-d-S_HDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in small HDL,PLG
6,161123451,0.0840185,0.00696834,1.80011e-33,115082,ebi-a-GCST90092945,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in small HDL,PLG
6,161123451,-0.0802596,0.00673884,1.9002e-33,,met-d-XS_VLDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in very small VLDL,PLG
6,161123451,-0.0821685,0.00693304,1.9002e-33,,met-d-L_VLDL_C,rs4252185,C,T,0.099681,Cholesterol in large VLDL,PLG
6,161123451,0.0798062,0.00680812,4.10015e-33,,met-d-M_VLDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in medium VLDL,PLG
6,161123451,0.0078146,0.000656285,1.10027e-32,337199,ukb-a-534,rs4252185,C,T,0.102146,Diagnoses - main ICD10: I25 Chronic ischaemic heart disease,PLG
6,161123451,0.294265,0.0247845,1.63983e-32,42457,ebi-a-GCST003116,rs4252185,C,T,0.059661,Coronary artery disease,PLG
6,161123451,0.294265,0.0247845,1.63983e-32,184305,ieu-a-7,rs4252185,C,T,0.059661,Coronary heart disease,PLG
6,161123451,0.151586,0.0125927,1.69278e-32,349222,ebi-a-GCST90104006,rs4252185,C,T,0.100922,Familial combined hyperlipidemia defined by Consensus criteria,PLG
6,161123451,-0.0793829,0.0067029,2.29985e-32,115082,ebi-a-GCST90093039,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in very small VLDL,PLG
6,161123451,-0.0816609,0.00691926,3.80014e-32,115082,ebi-a-GCST90092868,rs4252185,C,T,0.099677,Cholesterol levels in large VLDL,PLG
6,161123451,0.0243878,0.00206855,4.47816e-32,292053,ukb-a-201,rs4252185,C,T,0.102146,Illnesses of father: Heart disease,PLG
6,161123451,-0.080822,0.0069773,4.79954e-32,,met-d-XL_VLDL_CE,rs4252185,C,T,0.099681,Cholesteryl esters in very large VLDL,PLG
6,161123451,0.0798783,0.00680729,8.49963e-32,115082,ebi-a-GCST90092925,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in medium VLDL,PLG
6,161123451,-0.0803642,0.00697006,9.30037e-31,115082,ebi-a-GCST90093018,rs4252185,C,T,0.099677,Cholesteryl ester levels in very large VLDL,PLG
6,161123451,0.2129,0.0187,3.78443e-30,,finn-b-RX_STATIN,rs4252185,C,T,0.0623,Statin medication,PLG
6,161123451,0.0758827,0.00672295,5.30029e-30,,met-d-XS_VLDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in very small VLDL,PLG
6,161123451,0.152958,0.0134731,1.70569e-29,407746,ebi-a-GCST90013919,rs4252185,C,T,,Cholesterol lowering medication use (UKB data field 6177_1) (Firth correction),PLG
6,161123451,0.155112,0.0137601,1.79143e-29,407746,ebi-a-GCST90013969,rs4252185,C,T,,Cholesterol lowering medication use (UKB data field 6177_1) (SPA correction),PLG
6,161123451,0.0749476,0.00669032,4.00037e-29,115082,ebi-a-GCST90093029,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in very small VLDL,PLG
6,161123451,0.0248157,0.00223888,1.50003e-28,209638,ukb-b-11740,rs4252185,C,T,0.098876,"Medication for cholesterol, blood pressure or diabetes: Cholesterol lowering medication",PLG
6,161123451,0.00673958,0.00060958,1.99986e-28,462933,ukb-b-10008,rs4252185,C,T,0.099101,Treatment/medication code: atorvastatin,PLG
6,161123451,-0.0761232,0.00703598,2.29985e-28,,met-d-VLDL_FC,rs4252185,C,T,0.099681,Free cholesterol in VLDL,PLG
6,161123451,0.0730683,0.00668801,3.50026e-28,,met-d-XS_VLDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in very small VLDL,PLG
6,161123451,-0.076012,0.00700425,6.90081e-28,,met-d-M_LDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in medium LDL,PLG
6,161123451,0.0147483,0.00135603,1.51356e-27,337159,ukb-a-108,rs4252185,C,T,0.102146,Non-cancer illness code  self-reported: high cholesterol,PLG
6,161123451,-0.0723253,0.00674806,1.9002e-27,,met-d-S_HDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in small HDL,PLG
6,161123451,0.0720053,0.00664628,2.39994e-27,115082,ebi-a-GCST90093031,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in very small VLDL,PLG
6,161123451,-0.0748182,0.00694255,4.40048e-27,115082,ebi-a-GCST90092915,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in medium LDL,PLG
6,161123451,-0.0754881,0.00702116,5.79963e-27,115082,ebi-a-GCST90092998,rs4252185,C,T,0.099677,Free cholesterol levels in VLDL,PLG
6,161123451,0.00969888,0.000905246,8.00018e-27,484598,ebi-a-GCST90038605,rs4252185,C,T,0.095418,Cardiac problem,PLG
6,161123451,-0.0737536,0.00698552,1.29987e-26,,met-d-M_LDL_TG,rs4252185,C,T,0.099681,Triglycerides in medium LDL,PLG
6,161123451,-0.0729448,0.00687767,1.9002e-26,,met-d-S_HDL_TG,rs4252185,C,T,0.099681,Triglycerides in small HDL,PLG
6,161123451,0.0736042,0.00699518,2.09991e-26,,met-d-S_HDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in small HDL,PLG
6,161123451,-0.0733261,0.00699498,2.19989e-26,,met-d-HDL_TG,rs4252185,C,T,0.099681,Triglycerides in HDL,PLG
6,161123451,0.0158702,0.00149358,2.29985e-26,426240,ukb-b-12477,rs4252185,C,T,0.09921,Illnesses of mother: Heart disease,PLG
6,161123451,-0.0713772,0.00671784,2.29985e-26,115082,ebi-a-GCST90092955,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in small HDL,PLG
6,161123451,-0.0722012,0.00684251,5.00035e-26,115082,ebi-a-GCST90092954,rs4252185,C,T,0.099677,Triglyceride levels in small HDL,PLG
6,161123451,0.0065466,0.000622037,5.90065e-26,484598,ebi-a-GCST90038609,rs4252185,C,T,0.095418,Angina,PLG
6,161123451,0.00561256,0.000533494,7.00003e-26,462933,ukb-b-15829,rs4252185,C,T,0.099101,"Non-cancer illness code, self-reported: heart attack/myocardial infarction",PLG
6,161123451,0.005528,0.000528974,7.8001e-26,484598,ebi-a-GCST90038610,rs4252185,C,T,0.095418,Myocardial infarction,PLG
6,161123451,0.0728299,0.00693082,7.89951e-26,115082,ebi-a-GCST90092947,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in small HDL,PLG
6,161123451,-0.0726036,0.00691527,8.69961e-26,115082,ebi-a-GCST90092914,rs4252185,C,T,0.099677,Triglyceride levels in medium LDL,PLG
6,161123451,-0.0726777,0.00693233,1e-25,115082,ebi-a-GCST90092829,rs4252185,C,T,0.099677,Triglyceride levels in HDL,PLG
6,161123451,0.00562048,0.000536646,1.10002e-25,461880,ukb-b-11590,rs4252185,C,T,0.099077,Vascular/heart problems diagnosed by doctor: Heart attack,PLG
6,161123451,0.0731646,0.00704358,1.50003e-25,,met-d-XS_VLDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in very small VLDL,PLG
6,161123451,0.0730168,0.00704036,3.40017e-25,115082,ebi-a-GCST90093033,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in very small VLDL,PLG
6,161123451,0.00645375,0.000627836,8.69961e-25,462933,ukb-b-8650,rs4252185,C,T,0.099101,"Non-cancer illness code, self-reported: angina",PLG
6,161123451,0.0125257,0.00123462,3.50026e-24,363542,ukb-b-14371,rs4252185,C,T,0.09906,Illnesses of siblings: Heart disease,PLG
6,161123451,0.00638496,0.00063053,4.19952e-24,461880,ukb-b-8468,rs4252185,C,T,0.099077,Vascular/heart problems diagnosed by doctor: Angina,PLG
6,161123451,0.00664188,0.000657866,5.79162e-24,361194,ukb-d-I9_CHD,rs4252185,C,T,0.101344,Major coronary heart disease event,PLG
6,161123451,0.00664188,0.000657866,5.79162e-24,361194,ukb-d-I9_CHD_NOREV,rs4252185,C,T,0.101344,Major coronary heart disease event excluding revascularizations,PLG
6,161123451,0.00526457,0.000522004,6.4003e-24,463010,ukb-b-15686,rs4252185,C,T,0.099094,"Diagnoses - secondary ICD10: I20.9 Angina pectoris, unspecified",PLG
6,161123451,0.270659,0.0269491,9.82653e-24,171875,ieu-a-798,rs4252185,C,T,0.0578357,Myocardial infarction,PLG
6,161123451,0.0666448,0.00674854,1.50003e-23,,met-d-Unsaturation,rs4252185,C,T,0.099687,Degree of unsaturation,PLG
6,161123451,-0.0692229,0.00700618,1.59993e-23,,met-d-M_HDL_TG,rs4252185,C,T,0.099681,Triglycerides in medium HDL,PLG
6,161123451,0.00768946,0.000770334,1.80011e-23,463010,ukb-b-12651,rs4252185,C,T,0.099094,Diagnoses - secondary ICD10: E78.0 Pure hypercholesterolaemia,PLG
6,161123451,-0.0664164,0.00668395,2.39994e-23,,met-d-XL_HDL_TG_pct,rs4252185,C,T,0.099686,Triglycerides to total lipids ratio in very large HDL,PLG
6,161123451,-0.0335771,0.00335703,3.50026e-23,437532,ebi-a-GCST90025957,rs4252185,C,T,0.0999372,Triglyceride levels,PLG
6,161123451,0.00393177,0.000396838,3.90032e-23,463010,ukb-b-7436,rs4252185,C,T,0.099094,Diagnoses - secondary ICD10: I25.1 Atherosclerotic heart disease,PLG
6,161123451,-0.0657938,0.00665742,4.90004e-23,115056,ebi-a-GCST90093015,rs4252185,C,T,0.099683,Triglycerides to total lipids ratio in very large HDL,PLG
6,161123451,-0.0687234,0.00695463,5.00035e-23,115082,ebi-a-GCST90092902,rs4252185,C,T,0.099677,Triglyceride levels in medium HDL,PLG
6,161123451,0.0663572,0.0067253,5.79963e-23,115006,ebi-a-GCST90092994,rs4252185,C,T,0.099686,Degree of unsaturation,PLG
6,161123451,0.067082,0.00702848,8.69961e-23,,met-d-L_VLDL_FC_pct,rs4252185,C,T,0.099669,Free cholesterol to total lipids ratio in large VLDL,PLG
6,161123451,0.0891,0.0091,1.31492e-22,66580,ieu-b-4846,rs4252185,C,T,,LDL cholesterol,PLG
6,161123451,0.0680574,0.00702295,3.29989e-22,115071,ebi-a-GCST90092873,rs4252185,C,T,0.099665,Free cholesterol to total lipids ratio in large VLDL,PLG
6,161123451,0.0161958,0.00170487,2.11885e-21,308780,ukb-a-209,rs4252185,C,T,0.102146,Illnesses of mother: Heart disease,PLG
6,161123451,0.00684579,0.000722339,2.62664e-21,337159,ukb-a-62,rs4252185,C,T,0.102146,Non-cancer illness code  self-reported: angina,PLG
6,161123451,0.00679662,0.000723761,5.99515e-21,336683,ukb-a-436,rs4252185,C,T,0.102146,Vascular/heart problems diagnosed by doctor: Angina,PLG
6,161123451,0.0635633,0.00687995,6.4998e-21,,met-d-M_HDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in medium HDL,PLG
6,161123451,0.2456,0.0262,6.92787e-21,,finn-b-I9_CORATHER,rs4252185,C,T,0.06218,Coronary atherosclerosis,PLG
6,161123451,0.00370585,0.000395551,7.29962e-21,463010,ukb-b-16606,rs4252185,C,T,0.099094,Diagnoses - secondary ICD10: I25.8 Other forms of chronic ischaemic heart disease,PLG
6,161123451,-0.0638426,0.00700476,1.29987e-20,,met-d-L_VLDL_CE,rs4252185,C,T,0.099681,Cholesteryl esters in large VLDL,PLG
6,161123451,0.0240538,0.00258833,1.51635e-20,154702,ukb-a-488,rs4252185,C,T,0.102146,Medication for cholesterol  blood pressure or diabetes: Cholesterol lowering medication,PLG
6,161123451,0.321,0.0348,2.82813e-20,,finn-b-I9_REVASC,rs4252185,C,T,0.06192,Coronary revascularization (ANGIO or CABG),PLG
6,161123451,-0.0622752,0.0068052,3.10027e-20,,met-d-M_HDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in medium HDL,PLG
6,161123451,0.0628546,0.00684535,4.19952e-20,115082,ebi-a-GCST90092895,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in medium HDL,PLG
6,161123451,-0.0627039,0.00704077,5.00035e-20,,met-d-M_VLDL_L,rs4252185,C,T,0.099681,Total lipids in medium VLDL,PLG
6,161123451,-0.0616661,0.00677742,9.09913e-20,115082,ebi-a-GCST90092903,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in medium HDL,PLG
6,161123451,0.2082,0.0229,9.37346e-20,,finn-b-I9_IHD,rs4252185,C,T,0.0623,"Ischaemic heart disease, wide definition",PLG
6,161123451,-0.0317077,0.003494,1.13789e-19,389562,ebi-a-GCST90014014,rs4252185,C,T,,Triglyceride levels (UKB data field 30870),PLG
6,161123451,-0.0634381,0.00699165,1.20005e-19,115082,ebi-a-GCST90092870,rs4252185,C,T,0.099677,Cholesteryl ester levels in large VLDL,PLG
6,161123451,0.0598817,0.00675484,2.90001e-19,,met-d-M_HDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in medium HDL,PLG
6,161123451,0.2316,0.0259,3.6033e-19,,finn-b-I9_CORATHER_EXNONE,rs4252185,C,T,0.0623,Coronary atherosclerosis (no controls excluded),PLG
6,161123451,0.00491701,0.000550634,4.29042e-19,361194,ukb-d-I9_MI,rs4252185,C,T,0.101344,Myocardial infarction,PLG
6,161123451,0.00491701,0.000550634,4.29042e-19,361194,ukb-d-I9_MI_STRICT,rs4252185,C,T,0.101344,"Myocardial infarction, strict",PLG
6,161123451,0.4208,0.0474,6.32557e-19,,finn-b-I9_CABG,rs4252185,C,T,0.06162,Coronary artery bypass grafting,PLG
6,161123451,-0.0623793,0.00703141,7.19946e-19,115082,ebi-a-GCST90092922,rs4252185,C,T,0.099677,Total lipid levels in medium VLDL,PLG
6,161123451,0.00769253,0.000874314,1.39991e-18,445693,ukb-b-20300,rs4252185,C,T,0.099199,Treatment speciality of consultant (recoded): Cardiology,PLG
6,161123451,0.2941,0.0334,1.41906e-18,,finn-b-I9_REVASC_EXNONE,rs4252185,C,T,0.0623,Coronary revascularization (ANGIO or CABG) (no controls excluded),PLG
6,161123451,0.2941,0.0334,1.41906e-18,,finn-b-I9_REVACS_EXNONE,rs4252185,C,T,0.0623,Emergency coronary revascularization (for ACS) (no controls excluded),PLG
6,161123451,0.0592483,0.00673912,1.50003e-18,115082,ebi-a-GCST90092893,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in medium HDL,PLG
6,161123451,0.2018,0.023,1.55991e-18,,finn-b-I9_ISCHHEART,rs4252185,C,T,0.0623,Ischemic heart diseases,PLG
6,161123451,-0.0300481,0.00342477,1.69981e-18,,ieu-b-111,rs4252185,C,T,0.098914,triglycerides,PLG
6,161123451,0.0128093,0.00147221,3.31055e-18,361194,ukb-d-IX_CIRCULATORY,rs4252185,C,T,0.101344,Diseases of the circulatory system,PLG
6,161123451,0.00616353,0.00070859,3.38376e-18,337159,ukb-a-176,rs4252185,C,T,0.102146,Treatment/medication code: atorvastatin,PLG
6,161123451,-0.0595155,0.00688777,3.80014e-18,,met-d-L_VLDL_PL_pct,rs4252185,C,T,0.099669,Phospholipids to total lipids ratio in large VLDL,PLG
6,161123451,0.2477,0.0286,4.36114e-18,,finn-b-I9_ANGINA,rs4252185,C,T,0.06209,Angina pectoris,PLG
6,161123451,0.00435888,0.000503426,4.79954e-18,463010,ukb-b-2205,rs4252185,C,T,0.099094,Diagnoses - secondary ICD10: Z82.4 Family history of ischaemic heart disease and other diseases of the circulatory system,PLG
6,161123451,-0.0607147,0.007061,9.3994e-18,,met-d-GlycA,rs4252185,C,T,0.099681,Glycoprotein acetyls,PLG
6,161123451,0.0118997,0.00138679,9.47764e-18,259921,ukb-a-217,rs4252185,C,T,0.102146,Illnesses of siblings: Heart disease,PLG
6,161123451,-0.0590998,0.00685376,1.20005e-17,,met-d-IDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in IDL,PLG
6,161123451,-0.0579901,0.00695504,1.29987e-17,,met-d-LA,rs4252185,C,T,0.099687,Linoleic acid,PLG
6,161123451,-0.0587514,0.00687828,1.29987e-17,115071,ebi-a-GCST90092877,rs4252185,C,T,0.099665,Phospholipids to total lipids ratio in large VLDL,PLG
6,161123451,-0.0579437,0.00679991,1.59993e-17,115082,ebi-a-GCST90092842,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in IDL,PLG
6,161123451,-0.0595721,0.00701065,1.9002e-17,115082,ebi-a-GCST90092821,rs4252185,C,T,0.099677,Glycoprotein acetyls levels,PLG
6,161123451,0.2274,0.0269,2.84774e-17,,finn-b-I9_CHD,rs4252185,C,T,0.0623,Major coronary heart disease event,PLG
6,161123451,0.0135914,0.00161634,4.10015e-17,249710,ukb-b-17805,rs4252185,C,T,0.099375,"Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Cholesterol lowering medication",PLG
6,161123451,-0.0568856,0.00698255,6.00067e-17,,met-d-XS_VLDL_TG,rs4252185,C,T,0.099681,Triglycerides in very small VLDL,PLG
6,161123451,-0.0570686,0.00691633,6.09958e-17,,met-d-PUFA,rs4252185,C,T,0.099687,Polyunsaturated fatty acids,PLG
6,161123451,0.00516326,0.000617992,6.57355e-17,337159,ukb-a-63,rs4252185,C,T,0.102146,Non-cancer illness code  self-reported: heart attack/myocardial infarction,PLG
6,161123451,0.0575804,0.00692705,7.59976e-17,,met-d-IDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in IDL,PLG
6,161123451,-0.0579453,0.00695739,8.19974e-17,115006,ebi-a-GCST90092880,rs4252185,C,T,0.099686,Linoleic acid levels,PLG
6,161123451,0.00513116,0.000621094,1.44378e-16,336683,ukb-a-434,rs4252185,C,T,0.102146,Vascular/heart problems diagnosed by doctor: Heart attack,PLG
6,161123451,-0.0567135,0.00688167,1.69981e-16,115006,ebi-a-GCST90092939,rs4252185,C,T,0.099686,Polyunsaturated fatty acid levels,PLG
6,161123451,0.3681,0.0448,2.23718e-16,,finn-b-I9_CABG_EXNONE,rs4252185,C,T,0.0623,Coronary artery bypass grafting (no controls excluded),PLG
6,161123451,0.0564894,0.00688744,2.39994e-16,115082,ebi-a-GCST90092832,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in IDL,PLG
6,161123451,0.2227,0.0274,4.74351e-16,,finn-b-I9_ANGINA_EXNONE,rs4252185,C,T,0.0623,Angina pectoris (no controls excluded),PLG
6,161123451,0.2642,0.0327,6.62064e-16,,finn-b-I9_MI,rs4252185,C,T,0.06178,Myocardial infarction,PLG
6,161123451,0.2455,0.0304,6.74373e-16,456468,ebi-a-GCST90018932,rs4252185,C,T,0.0893108,Unstable angina pectoris,PLG
6,161123451,-0.0556445,0.00689926,7.29962e-16,115082,ebi-a-GCST90093038,rs4252185,C,T,0.099677,Triglyceride levels in very small VLDL,PLG
6,161123451,0.00643512,0.000802399,1.10002e-15,461416,ukb-b-16376,rs4252185,C,T,0.099107,Main speciality of consultant (recoded): Cardiology,PLG
6,161123451,-0.0543477,0.00699935,1.69981e-15,,met-d-S_VLDL_P,rs4252185,C,T,0.099681,Concentration of small VLDL particles,PLG
6,161123451,0.0426875,0.00536851,2.90001e-15,,ieu-b-5089,rs4252185,C,T,0.098583,LDL cholesterol,PLG
6,161123451,-0.053685,0.00705157,3.40017e-15,,met-d-VLDL_P,rs4252185,C,T,0.099681,Concentration of VLDL particles,PLG
6,161123451,0.0537308,0.0068526,4.49987e-15,115006,ebi-a-GCST90092817,rs4252185,C,T,0.099686,Ratio of docosahexaenoic acid to total fatty acid levels,PLG
6,161123451,0.00349825,0.000448262,6.00067e-15,463010,ukb-b-9592,rs4252185,C,T,0.099094,Operative procedures - main OPCS: K63.3 Angiocardiography of left side of heart NEC,PLG
6,161123451,0.0028333,0.000363589,6.59933e-15,462933,ukb-b-7869,rs4252185,C,T,0.099101,Operation code: coronary angioplasty (ptca) +/- stent,PLG
6,161123451,0.0538669,0.00690437,7.59976e-15,,met-d-DHA_pct,rs4252185,C,T,0.099687,Ratio of docosahexaenoic acid to total fatty acids,PLG
6,161123451,-0.0536687,0.00701272,7.59976e-15,,met-d-LDL_TG,rs4252185,C,T,0.099681,Triglycerides in LDL,PLG
6,161123451,0.0145909,0.00188163,8.92278e-15,180203,ukb-a-448,rs4252185,C,T,0.102146,Medication for cholesterol  blood pressure  diabetes  or take exogenous hormones: Cholesterol lowering medication,PLG
6,161123451,0.264,0.0341,9.30465e-15,,finn-b-I9_MI_STRICT,rs4252185,C,T,0.06171,"Myocardial infarction, strict",PLG
6,161123451,-0.0536288,0.00696761,1.39991e-14,115082,ebi-a-GCST90092975,rs4252185,C,T,0.099677,Concentration of small VLDL particles,PLG
6,161123451,-0.0524928,0.00701995,1.50003e-14,,met-d-S_VLDL_L,rs4252185,C,T,0.099681,Total lipids in small VLDL,PLG
6,161123451,-0.0521303,0.00692567,1.59993e-14,,met-d-Omega_6,rs4252185,C,T,0.099687,Omega-6 fatty acids,PLG
6,161123451,0.0120011,0.00157957,2.29985e-14,484598,ebi-a-GCST90038595,rs4252185,C,T,0.095418,Cardiovascular disease,PLG
6,161123451,-0.0508023,0.00672998,2.70023e-14,,met-d-M_HDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in medium HDL,PLG
6,161123451,-0.0530631,0.0069987,3.40017e-14,,met-d-SFA_pct,rs4252185,C,T,0.099687,Ratio of saturated fatty acids to total fatty acids,PLG
6,161123451,-0.0522038,0.00708064,3.40017e-14,,met-d-VLDL_C,rs4252185,C,T,0.099681,VLDL cholesterol,PLG
6,161123451,-0.03,0.004,3.50268e-14,343992,ebi-a-GCST90018975,rs4252185,C,T,0.10121,Triglycerides,PLG
6,161123451,-0.030028,0.0039624,3.51237e-14,343992,ukb-d-30870_irnt,rs4252185,C,T,0.10121,Triglycerides,PLG
6,161123451,-0.0524905,0.00693481,3.80014e-14,115082,ebi-a-GCST90092890,rs4252185,C,T,0.099677,Triglyceride levels in LDL,PLG
6,161123451,-0.0530468,0.0070279,4.40048e-14,115082,ebi-a-GCST90093000,rs4252185,C,T,0.099677,Concentration of VLDL particles,PLG
6,161123451,-0.0519357,0.00692064,6.20012e-14,115006,ebi-a-GCST90092933,rs4252185,C,T,0.099686,Omega-6 fatty acid levels,PLG
6,161123451,-0.0524485,0.00699113,6.29941e-14,115006,ebi-a-GCST90092981,rs4252185,C,T,0.099686,Ratio of saturated fatty acids to total fatty acids,PLG
6,161123451,-0.0502452,0.00672767,8.10028e-14,115082,ebi-a-GCST90092901,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in medium HDL,PLG
6,161123451,-0.0493558,0.00681423,1e-13,,met-d-L_HDL_TG,rs4252185,C,T,0.099681,Triglycerides in large HDL,PLG
6,161123451,-0.0138068,0.00185784,1.10002e-13,402586,ukb-b-15169,rs4252185,C,T,0.098998,Illnesses of father: None of the above (group 1),PLG
6,161123451,-0.0234942,0.00341891,1.10002e-13,397043,ebi-a-GCST90025958,rs4252185,C,T,0.0998942,Sex hormone-binding globulin levels,PLG
6,161123451,-0.0517764,0.00699035,1.29987e-13,115082,ebi-a-GCST90092974,rs4252185,C,T,0.099677,Total lipid levels in small VLDL,PLG
6,161123451,0.0497463,0.00672017,1.29987e-13,115082,ebi-a-GCST90092949,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in small HDL,PLG
6,161123451,-0.0504609,0.00707276,1.69981e-13,,met-d-M_VLDL_P,rs4252185,C,T,0.099681,Concentration of medium VLDL particles,PLG
6,161123451,-0.0517003,0.00707046,2.60016e-13,115082,ebi-a-GCST90092996,rs4252185,C,T,0.099677,VLDL cholesterol levels,PLG
6,161123451,0.0491229,0.00673116,2.80027e-13,,met-d-S_HDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in small HDL,PLG
6,161123451,-0.0489432,0.00673988,3.80014e-13,115082,ebi-a-GCST90092854,rs4252185,C,T,0.099677,Triglyceride levels in large HDL,PLG
6,161123451,0.00320467,0.000444054,5.33212e-13,337199,ukb-a-533,rs4252185,C,T,0.102146,Diagnoses - main ICD10: I21 Acute myocardial infarction,PLG
6,161123451,0.00866484,0.00120806,7.39946e-13,462933,ukb-b-8755,rs4252185,C,T,0.099101,Treatment/medication code: aspirin,PLG
6,161123451,0.0499327,0.00696259,7.59976e-13,,met-d-IDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in IDL,PLG
6,161123451,-0.0504805,0.00695609,8.00018e-13,,met-d-L_LDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in large LDL,PLG
6,161123451,-0.0492131,0.00688686,8.9002e-13,115082,ebi-a-GCST90092867,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in large LDL,PLG
6,161123451,-0.0487696,0.00686049,9.09913e-13,,met-d-S_HDL_PL_pct,rs4252185,C,T,0.099681,Phospholipids to total lipids ratio in small HDL,PLG
6,161123451,0.00885998,0.00124375,1.10002e-12,457547,ukb-b-7137,rs4252185,C,T,0.099096,"Medication for pain relief, constipation, heartburn: Aspirin",PLG
6,161123451,-0.0487109,0.0068418,1.10002e-12,115082,ebi-a-GCST90092953,rs4252185,C,T,0.099677,Phospholipids to total lipids ratio in small HDL,PLG
6,161123451,-0.0501408,0.00706514,1.29987e-12,115082,ebi-a-GCST90092923,rs4252185,C,T,0.099677,Concentration of medium VLDL particles,PLG
6,161123451,-0.0152305,0.00214846,1.35363e-12,292053,ukb-a-202,rs4252185,C,T,0.102146,Illnesses of father: None of the above (group 1),PLG
6,161123451,-0.0176934,0.0024988,1.39991e-12,209638,ukb-b-12014,rs4252185,C,T,0.098876,"Medication for cholesterol, blood pressure or diabetes: None of the above",PLG
6,161123451,-0.0484919,0.00697728,1.59993e-12,,met-d-Total_L,rs4252185,C,T,0.099681,Total lipids in lipoprotein particles,PLG
6,161123451,0.0487943,0.00690331,1.59993e-12,115082,ebi-a-GCST90092834,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in IDL,PLG
6,161123451,0.2234,0.0317,1.91514e-12,,finn-b-I9_MI_EXNONE,rs4252185,C,T,0.0623,Myocardial infarction (no controls excluded),PLG
6,161123451,0.0101117,0.00143866,2.09122e-12,333581,ukb-a-452,rs4252185,C,T,0.102146,Medication for pain relief  constipation  heartburn: Aspirin,PLG
6,161123451,0.0495926,0.00705743,2.09991e-12,115056,ebi-a-GCST90093007,rs4252185,C,T,0.099683,Cholesteryl esters to total lipids ratio in very large HDL,PLG
6,161123451,6.50194,0.926716,2.28139e-12,17373,ebi-a-GCST008037,rs4252185,C,T,0.03119,Low density lipoprotein cholesterol levels,PLG
6,161123451,0.0465969,0.00677756,2.90001e-12,,met-d-XL_HDL_C_pct,rs4252185,C,T,0.099686,Cholesterol to total lipids ratio in very large HDL,PLG
6,161123451,0.0502266,0.00709057,2.99985e-12,,met-d-XL_HDL_CE_pct,rs4252185,C,T,0.099686,Cholesteryl esters to total lipids ratio in very large HDL,PLG
6,161123451,0.1578,0.0227,3.83089e-12,,finn-b-I9_CVD_HARD,rs4252185,C,T,0.0623,Hard cardiovascular diseases,PLG
6,161123451,-0.0475752,0.00698077,4.00037e-12,,met-d-Omega_3,rs4252185,C,T,0.099687,Omega-3 fatty acids,PLG
6,161123451,-0.0482217,0.00696674,4.49987e-12,115082,ebi-a-GCST90092989,rs4252185,C,T,0.099677,Total lipid levels in lipoprotein particles,PLG
6,161123451,-0.0469071,0.00679518,5.10035e-12,115006,ebi-a-GCST90092931,rs4252185,C,T,0.099686,Omega-3 fatty acid levels,PLG
6,161123451,0.2756,0.0401,6.03254e-12,,finn-b-I9_ANGIO,rs4252185,C,T,0.06153,Coronary angiopasty,PLG
6,161123451,0.0958,0.0139,6.04644e-12,27475,ieu-b-4845,rs4252185,C,T,,LDL cholesterol,PLG
6,161123451,0.0461973,0.00674793,7.59976e-12,115056,ebi-a-GCST90093005,rs4252185,C,T,0.099683,Cholesterol to total lipids ratio in very large HDL,PLG
6,161123451,0.00953199,0.00140028,9.96782e-12,337159,ukb-a-132,rs4252185,C,T,0.102146,Treatment/medication code: aspirin,PLG
6,161123451,0.0463589,0.00683506,1.20005e-11,115006,ebi-a-GCST90092881,rs4252185,C,T,0.099686,Ratio of linoleic acid to total fatty acids,PLG
6,161123451,-0.027612,0.004094,1.53886e-11,343992,ukb-d-30870_raw,rs4252185,C,T,0.10121,Triglycerides,PLG
6,161123451,0.00259433,0.000385019,1.59993e-11,461137,ukb-b-11247,rs4252185,C,T,0.099088,Main speciality of consultant (recoded): Cardiothoracic surgery,PLG
6,161123451,-0.0447584,0.00669906,1.9002e-11,,met-d-L_HDL_TG_pct,rs4252185,C,T,0.099681,Triglycerides to total lipids ratio in large HDL,PLG
6,161123451,0.0474651,0.00693871,2.29985e-11,,met-d-LA_pct,rs4252185,C,T,0.099687,Ratio of linoleic acid to total fatty acids,PLG
6,161123451,0.0103315,0.00157157,2.39994e-11,477807,ebi-a-GCST90029019,rs4252185,C,T,0.099417,Cardiovascular disease,PLG
6,161123451,0.0791,0.0119,2.83074e-11,153639,ebi-a-GCST90018982,rs4252185,C,T,0.0923421,Medication use (antithrombotic agents),PLG
6,161123451,-0.0442144,0.00667081,3.40017e-11,115082,ebi-a-GCST90092855,rs4252185,C,T,0.099677,Triglycerides to total lipids ratio in large HDL,PLG
6,161123451,0.2182,0.0329,3.46497e-11,,finn-b-I9_MI_STRICT_EXNONE,rs4252185,C,T,0.0623,"""Myocardial infarction, strict"" (no controls excluded)",PLG
6,161123451,0.025377,0.00384068,3.50026e-11,389166,ebi-a-GCST006697,rs4252185,C,T,0.100248,"Parental longevity (combined parental attained age, Martingale residuals)",PLG
6,161123451,0.00253077,0.000382496,3.69999e-11,463010,ukb-b-13566,rs4252185,C,T,0.099094,Operative procedures - main OPCS: K63.6 Coronary arteriography NEC,PLG
6,161123451,0.00209403,0.000319698,5.79963e-11,463010,ukb-b-15748,rs4252185,C,T,0.099094,Diagnoses - secondary ICD10: Z95.5 Presence of coronary angioplasty implant and graft,PLG
6,161123451,0.00208312,0.000318547,6.18301e-11,337159,ukb-a-191,rs4252185,C,T,0.102146,Treatment/medication code: ezetimibe,PLG
6,161123451,0.00261008,0.000400233,7.00003e-11,463010,ukb-b-8184,rs4252185,C,T,0.099094,"Diagnoses - secondary ICD10: I25.9 Chronic ischaemic heart disease, unspecified",PLG
6,161123451,-0.0443416,0.00707965,7.8001e-11,,met-d-M_VLDL_PL,rs4252185,C,T,0.099681,Phospholipids in medium VLDL,PLG
6,161123451,6.83492,1.0516,8.05749e-11,17802,ebi-a-GCST008045,rs4252185,C,T,0.0309842,Total cholesterol levels,PLG
6,161123451,0.0454516,0.00704208,1.09999e-10,115082,ebi-a-GCST90092836,rs4252185,C,T,0.099677,Free cholesterol to total lipids ratio in IDL,PLG
6,161123451,0.00482577,0.000750882,1.29999e-10,462933,ukb-b-11895,rs4252185,C,T,0.099101,Treatment/medication code: ramipril,PLG
6,161123451,0.2337,0.0365,1.49599e-10,,finn-b-Z21_PRESENCE_CARDIAC_VASCULAR_IMPLANTNTS_GRAFTS,rs4252185,C,T,0.06225,Presence of cardiac and vascular implants and grafts,PLG
6,161123451,0.0453331,0.00704136,1.79999e-10,,met-d-IDL_FC_pct,rs4252185,C,T,0.099681,Free cholesterol to total lipids ratio in IDL,PLG
6,161123451,-0.1458,0.023,2.31798e-10,10708,ebi-a-GCST90019437,rs4252185,C,T,0.0964,Angiostatin measurement,PLG
6,161123451,0.00217958,0.000345542,2.80001e-10,444235,ukb-b-6951,rs4252185,C,T,0.099178,Treatment speciality of consultant (recoded): Cardiothoracic surgery,PLG
6,161123451,0.00702842,0.00112819,4.70002e-10,462933,ukb-b-11268,rs4252185,C,T,0.099101,Treatment/medication code: simvastatin,PLG
6,161123451,-0.0440303,0.00707259,4.79999e-10,115082,ebi-a-GCST90092924,rs4252185,C,T,0.099677,Phospholipid levels in medium VLDL,PLG
6,161123451,0.0423437,0.0070799,2.19999e-09,115082,ebi-a-GCST90092960,rs4252185,C,T,0.099677,Free cholesterol levels in small LDL,PLG
6,161123451,0.0424659,0.0070827,2.30001e-09,,met-d-S_LDL_FC,rs4252185,C,T,0.099681,Free cholesterol in small LDL,PLG
6,161123451,0.111158,0.0183867,2.37159e-09,349222,ebi-a-GCST90104005,rs4252185,C,T,0.100922,Familial combined hyperlipidemia defined by Dutch criteria,PLG
6,161123451,-0.017268,0.00289438,2.4359e-09,154702,ukb-a-489,rs4252185,C,T,0.102146,Medication for cholesterol  blood pressure or diabetes: None of the above,PLG
6,161123451,-0.0209122,0.00364147,2.5e-09,400938,ebi-a-GCST90025992,rs4252185,C,T,0.0999509,Serum albumin levels,PLG
6,161123451,0.0409002,0.00686699,2.59998e-09,115082,ebi-a-GCST90092835,rs4252185,C,T,0.099677,Free cholesterol levels in IDL,PLG
6,161123451,0.1074,0.0181,2.70901e-09,,finn-b-DM_COMORB_EXMORE,rs4252185,C,T,0.0625,Diabetes-related co-morbidities/complications (more controls excluded),PLG
6,161123451,0.040789,0.00686872,2.99999e-09,,met-d-IDL_FC,rs4252185,C,T,0.099681,Free cholesterol in IDL,PLG
6,161123451,0.0403773,0.00685218,2.99999e-09,,met-d-IDL_C,rs4252185,C,T,0.099681,Cholesterol in IDL,PLG
6,161123451,0.2289,0.0387,3.31002e-09,,finn-b-I9_HEARTFAIL_AND_CHD,rs4252185,C,T,0.06173,NA,PLG
6,161123451,-0.00763593,0.00143826,3.79997e-09,368929,ebi-a-GCST90012110,rs4252185,C,T,0.100128,Sex hormone-binding globulin levels adjusted for BMI,PLG
6,161123451,0.0403594,0.00685399,3.89996e-09,115082,ebi-a-GCST90092831,rs4252185,C,T,0.099677,Cholesterol levels in IDL,PLG
6,161123451,0.2245,0.0381,3.93904e-09,,finn-b-I9_ANGIO_EXNONE,rs4252185,C,T,0.0623,Coronary angiopasty (no controls excluded),PLG
6,161123451,0.0399062,0.00685003,4.09996e-09,,met-d-IDL_CE,rs4252185,C,T,0.099681,Cholesteryl esters in IDL,PLG
6,161123451,0.0404894,0.00696662,5.1e-09,,met-d-L_LDL_FC,rs4252185,C,T,0.099681,Free cholesterol in large LDL,PLG
6,161123451,0.0398513,0.00685281,6.1e-09,115082,ebi-a-GCST90092833,rs4252185,C,T,0.099677,Cholesteryl ester levels in IDL,PLG
6,161123451,0.0402998,0.00696869,7.29995e-09,115082,ebi-a-GCST90092860,rs4252185,C,T,0.099677,Free cholesterol levels in large LDL,PLG
6,161123451,0.195,0.0338,8.02103e-09,242659,ebi-a-GCST90018983,rs4252185,C,T,0.0916541,Medication use (vasodilators used in cardiac diseases),PLG
6,161123451,0.00133801,0.000233882,1.06062e-08,361194,ukb-d-I9_PAD,rs4252185,C,T,0.101344,Peripheral artery disease,PLG
6,161123451,0.0212682,0.00373211,1.09999e-08,415311,ebi-a-GCST006701,rs4252185,C,T,0.10027,Parental longevity (father's attained age),PLG
6,161123451,0.00743254,0.00131206,1.47316e-08,337159,ukb-a-121,rs4252185,C,T,0.102146,Treatment/medication code: simvastatin,PLG
6,161123451,0.184128,0.0320053,1.91576e-08,349222,ebi-a-GCST90104007,rs4252185,C,T,0.100922,Familial combined hyperlipidemia defined by Mexico criteria,PLG
6,161123451,0.1901,0.034,2.15899e-08,483078,ebi-a-GCST90018890,rs4252185,C,T,0.0904429,Peripheral artery disease,PLG
6,161123451,0.1541,0.0276,2.28202e-08,,finn-b-E4_LIPOPROT,rs4252185,C,T,0.06239,Disorders of lipoprotein metabolism and other lipidaemias,PLG
6,161123451,0.0390199,0.00701904,2.39999e-08,,met-d-LDL_FC,rs4252185,C,T,0.099681,Free cholesterol in LDL,PLG
6,161123451,0.3947,0.0711,2.848e-08,,ukb-e-30790_CSA,rs4252185,C,T,0.98572,Lipoprotein A,PLG
6,161123451,-0.00798206,0.00160272,3.09999e-08,370125,ebi-a-GCST90012111,rs4252185,C,T,0.100135,Sex hormone-binding globulin levels,PLG
6,161123451,0.0388792,0.00702035,3.09999e-08,115082,ebi-a-GCST90092885,rs4252185,C,T,0.099677,Free cholesterol levels in LDL,PLG
6,161123451,0.0165077,0.00336062,6.59994e-08,400754,ebi-a-GCST90025956,rs4252185,C,T,0.0999546,HDL cholesterol levels,PLG
6,161123451,-0.0377665,0.0071121,7.10003e-08,,met-d-L_LDL_CE_pct,rs4252185,C,T,0.099681,Cholesteryl esters to total lipids ratio in large LDL,PLG
6,161123451,-0.0381873,0.00710598,7.69999e-08,115082,ebi-a-GCST90092859,rs4252185,C,T,0.099677,Cholesteryl esters to total lipids ratio in large LDL,PLG
6,161123451,0.0813,0.0152,9.59511e-08,977323,ebi-a-GCST009541,rs4252185,C,T,,Heart failure,PLG
6,161123451,-0.00857559,0.0016111,1e-07,461880,ukb-b-13352,rs4252185,C,T,0.099077,Vascular/heart problems diagnosed by doctor: None of the above,PLG
6,161123451,0.0199683,0.00375169,1e-07,412937,ebi-a-GCST006696,rs4252185,C,T,0.100223,Parental longevity (mother's attained age),PLG
6,161123451,0.4381,0.08288,1.253e-07,,ukb-e-104410_AFR,rs4252185,C,T,0.98554,Stewed fruit intake,PLG
6,161123451,0.00174069,0.000329462,1.26862e-07,337159,ukb-a-180,rs4252185,C,T,0.102146,Treatment/medication code: clopidogrel,PLG
6,161123451,0.2254,0.0427,1.27201e-07,,finn-b-DM_PERIPHATHERO,rs4252185,C,T,0.06138,Peripheral atherosclerosis,PLG
6,161123451,0.0374226,0.00691232,1.29999e-07,,met-d-L_LDL_C_pct,rs4252185,C,T,0.099681,Cholesterol to total lipids ratio in large LDL,PLG
6,161123451,0.0363215,0.00688016,1.29999e-07,115082,ebi-a-GCST90092857,rs4252185,C,T,0.099677,Cholesterol to total lipids ratio in large LDL,PLG
6,161123451,0.00713287,0.00136114,1.6e-07,461894,ukb-b-15784,rs4252185,C,T,0.099101,Main speciality of consultant (recoded): General medicine,PLG
6,161123451,-0.00983554,0.00188762,1.89998e-07,364971,ukb-b-17360,rs4252185,C,T,0.09904,Illnesses of siblings: None of the above (group 1),PLG
6,161123451,0.0721,0.0139,2.17901e-07,112010,ebi-a-GCST90018995,rs4252185,C,T,0.0931419,Medication use (salicylic acid and derivatives),PLG
6,161123451,-0.0173735,0.00336539,2.43809e-07,354620,ebi-a-GCST90014011,rs4252185,C,T,,Sex hormone binding globulin levels (UKB data field 30830),PLG
6,161123451,0.00200785,0.000389463,2.5318e-07,361194,ukb-d-I9_UAP,rs4252185,C,T,0.101344,Unstable angina pectoris,PLG
6,161123451,-0.00941259,0.00212326,3.09999e-07,188908,ebi-a-GCST90012106,rs4252185,C,T,0.100217,Sex hormone-binding globulin levels adjusted for BMI,PLG
6,161123451,0.00444513,0.000873974,3.65671e-07,337159,ukb-a-117,rs4252185,C,T,0.102146,Treatment/medication code: ramipril,PLG
6,161123451,0.0515637,0.0101765,4.53336e-07,407746,ebi-a-GCST90013912,rs4252185,C,T,,Chest pain or discomfort (UKB data field 2335) (Firth correction),PLG
6,161123451,0.0519913,0.0103105,4.59325e-07,407746,ebi-a-GCST90013962,rs4252185,C,T,,Chest pain or discomfort (UKB data field 2335) (SPA correction),PLG
6,161123451,0.0164977,0.00329139,5.38431e-07,105569,ukb-a-366,rs4252185,C,T,0.102146,Non-accidental death in close genetic family,PLG
6,161123451,-0.00966106,0.0019319,5.71176e-07,360291,ukb-d-1428_1,rs4252185,C,T,0.101344,Spread type: Butter/spreadable butter,PLG
6,161123451,0.0342105,0.00685885,6.1e-07,115082,ebi-a-GCST90092837,rs4252185,C,T,0.099677,Total lipid levels in IDL,PLG
6,161123451,0.0340845,0.00685989,6.19998e-07,,met-d-IDL_L,rs4252185,C,T,0.099681,Total lipids in IDL,PLG
6,161123451,0.188288,0.036888,6.31961e-07,349222,ebi-a-GCST90104003,rs4252185,C,T,0.100922,Familial combined hyperlipidemia defined by Brunzell criteria,PLG
6,161123451,-0.0141862,0.00312769,6.59994e-07,444866,ebi-a-GCST90025951,rs4252185,C,T,0.100121,Platelet count,PLG
